Report Preview Details

0001104659-12-057017.txt : 20120810 0001104659-12-057017.hdr.sgml : 20120810 20120810163052 ACCESSION NUMBER: 0001104659-12-057017 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 11 CONFORMED PERIOD OF REPORT: 20120630 FILED AS OF DATE: 20120810 DATE AS OF CHANGE: 20120810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CombiMatrix Corp CENTRAL INDEX KEY: 0001383183 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 470899439 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-33523 FILM NUMBER: 121024931 BUSINESS ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-753-0624 MAIL ADDRESS: STREET 1: 310 GODDARD STREET 2: SUITE 150 CITY: IRVINE STATE: CA ZIP: 92618 10-Q 1 a12-13980_110q.htm 10-Q

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Quarterly Period Ended June 30, 2012

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO .

Commission File Number 001-33523

COMBIMATRIX CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

Delaware		47-0899439
(State or Other Jurisdiction of		(I.R.S. Employer
Incorporation or Organization)		Identification No.)

310 Goddard, Suite 150,
Irvine, CA		92618
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (949) 753-0624

N/A

(Former name, former address and former fiscal year, if changed since last report.)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o		Non-accelerated filer o		Smaller reporting company x
				(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes o No x

As of August 6, 2012, 10,704,121 shares of CombiMatrix Corporation common stock, $0.001 par value were issued and outstanding.

Table of Contents

COMBIMATRIX CORPORATION

Table of Contents

Part I. Financial Information

Item 1.	Financial Statements (Unaudited)

	Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011	3

	Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2012 and 2011	4

	Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2012 and 2011	5

	Notes to Consolidated Financial Statements	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	18

Item 4.	Controls and Procedures	18


Part II. Other Information

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	19

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19

Item 3.	Defaults Upon Senior Securities	19

Item 4.	Mine Safety Disclosures	19

Item 5.	Other Information	19

Item 6.	Exhibits	19


Signatures		20

Exhibit Index		21

Table of Contents

COMBIMATRIX CORPORATION

CONSOLIDATED BALANCE SHEETS

(In thousands)

	June 30,			December 31,
	2012			2011
	(unaudited)
ASSETS

Current assets:
Cash and cash equivalents	$	3,159		$	6,385
Accounts receivable, net of allowance for doubtful accounts of $464 and $333	985			1,462
Supplies	298			476
Prepaid expenses and other assets	145			259
Total current assets	4,587			8,582

Property and equipment, net	504			607
Investments in unconsolidated subsidiaries	127			127
Patents and licenses, net	99			132
Total assets	$	5,317		$	9,448

LIABILITIES AND SHAREHOLDERS’ EQUITY

Current liabilities:
Accounts payable, accrued expenses and other	$	1,060		$	1,004
Current portion, capital lease obligations	114			115
Total current liabilities	1,174			1,119

Capital lease obligations, net of current portion	140			179
Total liabilities	1,314			1,298

Commitments and contingencies

Shareholders’ equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized; none issued and outstanding	—			—
Common stock; $0.001 par value; 25,000,000 shares authorized; 10,704,121 shares issued and outstanding, respectively	11			11
Additional paid-in capital	66,353			66,099
Accumulated net losses	(62,361		)	(57,960		)
Total shareholders’ equity	4,003			8,150
Total liabilities and shareholders’ equity	$	5,317		$	9,448

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share information)

(Unaudited)

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2012			2011			2012			2011

Revenues
Services	$	1,252		$	1,209		$	2,496		$	2,122
Royalty	54			25			79			50
Total revenues	1,306			1,234			2,575			2,172

Operating expenses:
Cost of services	677			693			1,336			1,323
Research and development	342			321			792			660
Sales and marketing	679			671			1,552			1,228
General and administrative	1,569			1,369			3,143			2,695
Patent amortization and royalties	66			66			142			131
Total operating expenses	3,333			3,120			6,965			6,037
Operating loss	(2,027		)	(1,886		)	(4,390		)	(3,865		)
Other income (expense):
Interest income	—			1			1			2
Interest expense	(6		)	(4		)	(12		)	(9		)
Total other expense	(6		)	(3		)	(11		)	(7		)
Net loss from continuing operations	(2,033		)	(1,889		)	(4,401		)	(3,872		)
Income from discontinued operations	—			205			—			236
Net loss	$	(2,033	)	$	(1,684	)	$	(4,401	)	$	(3,636	)

Basic and diluted net loss per share from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.41	)	$	(0.43	)
Basic and diluted net income per share from discontinued operations	—			0.02			—			0.03

Basic and diluted net loss per share	$	(0.19	)	$	(0.16	)	$	(0.41	)	$	(0.40	)

Basic and diluted weighted average common shares outstanding	10,704,121			10,466,912			10,704,121			9,051,518

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

COMBIMATRIX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

	Six Months Ended
	June 30,
	2012			2011

Operating activities:
Net loss	$	(4,401	)	$	(3,636	)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	175			160
Non-cash stock compensation	254			678
Provision for bad debts	278			117
Changes in assets and liabilities:
Accounts receivable	199			(303		)
Supplies, prepaid expenses and other assets	292			(153		)
Accounts payable, accrued expenses and other	56			16
Net cash flows from operating activities	(3,147		)	(3,121		)
Investing activities:
Purchases of property and equipment	(20		)	(50		)
Net cash flows from investing activities	(20		)	(50		)
Financing activities:
Net proceeds from issuance of common stock, net	—			6,638
Repayment of capital lease obligations	(59		)	(35		)
Net cash flows from financing activities	(59		)	6,603

(Decrease) increase in cash and cash equivalents	(3,226		)	3,432
Cash and cash equivalents, beginning	6,385			6,556
Cash and cash equivalents, ending	$	3,159		$	9,988

Non-cash financing activities:
Property and equipment purchased under capital lease	$	19		$	71

The accompanying notes are an integral part of these consolidated financial statements.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. OVERVIEW AND BACKGROUND

CombiMatrix Corporation (the “Company,” “we,” “us” and “our”) was originally incorporated in October 1995 as a California corporation and later reincorporated as a Delaware corporation in September 2000. In December 2002, we merged with and became a wholly owned subsidiary of Acacia Research Corporation (“Acacia”). In December 2006, we filed a registration statement with the U.S. Securities and Exchange Commission (“SEC”) in order to register our common stock as part of a plan to split-off from Acacia (the “Split-Off”). On August 15, 2007 (the “Split-Off Date”), the Split-Off was effected and our common stock became publicly traded on the Nasdaq Stock Market (symbol: “CBMX”). As of the Split-Off Date, we ceased to be a subsidiary of, or affiliated with, Acacia.

Description of the Company

We are a molecular diagnostics company that operates primarily in the field of genetic analysis and molecular diagnostics through our wholly owned subsidiary, CombiMatrix Molecular Diagnostics, Inc. (“CMDX”), located in Irvine, California. CMDX operates as a diagnostics reference laboratory providing DNA-based clinical diagnostic testing services to physicians, hospitals, clinics and other laboratories in two primary areas: (i) prenatal and postnatal developmental disorders; and (ii) hematology/oncology genomics. CMDX provides its services primarily through the use of array-comparative genomic hybridization (“aCGH”), which enables the analysis of genetic anomalies, as well as through other test offerings including fluorescent in-situ hybridization (“FISH”) and G-Band Chromosome analysis. Our mission is to empower physicians to positively impact patient care through the delivery of innovative molecular diagnostics services.

On April 19, 2010, we announced a strategic and operational restructuring plan (the “Restructuring Plan”) intended to significantly reduce operating costs, increase the focus on the Company’s diagnostic services business and transition senior management. As part of the Restructuring Plan, we closed our Mukilteo, Washington facility, which had been focused primarily on research, development and commercialization of the Company’s oligonucleotide microarray technologies, also known as our “CustomArray” business.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, certain information and footnotes required by generally accepted accounting principles in annual financial statements have been omitted or condensed. These interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto for the year ended December 31, 2011, as reported by us in our Annual Report on Form 10-K filed with the SEC on March 16, 2012. The year-end consolidated balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States of America. The consolidated financial statements include all adjustments of a normal recurring nature which, in the opinion of management, are necessary for a fair statement of our financial position as of June 30, 2012, and results of operations and cash flows for the interim periods presented. The results of operations for the three months ended June 30, 2012 are not necessarily indicative of the results to be expected for the entire year.

As a result of executing the Restructuring Plan, the financial results of our CustomArray business have been classified as discontinued operations in the consolidated statements of operations for all periods presented. See Note 3 for additional information regarding discontinued operations. Unless otherwise noted, amounts and disclosures throughout the notes to our consolidated financial statements relate to our continuing operations.

Liquidity and Risks

We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop commercial tests and products.

At June 30, 2012, we had cash and cash equivalents of $3.2 million and anticipate that our cash and cash equivalent balances will be sufficient to meet our cash requirements into the fourth quarter of 2012. The uncertainty regarding our ability to execute our business plans beyond this point raises substantial doubt about our ability to continue as a going concern.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

In order for us to continue as a going concern beyond 2012 and ultimately to achieve profitability, we may be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities would cause dilution to our shareholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including but not limited to personnel across all operational functions, which could jeopardize our future strategic initiatives and business plans.

Our business operations are also subject to certain risks and uncertainties, including:

· market acceptance of our products and services;

· technological advances that may make our products and services obsolete or less competitive;

· increases in operating costs, including costs for supplies, personnel and equipment;

· the availability and cost of capital; and

· government regulation that may restrict our business.

Our services are concentrated in a highly competitive market that is characterized by rapid technological advances, frequent changes in customer requirements and evolving regulatory requirements and industry standards. Failure to anticipate or respond adequately to technological advances, changes in customer requirements, changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of planned products or services, could have a material adverse effect on our business and operating results. The accompanying consolidated financial statements have been prepared assuming that the Company continues as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the matters discussed herein.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic. These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid and individuals. We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests. We report revenues from non-contracted payors based on the amount expected to be collected. The difference between the amount billed and the amount expected to be collected from non-contracted payors is recorded as a contractual allowance to arrive at net recognized revenues. The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate. In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly. We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received. For the three and six months ended June 30, 2012 and 2011, net positive revenue adjustments were $154,000, $375,000, $150,000 and $181,000, respectively. Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make positive or negative adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations.

Cash and Cash Equivalents. We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:

· Level 1: Observable market inputs such as quoted prices in active markets;

· Level 2: Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

· Level 3: Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

Concentration of Credit Risks. Cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for products and services. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Stock-Based Compensation. The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally three years. The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories were as follows (in thousands):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2012			2011			2012		2011

Cost of products and services	$	1		$	16		$	4	$	32
Research and development	2			18			6		37
Sales and marketing	(7		)	17			4		34
General and administrative	85			318			240		607
Discontinued operations	—			(5		)	—		(32		)
Total non-cash stock compensation	$	81		$	364		$	254	$	678

Net Loss Per Share. Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented. Options and warrants to purchase common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share. The following table presents a reconciliation of basic and diluted loss per share from continuing operations for all periods presented (in thousands, except share and per-share data):

	Three Months Ended						Six Months Ended
	June 30,						June 30,
	2012			2011			2012			2011
Numerator:
Loss from continuing operations applicable to common shareholders	$	(2,033	)	$	(1,889	)	$	(4,401	)	$	(3,872	)
Denominator:
Weighted-average common shares outstanding	10,704,121			10,466,912			10,704,121			9,051,518
Basic and diluted loss per share from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.41	)	$	(0.43	)

Common stock options	2,019,536			2,336,018			2,019,536			2,336,018
Common stock warrants	2,807,244			4,894,570			2,807,244			4,894,570
Excluded potentially dilutive securities	4,826,780			7,230,588			4,826,780			7,230,588

Segments. We have determined that we operate in one segment for financial reporting purposes.

Reclassifications. Certain prior period amounts, including royalty revenues, have been reclassified to conform with the current period presentation.

Recent and Adopted Accounting Pronouncements. In July 2011, the Financial Accounting Standards Board (“FASB”) issued an amendment to the accounting standards related to the revenue recognition practices of health care entities that recognize significant amounts of patient service revenues at the time services are rendered even though the entity does not assess the patient’s ability to pay for those services. The amendment requires such entities to classify its provision for bad debts related to such revenues as a reduction from patient service revenues rather than as an operating expense as well as enhanced disclosures about an entity’s policy for recognizing revenue and bad debt expense for patient service transactions along with quantitative information about the effects of changes in the assessment of collectability of patient service revenue. This amendment was effective for us beginning January 1, 2012. Given that we do not recognize significant amounts of patient service revenues from individual payments but primarily from contracted and non-contracted third-party payors, we do not believe this standard is applicable to us and therefore its adoption did not result in a material impact on our consolidated financial position, results of operations or cash flows.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income. This standard revises the manner in which entities present comprehensive income in their financial statements and removes the option to present items of other comprehensive income in the statement of changes in shareholders’ equity. This standard requires an entity to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements of net income and other comprehensive income. The adoption of this standard did not result in a material impact on our consolidated financial position, results of operations or cash flows.

3. RESTRUCTURING

On April 19, 2010, we announced a Restructuring Plan intended to focus our Company on our diagnostic services business while shutting down our CustomArray business. Certain activities relating to completion of our former Department of Defense contracts continued into the first six months of 2011. There have been no activities from discontinued operations subsequent to June 30, 2011.

4. FAIR VALUE MEASUREMENTS

The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2012 and December 31, 2011 and the classification by level of input within the fair value hierarchy defined above (in thousands):

			Fair Value Measurements at
June 30, 2012	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	2,572	$	2,572	$	—	$	—

			Fair Value Measurements at
December 31, 2011	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	5,771	$	5,771	$	—	$	—

5. SHAREHOLDERS’ EQUITY

Equity Financings

There were no equity financing transactions in the periods ended June 30, 2012.

On April 7, 2011 (the “Closing Date”), we completed a private placement transaction (the “Private Placement”) with accredited investors in which we sold $6.76 million of newly-issued shares of our common stock and common stock purchase warrants. Under the terms of the Private Placement, we sold 3.08 million units for $2.193125 per unit. Each unit consisted of one share of CombiMatrix common stock and one warrant to purchase 0.425 shares of common stock at an exercise price of $2.14 per share. The unit price reflects the market value of our common stock as determined by Nasdaq rules plus $0.053125 for the warrant component. The warrants may be exercised beginning six months after the Closing Date and have a term of five years. The proceeds of the transaction, net of legal costs, will be used to fund growth initiatives and for general working capital purposes. No investment banking or advisory fees were paid by the Company. Attorney’s fees and related costs were approximately $122,000, bringing the net proceeds from the Private Placement to $6.64 million.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

Warrants

Outstanding warrants to purchase CombiMatrix stock are as follows:

	Shares of Common Stock
	Issuable from Warrants
	Outstanding as of
	June 30,	December 31,	Exercise
Date of Issue	2012	2011	Price	Expiration

April 2011	1,310,572	1,310,572	$2.14	April 2016
October 2009	30,000	30,000	$7.78	October 2014
May 2009	29,688	29,688	$7.50 - $9.00	May 2014 - June 2014
May 2009	1,100,000	1,100,000	$9.00	May 2014
July 2008	336,984	336,984	$11.87 - $13.65	July 2013
May 2007	—	959,390	$5.50	May 2012
Total	2,807,244	3,766,634

6. COMMITMENTS AND CONTINGENCIES

Human Resources

We provide certain severance benefits such that if an executive officer of CombiMatrix Corporation is terminated for other than cause, death or disability, the executive will receive payments equal to three months’ base salary plus medical and dental benefits. In addition, we have implemented a Restated Executive Change of Control Severance Plan (the “Severance Plan”) that affects certain members of our senior management-level employees who are classified as “Section 16 Officers” of CombiMatrix Corporation. Pursuant to the Severance Plan, if a participating employee is involuntarily terminated (other than for death, disability or for cause) or resigns for “good reason” (as defined in the Severance Plan) during the two-year period following a “change of control” (as defined in the Severance Plan) of the Company, then, subject to execution of a release of claims against the Company, the employee will be entitled to receive: (i) one-half times annual base salary; (ii) immediate vesting of outstanding compensatory equity awards; and (iii) payment of COBRA premiums for the participating employee and eligible dependants for a pre-determined period of time. Payment of benefits under the Severance Plan will be limited by provisions contained in Section 409A of the U.S. Internal Revenue Code. The Severance Plan is administered by a plan administrator, which is the Compensation Committee of the Board of Directors. In order to participate in the Severance Plan, an eligible employee must waive any prior retention or severance agreements.

Litigation

In 2002, we entered into a settlement agreement with Nanogen, Inc. (“Nanogen”) to settle all pending litigation between the parties. Pursuant to the terms of the settlement agreement, we agreed to make quarterly payments to Nanogen equal to 12.5% of total sales of products developed by us and our affiliates based on the patents that had been in dispute in the litigation, up to an annual maximum amount of $1.5 million. The minimum quarterly payments under the settlement agreement are $25,000 per quarter until the patents expire in 2018. Royalty expenses recognized under the agreement were $25,000, $50,000, $25,000, and $50,000, for the three and six months ended June 30, 2012 and 2011, respectively, and are included in patent amortization and royalties in the accompanying consolidated statements of operations.

Table of Contents

COMBIMATRIX CORPORATION

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

(Unaudited)

On February 14, 2011, Relator Michael Strathmann (“Strathmann”) served us with a complaint (“the Complaint”) filed in the Superior Court of the State of California for the County of Orange. The Complaint alleged that we submitted false and fraudulent insurance claims to National Union Fire Insurance Company of Pittsburgh, PA in connection with a prior lawsuit that was settled with Nanogen, Inc., thereby allegedly violating the California Insurance Fraud Prevention Act, and sought penalties and unspecified treble damages. On May 4, 2011, the Superior Court dismissed the Complaint by ordering that it be stricken for violation of the California Anti-SLAPP statute, which prevents plaintiffs from filing abusive lawsuits against public policy. On June 15, 2011, Strathmann filed a Notice of Appeal with the California Court of Appeals, appealing the granting of the Motion to Strike. Subsequently, Strathmann filed a Notice of Appeal of the award of attorneys’ fees against him, which appeals have now been consolidated and are in the briefing stage. Strathmann filed his Opening Brief on January 18, 2012, and we filed our Respondents’ Brief on May 3, 2012. Oral arguments before the California Court of Appeals will take place on August 24, 2012. We believe that this litigation is frivolous and intend to vigorously defend against the appeal, but there can be no assurance that we will ultimately be successful in defending against it.

From time to time, we are subject to other claims and legal actions that arise in the ordinary course of business. We believe that the ultimate liability with respect to these other claims and legal actions, if any, will not have a material effect on our financial position, results of operations or cash flows. Based on a distribution agreement executed between us and Acacia, it is expected that such claims and legal actions attributable to CombiMatrix Corporation prior to the Split-Off Date will remain with us subsequent to the Split-Off Date. As of the date of this report and prior to such date, we are not aware of the existence of any such claims or legal actions.

Table of Contents

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Cautionary Statement

You should read the following discussion and analysis in conjunction with the consolidated financial statements and related notes thereto contained in Part I, Item 1 of this report. The information contained in this Quarterly Report on Form 10-Q is not a complete description of our businesses or the risks associated with an investment in our common stock. We urge you to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the U.S. Securities and Exchange Commission, or “SEC,” including our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the SEC on March 16, 2012.

This report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact included in this report, are forward-looking statements. Reference is made in particular to the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking statements included in this report. Such statements may be identified by the use of forward-looking terminology such as “may,” “will,” “should,” “would,” “could,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “plan,” “predict,” “seek,” “potential,” “continue,” “focus,” “ongoing,” or similar terms, variations of such terms or the negative of such terms, and include, but are not limited to, statements regarding projected results of operations, capital expenditures, earnings, management’s future strategic plans, product development, litigation, regulatory matters, market acceptance and performance of our products and services, the success and effectiveness of our technologies, planned clinical trials by our minority-owned subsidiary, our ability to retain and hire key personnel, the competitive nature of and anticipated growth in our markets, market position of our products and services, marketing efforts and partnerships, liquidity and capital resources, our accounting estimates, and our assumptions and judgments. Such statements are based on management’s current expectations, estimates and projections about our industry, management’s beliefs, and certain assumptions made by us, all of which are subject to change. These forward looking statements are not guarantees of future results and are subject to a number of risks, uncertainties and assumptions that are difficult to predict and that could cause actual results to differ materially and adversely from those described in the forward-looking statements. The risks and uncertainties referred to above include, but are not limited to, our ability to obtain additional financing for working capital on acceptable terms and in a timely manner; our ability to successfully increase the volume of our existing tests, expand the number of tests offered by our laboratory, increase the number of customers and partners and improve reimbursement for our testing; our ability to continue as a going concern; changes in consumer demand; our ability to attract and retain a qualified sales force and key technical personnel; our ability to successfully develop products; our ability to successfully introduce new technologies and services; rapid technological change in our markets; supply availability; the outcome of existing litigation; our ability to bill and obtain reimbursement for highly specialized tests; our ability to comply with regulations to which our business is subject; legislative, regulatory and competitive developments in markets in which we and our subsidiaries operate; our limited market capitalization; future economic conditions; other circumstances affecting anticipated revenues and costs; and other factors as more fully disclosed in our discussion of risk factors in Item 1A of Part II of this report and in the “Risk Factors” described in our Annual Report on Form 10-K for the year ended December 31, 2011 filed with the SEC on March 16, 2012. Additional factors that could cause such results to differ materially from those described in the forward-looking statements are set forth in connection with the forward-looking statements. These forward-looking statements speak only as of the date of this report and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

General

Table of Contents

Prior to 2010, we were primarily focused on developing proprietary DNA array-based tools and instruments for the genetic research community, under the brand formerly known as “CustomArray,” as well as providing molecular diagnostics services through CMDX. On April 19, 2010, we announced a strategic and operational restructuring plan (the “Restructuring Plan”) intended to significantly reduce operating costs, increase the focus on our diagnostic services business and transition senior management. As part of the Restructuring Plan, we closed our CustomArray business and facilities located in Mukilteo, Washington and relocated our corporate headquarters to Irvine, California. Since the restructuring, our primary focus has been on our diagnostics services business. Our goals include increasing utilization of our existing tests, expanding our diagnostic test menu, increasing and diversifying our client base, and improving reimbursement for our testing services.

As a result of executing the Restructuring Plan, the financial results of our CustomArray business have been classified as discontinued operations in the consolidated statements of operations for all periods presented. Unless otherwise noted, amounts and disclosures throughout this report relate to our continuing operations.

We also own a one-third minority interest in Leuchemix, Inc. (“Leuchemix”), a private drug development company focused on developing a series of compounds to address a number of oncology-related diseases.

Overview

For the three and six months ended June 30, 2012, our operating activities included the recognition of $1.3 million and $2.5 million of total revenues, respectively, which increased by $72,000 and $403,000, respectively, from the comparable periods in 2011 due primarily to increased volumes of tests performed as well as an overall increase in our customer base as a result of increased sales and marketing efforts. Our net loss from continuing operations also increased over the comparable periods due to increased operating expenses, partially from increased sales and marketing expenses from expansion of our sales force as well as from increased general and administrative expenses due primarily to increased headcount and from increased litigation costs.

For the six months ended June 30, 2012, our activities included adding Richard Ding, Chief Executive Officer of bioTheranostics Inc., and Joseph M. Limber, President and Chief Executive Officer of Prometheus Laboratories Inc., to our Board of Directors. On April 11, 2012, we announced the hiring of Richard Hockett, MD as our Chief Medical Officer, who joined us on May 1, 2012. Dr. Hockett was formerly the Chief Medical Officer of Affymetrix, Inc. Also, on May 11, 2012, we announced the appointment of Dr. Ronald J. Wapner to our Scientific Advisory Board. Dr. Wapner is the Vice Chair for Research in Obstetrics and Gynecology for Columbia University Medical Center and Director of Reproductive Genetics. He pioneered the development of chorionic villus sampling (CVS) and multi-fetal reduction, and has authored more than 250 publications. Dr. Wapner is also an active investigator in the area of Maternal-Fetal Medicine and the principal investigator for the recently completed National Institute of Child Health and Human Development (NICHD)-sponsored prospective, multi-center study comparing chromosomal microarray testing to karyotyping.

Critical Accounting Estimates

Our unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. Preparation of these statements requires management to make judgments and estimates. Some accounting policies have a significant impact on amounts reported in these financial statements. A summary of significant accounting policies and a description of accounting policies that are considered critical may be found in our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the SEC on March 16, 2012, in the Notes to the Consolidated Financial Statements and the Critical Accounting Estimates sections. In addition, refer to Note 2 to the consolidated interim financial statements included in Part I, Item 1 of this report.

Table of Contents

Comparison of the Results of Operations for the Three and Six Months Ended June 30, 2012 and 2011

Revenues and Cost of Revenues (dollars in thousands):

	Three Months Ended									Six Months Ended
	June 30,						Change			June 30,						Change
	2012			2011			$		%	2012			2011			$			%

Services	$	1,252		$	1,209		$	43	4%	$	2,496		$	2,122		$	374		18%
Royalties	54			25			29		116%	79			50			29			58%
Cost of services	(677		)	(693		)	16		2%	(1,336		)	(1,323		)	(13		)	(1%)

Services. Services revenues are generated from providing DNA-based genomic testing services primarily in the areas of prenatal and postnatal development disorders in children and, to a lesser extent, in oncology. Services revenues increased primarily due to volume increases of our genomic tests. Billable test volumes were 1,459 and 2,836 for the three and six months ended June 30, 2012, respectively, compared to 1,201 and 2,159 for the comparable respective periods in 2011. For the six months ended June 30, 2012 and 2011, our average revenue per test was approximately $880 and $983, respectively. This decrease was due primarily to the introduction of additional cytogenetic tests, primarily FISH and chromosome analysis, that are priced and reimbursed at lower rates than our array-based test offerings as well as from a change in mix of tests performed for customers with governmental third-party insurance coverage including various state Medicaid programs and Medicare, which tend to have lower reimbursement per test than do commercial insurance or direct-bill customers. Services revenues also includes adjustments relating to our revenue recognition policy of periodically adjusting our estimate for contractual allowances for revenues from non-contracted payors as well as from receiving cash payments in excess of amounts previously recognized for services revenues. For the three and six months ended June 30, 2012 and 2011, net positive revenue adjustments were $154,000, $375,000, $150,000 and $181,000, respectively.

Royalties. In 2010, we entered into an exclusive licensing agreement with CustomArray, Inc. (“CA”), a private company located in Washington State, for certain of our patents and intellectual property developed as part of our prior microarray manufacturing business. This agreement requires CA to pay us royalties as a percentage of their gross revenues, not less than $25,000 per quarter. During the quarter ended June 30, 2012, CA’s gross revenues exceeded the minimum threshold stipulated in the agreement, resulting in higher royalties than previous periods, which up until the current quarter have never exceeded the minimum threshold. It is uncertain whether CA’s revenues will continue at current levels or return to the minimum payments in future periods.

Cost of Services. Cost of services includes direct materials such as array and laboratory costs, direct laboratory labor (wages and benefits), allocation of overhead and stock-compensation expenses. Due primarily to favorable pricing obtained on certain of our direct materials used in providing our services, the percentage changes from 2011 to 2012 is not proportional to the change in revenues during the same period. For the three and six months ended June 30, 2012 and 2011, cost of services included $1,000, $4,000 $16,000 and $32,000, respectively, of non-cash stock compensation expense. See Note 2 to our consolidated interim financial statements included elsewhere in this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

Operating Expenses (dollars in thousands):

	Three Months Ended							Six Months Ended
	June 30,				Change			June 30,				Change
	2012		2011		$		%	2012		2011		$		%

Research and development	$	342	$	321	$	21	7%	$	792	$	660	$	132	20%
Sales and marketing	679		671		8		1%	1,552		1,228		324		26%
General and administrative	1,569		1,369		200		15%	3,143		2,695		448		17%

Research and Development. These expenses include labor and laboratory supply costs associated with investigating and validating new tests, costs to maintain and improve our existing suite of diagnostic tests offered and process improvement projects. Prior to launching a new test or modifying an existing test, appropriate clinical trials and extensive laboratory validations, consistent with the various regulations that govern our industry, must be performed. These costs are classified as research and development for all periods presented. The increase in research and development expenses was due primarily to additional labor and materials costs from test validations of new cytogenetics tests that were launched during the first and second quarters of 2012. In addition, for the three and six months ended June 30, 2012 and 2011, research and development expenses included $2,000, $6,000, $18,000 and $37,000, respectively, of non-cash stock compensation expense. The decreases from prior periods were due primarily to prior stock option awards granted to our employees that were or became fully vested during the current periods. See Note 2 to our consolidated interim financial statements included elsewhere in this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

Table of Contents

Sales and Marketing. These expenses include salaries and wages associated with our sales force and marketing resources, sales commissions and other expenses associated with promotional and advertising efforts. The increase in sales and marketing expenses was due to greater emphasis during the first half of 2012 on our sales and marketing efforts in order to expand and increase market awareness and penetration of our suite of molecular diagnostic tests. In addition, for the three and six months ended June 30, 2012 and 2011, sales and marketing expenses (credits) included $(7,000), $4,000, $17,000 and $34,000, respectively, of non-cash stock compensation expense. The decreases from prior periods were due primarily to prior stock option awards granted to our employees that were or became fully vested during the current periods. See Note 2 to our consolidated interim financial statements included elsewhere in this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

General and Administrative. These expenses include compensation and benefit costs of our administrative staff, client billing and collections, information technology, executive management, human resources and accounting personnel, as well as facilities-related costs, insurance, legal, audit and other professional services. General and administrative expenses increased for the three and six months ended June 30, 2012 primarily due to increased headcount in Billing and Information Technology departments, recruitment expenses associated with new board members and executive management and from increased litigation defense costs as compared to 2011. Also included in general and administrative expenses are non-cash stock-based compensation expenses, which were $85,000, $240,000, $318,000 and $607,000 for the three and six months ended June 30, 2012 and 2011, respectively. The decreases from prior periods were due primarily to prior stock option awards granted to our employees that were or became fully vested during the current periods. See Note 2 to our consolidated interim financial statements included elsewhere in this report for a detailed description of the amounts of non-cash stock compensation expense recognized for the periods presented.

Discontinued Operations (dollars in thousands):

	Three Months Ended								Six Months Ended
	June 30,				Change				June 30,				Change
	2012		2011		$			%	2012		2011		$			%

Income (loss) from discontinued operations	$	—	$	205	$	(205	)	(100%)	$	—	$	236	$	(236	)	(100%)

On April 19, 2010, we announced a Restructuring Plan intended to focus our Company on our diagnostic services business while shutting down our CustomArray business. The operations of our former CustomArray business are classified as discontinued operations for all periods presented. Income from final billings on former Department of Defense contracts occurred and was recognized during the first half of 2011.

Inflation

Inflation has not had a significant impact on our business, results of operations or financial condition.

Table of Contents

Liquidity and Capital Resources

At June 30, 2012, cash and cash equivalents totaled $3.2 million, compared to $6.4 million at December 31, 2011. Cash is held primarily in general checking accounts as well as in money market mutual funds backed by U.S. government securities. Working capital at June 30, 2012 was $3.4 million, compared to $7.5 million at December 31, 2011. The change in working capital was due primarily to the impact of net cash flow activities as discussed below. The net change in cash and cash equivalents for the periods presented was comprised of the following (in thousands):

	Six Months Ended
	June 30,
	2012			2011			Change
Net cash provided by (used in):
Operating activities	$	(3,147	)	$	(3,121	)	$	(26	)
Investing activities	(20		)	(50		)	30
Financing activities	(59		)	6,603			(6,662		)
Increase cash and cash equivalents	$	(3,226	)	$	3,432		$	(6,658	)

Operating Activities. Higher cash reimbursement from increased sales, billing and collection efforts experienced during the first six months of 2012 were offset by increased operating expenses described above, resulting in an insignificant change from the comparable 2011 period.

Investing Activities. The decrease in net cash flows used in investing activities was due to a decrease in capital expenditures.

Financing Activities. The decrease in net cash flows from financing activities was due primarily to the $6.64 million of net proceeds received from closing a private placement offering in April of 2011 compared to no such activities during 2012, as well as from higher principal payments from additional capital lease obligations incurred since 2011.

Future Liquidity. We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop commercial services. We believe that our cash and cash equivalent balances, anticipated cash flows from operations and anticipated operating cash savings from our Restructuring Plan will be sufficient to meet our cash requirements into the fourth quarter of 2012. In May 2012, we announced and implemented cost reduction measures, including the restructuring of our sales force and headcount reductions as part of a program to decrease overall expenses and our cash burn. We estimate that the reductions from the headcount and associated expenses alone will result in savings of nearly 300,000 per quarter going forward.

In order for us to continue as a going concern beyond this point and ultimately to achieve profitability, we will be required to obtain capital from external sources, increase revenues and reduce operating costs. However, there can be no assurance that our operations will become profitable or that external sources of financing, including the issuance of debt and/or equity securities, will be available at times and at terms acceptable to us, or at all. The issuance of additional equity or convertible debt securities would also cause dilution to our shareholders. If external financing sources are not available or are inadequate to fund our operations, we will be required to reduce operating costs, including but not limited to reducing personnel across all operational functions, which could jeopardize our future strategic initiatives and business plans. See Note 1 to the consolidated interim financial statements included elsewhere in this report for additional discussion of these matters.

Capital Requirements. We may also encounter unforeseen difficulties that may deplete our capital resources more rapidly than anticipated. As a result, we may be required to seek additional funding through equity, debt or other external financing, and there can be no assurance that additional funding will be available on favorable terms, in a timely fashion or at all. At this time, we have no significant commitments for capital expenditures in 2012 or beyond. However, our long-term capital requirements could be substantial and the adequacy of available funds will depend upon many factors, including:

· the costs of commercialization activities, including sales and marketing costs and capital equipment;

· competing technological developments;

· the creation and formation of strategic partnerships;

· the costs associated with leasing and improving our Irvine, California facility; and

· other factors that may not be within our control.

Table of Contents

Off-Balance Sheet Arrangements

As of June 30, 2012, we did not have any significant off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K promulgated by the SEC. However, we have entered into an operating lease for our laboratory space and corporate offices, totaling approximately 12,200 square feet. We have no significant commitments for capital expenditures in 2012 or beyond. We have executed nine capital leases totaling $477,000 for certain laboratory equipment.

Recent Accounting Pronouncements

Refer to Note 2 to our consolidated interim financial statements included in Part I, Item 1 of this report.

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

Item 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and our principal financial officer concluded that as of June 30, 2012, our disclosure controls and procedures were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods prescribed by the SEC and (ii) accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our last fiscal quarter (the quarter ended June 30, 2012) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

From time to time, we are involved in other litigation arising in the normal course of business. Management believes that resolution of these other matters will not result in any payment that, in the aggregate, would be material to our financial position or results of operations.

Table of Contents

Item 1A. RISK FACTORS

The following risk factors include any and all material changes to, and should be read in conjunction with, the risk factors contained in Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2011, filed with the SEC on March 16, 2012.

We will not be able to meet our cash requirements beyond 2012 without obtaining additional capital from external sources, and if we are unable to do so, we may not be able to continue as a going concern.

We anticipate that our cash and cash equivalents of $3.2 million as of June 30, 2012 will meet our cash requirements into the fourth quarter of 2012. However, in order for us to continue as a going concern beyond that point, we will be required to obtain capital from external sources. If external financing sources are not available in a timely manner or at all, or are inadequate to fund our operations, it could result in reduced revenues and cash flows from the sales of our diagnostic services and/or could jeopardize our ability to launch, market and sell additional products and services necessary to grow and sustain our operations, and we will be required to reduce operating costs, including but not limited to reducing personnel across all operational functions, which could jeopardize our future strategic initiatives and business plans.

Our Common Stock may be delisted by the Nasdaq Capital Market if we cannot maintain Nasdaq’s listing requirements.

We are not currently in compliance with Nasdaq’s minimum bid price requirements. Our common stock is currently listed on the Nasdaq Capital Market which requires that, to maintain this listing, our common stock must continue to trade above $1.00 per share. In May and June 2012, our common stock had failed to meet this criterion for over 30 consecutive trading days. As a result, we were notified by Nasdaq that we have 180 calendar days from June 26, 2012 to regain compliance with Nasdaq Listing Rule 5550(a)(2) by reestablishing a minimum bid price of $1.00 per share or greater for ten consecutive trading days. In the event we do not regain compliance with Rule 5550(a)(2) prior to the expiration of the 180 calendar day period, Nasdaq will provide us with written notification that our securities are subject to delisting from the Nasdaq Capital Market. We cannot assure you that the bid price of our common stock will regain compliance with, or continue to meet, Nasdaq’s minimum listing standard. As a result, the market for your shares may be limited, and it may be difficult for you to sell your shares at an acceptable price, or at all. In addition, a delisting may make it more difficult or expensive for us to raise additional capital in the future.

If we are delisted from the Nasdaq Capital Market, your ability to sell your shares of our common stock would also be limited by the penny stock restrictions, which could further limit the marketability of your shares.

If our common stock is delisted, it would come within the definition of “penny stock” as defined in the Securities Exchange Act of 1934 and would be covered by Rule 15g-9 of the Securities Exchange Act of 1934. That Rule imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors. For transactions covered by Rule 15g-9, the broker-dealer must make a special suitability determination for the purchaser and receive the purchaser’s written agreement to the transaction prior to the sale. Consequently, Rule 15g-9, if it were to become applicable, would affect the ability or willingness of broker-dealers to sell our securities, and accordingly would affect the ability of stockholders to sell their securities in the public market. These additional procedures could also limit our ability to raise additional capital in the future.

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

Item 3. DEFAULTS UPON SENIOR SECURITIES

None.

Item 4. MINE SAFETY DISCLOSURES

Not applicable.

Item 5. OTHER INFORMATION

None.

Item 6. EXHIBITS

An index of exhibits is found on page 21 of this report.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	COMBIMATRIX CORPORATION


	By:	/s/ R. JUDD JESSUP
		R. Judd Jessup
		Chief Executive Officer
		(Principal Executive Officer)


	By:	/s/ SCOTT R. BURELL
		Scott R. Burell
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

Date: August 10, 2012

Table of Contents

EXHIBIT INDEX

Exhibit Number		Description

3.1		Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form S-1 (SEC File No. 333-139679) filed with the SEC on December 26, 2006.
3.2		Certificate of Amendment to Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1A to the Company’s Quarterly Report on Form 10-Q (File No. 001-33523) filed with the SEC on August 14, 2008.
3.3		Second Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 10-K (File No. 001-33523) filed with the SEC on March 18, 2010.
10.1		Employment Agreement for Richard Hockett, M.D. Incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 001-33523) filed with the SEC on May 11, 2012.
31.1		Certification of Chief Executive Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)
31.2		Certification of Chief Financial Officer pursuant to section 302 of the Sarbanes-Oxley Act of 2002 (*)
32.1		Certification of Chief Executive Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
32.2		Certification of Chief Financial Officer pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)
101.0		The following materials from CombiMatrix Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets as of June 30, 2012 and December 31, 2011; (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2012 and 2011; (iii) Consolidated Statements of Cash Flows for the six months ended June 30, 2012 and 2011; and (iv) Notes to Consolidated Financial Statements (**).

(*)		Included herewith.
(**)		Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101.0 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.

EX-31.1 2 a12-13980_1ex31d1.htm EX-31.1

EXHIBIT 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, R. Judd Jessup, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in the Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2012	/s/ R. JUDD JESSUP
	R. Judd Jessup
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 a12-13980_1ex31d2.htm EX-31.2

EXHIBIT 31.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Scott R. Burell, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of CombiMatrix Corporation;

b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 10, 2012	/s/ SCOTT R. BURELL
	Scott R. Burell
	Chief Financial Officer
	(Principal Financial and Accounting Officer)

EX-32.1 4 a12-13980_1ex32d1.htm EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2012, as filed with the Securities and Exchange Commission on August 10, 2012 (the “Report”), I, R. Judd Jessup, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:

	/s/ R. JUDD JESSUP
	R. Judd Jessup
	Chief Executive Officer
	(Principal Executive Officer)
	August 10, 2012

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 (“Section 906”), or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies this report and is being furnished pursuant to Item 601(b)(32) of Regulation S-K promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This certification shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed “filed” by the Registrant for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, or incorporated by reference into any filing under the Securities Act or the Exchange Act, except to the extent that the Registrant specifically incorporates it by reference into such a filing.

EX-32.2 5 a12-13980_1ex32d2.htm EX-32.2

EXHIBIT 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of CombiMatrix Corporation (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2012, as filed with the Securities and Exchange Commission on August 10, 2012 (the “Report”), I, Scott R. Burell, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	By:

	/s/ SCOTT R. BURELL
	Scott R. Burell
	Chief Financial Officer
	(Principal Financial and Accounting Officer)
	August 10, 2012

EX-101.INS 6 cbmx-20120630.xml XBRL INSTANCE DOCUMENT 0001383183 2012-06-30 0001383183 2011-12-31 0001383183 2012-04-01 2012-06-30 0001383183 2011-04-01 2011-06-30 0001383183 2012-01-01 2012-06-30 0001383183 2011-01-01 2011-06-30 0001383183 2010-12-31 0001383183 2011-06-30 0001383183 2012-08-06 0001383183 us-gaap:MinimumMember 2012-06-30 0001383183 us-gaap:MaximumMember 2012-06-30 0001383183 us-gaap:CostOfSalesMember 2012-04-01 2012-06-30 0001383183 us-gaap:CostOfSalesMember 2011-04-01 2011-06-30 0001383183 us-gaap:CostOfSalesMember 2012-01-01 2012-06-30 0001383183 us-gaap:CostOfSalesMember 2011-01-01 2011-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2012-04-01 2012-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2011-04-01 2011-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2012-01-01 2012-06-30 0001383183 us-gaap:ResearchAndDevelopmentExpenseMember 2011-01-01 2011-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2012-04-01 2012-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2011-04-01 2011-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2012-01-01 2012-06-30 0001383183 us-gaap:SellingAndMarketingExpenseMember 2011-01-01 2011-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2012-04-01 2012-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2011-04-01 2011-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2012-01-01 2012-06-30 0001383183 us-gaap:GeneralAndAdministrativeExpenseMember 2011-01-01 2011-06-30 0001383183 us-gaap:SegmentDiscontinuedOperationsMember 2011-04-01 2011-06-30 0001383183 us-gaap:SegmentDiscontinuedOperationsMember 2011-01-01 2011-06-30 0001383183 us-gaap:StockOptionsMember 2012-04-01 2012-06-30 0001383183 us-gaap:StockOptionsMember 2011-04-01 2011-06-30 0001383183 us-gaap:StockOptionsMember 2012-01-01 2012-06-30 0001383183 us-gaap:StockOptionsMember 2011-01-01 2011-06-30 0001383183 us-gaap:WarrantMember 2012-04-01 2012-06-30 0001383183 us-gaap:WarrantMember 2011-04-01 2011-06-30 0001383183 us-gaap:WarrantMember 2012-01-01 2012-06-30 0001383183 us-gaap:WarrantMember 2011-01-01 2011-06-30 0001383183 us-gaap:FairValueInputsLevel1Member 2012-06-30 0001383183 2012-12-31 0001383183 us-gaap:FairValueInputsLevel1Member 2012-12-31 0001383183 cbmx:GrossMember 2012-01-01 2012-06-30 0001383183 cbmx:PerWarrantMember 2012-06-30 0001383183 cbmx:WarrantComponentMember 2012-06-30 0001383183 cbmx:NetMember 2012-01-01 2012-06-30 0001383183 cbmx:April2011Member 2012-06-30 0001383183 cbmx:April2011Member 2011-12-31 0001383183 cbmx:April2011Member 2012-01-01 2012-06-30 0001383183 cbmx:October2009Member 2012-06-30 0001383183 cbmx:October2009Member 2011-12-31 0001383183 cbmx:October2009Member 2012-01-01 2012-06-30 0001383183 cbmx:May2009Member 2012-06-30 0001383183 cbmx:May2009Member 2011-12-31 0001383183 cbmx:May2009Member us-gaap:MinimumMember 2012-01-01 2012-06-30 0001383183 cbmx:May2009Member us-gaap:MaximumMember 2012-01-01 2012-06-30 0001383183 cbmx:May2009IIMember 2012-06-30 0001383183 cbmx:May2009IIMember 2011-12-31 0001383183 cbmx:May2009IIMember 2012-01-01 2012-06-30 0001383183 cbmx:July2008Member 2012-06-30 0001383183 cbmx:July2008Member 2011-12-31 0001383183 cbmx:July2008Member us-gaap:MinimumMember 2012-01-01 2012-06-30 0001383183 cbmx:July2008Member us-gaap:MaximumMember 2012-01-01 2012-06-30 0001383183 cbmx:May2007Member 2011-12-31 0001383183 cbmx:May2007Member 2012-01-01 2012-06-30 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure

3159000

6385000

985000

1462000

464000

333000

298000

476000

145000

259000

4587000

8582000

504000

607000

127000

99000

132000

5317000

9448000

1060000

1004000

114000

115000

1174000

1119000

140000

179000

1314000

1298000

0.001

5000000

11000

0.001

25000000

10704121

66353000

66099000

-62361000

-57960000

4003000

8150000

5317000

9448000

1252000

1209000

2496000

2122000

54000

25000

79000

50000

1306000

1234000

2575000

2172000

677000

693000

1336000

1323000

342000

321000

792000

660000

679000

671000

1552000

1228000

1569000

1369000

3143000

2695000

66000

142000

131000

3333000

3120000

6965000

6037000

-2027000

-1886000

-4390000

-3865000

1000

2000

6000

4000

12000

9000

-6000

-3000

-11000

-7000

-2033000

-1889000

-4401000

-3872000

205000

236000

-2033000

-1684000

-4401000

-3636000

-0.19

-0.18

-0.41

-0.43

0.02

0.03

-0.19

-0.16

-0.41

-0.40

10704121

10466912

10704121

9051518

175000

160000

254000

678000

278000

117000

-199000

303000

-292000

153000

56000

16000

-3147000

-3121000

20000

50000

-20000

-50000

6638000

59000

35000

-59000

6603000

-3226000

3432000

6556000

9988000

19000

71000

CombiMatrix Corp 10-Q --12-31 10704121 false 0001383183 Yes No Smaller Reporting Company No 2012 Q2 2012-06-30

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> 2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Use of Estimates.  The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Principles of Consolidation.  The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries.  Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method.  Material intercompany transactions and balances have been eliminated in consolidation.  Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method.  The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Revenue Recognition. We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic.  These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid and individuals.  We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests.  We report revenues from non-contracted payors based on the amount expected to be collected.  The difference between the amount billed and the amount expected to be collected from non-contracted payors is recorded as a contractual allowance to arrive at net recognized revenues.  The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate.  In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly.  We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received.  For the three and six months ended June 30, 2012 and 2011, net positive revenue adjustments were $154,000, $375,000, $150,000 and $181,000, respectively.  Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make positive or negative adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Cash and Cash Equivalents.  We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Fair Value Measurements.  We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.  As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.  We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </div> <table border="0" cellpadding="0" cellspacing="0" id="hangingindent-6" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 18pt">   </td> <td align="right" style="WIDTH: 18pt"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> · </div> </td> <td align="left"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> Level 1:    Observable market inputs such as quoted prices in active markets; </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" id="hangingindent-7" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 18pt">   </td> <td align="right" style="WIDTH: 18pt"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> · </div> </td> <td align="left"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> Level 2:    Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and </div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" id="hangingindent-8" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr valign="top"> <td style="WIDTH: 18pt">   </td> <td align="right" style="WIDTH: 18pt"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> · </div> </td> <td align="left"> <div style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> Level 3:    Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions. </div> </td> </tr> </table> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Concentration of Credit Risks.  Cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits.  We have not experienced any significant losses on our deposits of cash and cash equivalents. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Accounts Receivable and Allowance for Doubtful Accounts.  Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for products and services.  An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals.  The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments.  Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts.  We also review the age of receivables by payor class to assess our allowance at each period end.  The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant.  Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.  Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.  Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Stock-Based Compensation.  The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally three years.  The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.  Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate.  We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.  Stock-based compensation expense for all periods presented attributable to our functional expense categories were as follows (in thousands): </div> <table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Three Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Six Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" width="48%">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cost of products and services </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 16 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 4 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 32 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Research and development </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 2 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 18 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 6 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 37 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Sales and marketing </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> (7 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> ) </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 17 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 4 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 34 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> General and administrative </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 85 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 318 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 240 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 607 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Discontinued operations </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> (5 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> (32 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> ) </td> </tr> <tr> <td valign="bottom" width="48%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> Total non-cash stock compensation </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 81 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 364 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 254 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 678 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Net Loss Per Share.  Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented.  Options and warrants to purchase common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share.  The following table presents a reconciliation of basic and diluted loss per share from continuing operations for all periods presented (in thousands, except share and per-share data): </div> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Three Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Six Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Numerator: </div> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> Loss from continuing operations applicable to common shareholders </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (2,033 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (1,889 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (4,401 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (3,872 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Denominator: </div> </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Weighted-average common shares outstanding </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,704,121 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,466,912 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,704,121 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 9,051,518 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> Basic and diluted loss per share from continuing operations </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.19 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.18 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.41 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.43 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> </tr> <tr> <td valign="bottom" width="52%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Common stock options </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,019,536 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,336,018 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,019,536 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,336,018 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Common stock warrants </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 2,807,244 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 4,894,570 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 2,807,244 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 4,894,570 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Excluded potentially dilutive securities </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 4,826,780 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 7,230,588 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 4,826,780 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 7,230,588 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Segments.  We have determined that we operate in one segment for financial reporting purposes. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Reclassifications.  Certain prior period amounts, including royalty revenues, have been reclassified to conform with the current period presentation. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Recent and Adopted Accounting Pronouncements.  In July 2011, the Financial Accounting Standards Board (“FASB”) issued an amendment to the accounting standards related to the revenue recognition practices of health care entities that recognize significant amounts of patient service revenues at the time services are rendered even though the entity does not assess the patient’s ability to pay for those services.  The amendment requires such entities to classify its provision for bad debts related to such revenues as a reduction from patient service revenues rather than as an operating expense as well as enhanced disclosures about an entity’s policy for recognizing revenue and bad debt expense for patient service transactions along with quantitative information about the effects of changes in the assessment of collectability of patient service revenue.  This amendment was effective for us beginning January 1, 2012.  Given that we do not recognize significant amounts of patient service revenues from individual payments but primarily from contracted and non-contracted third-party payors, we do not believe this standard is applicable to us and therefore its adoption did not result in a material impact on our consolidated financial position, results of operations or cash flows. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income.  This standard revises the manner in which entities present comprehensive income in their financial statements and removes the option to present items of other comprehensive income in the statement of changes in shareholders’ equity.  This standard requires an entity to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements of net income and other comprehensive income.  The adoption of this standard did not result in a material impact on our consolidated financial position, results of operations or cash flows. </div>

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation .The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries.Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method.Material intercompany transactions and balances have been eliminated in consolidation.Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method.The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

0.20

0.50

0.20

Revenue Recognition . We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic.These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid and individuals.We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests.We report revenues from non-contracted payors based on the amount expected to be collected.The difference between the amount billed and the amount expected to be collected from non-contracted payors is recorded as a contractual allowance to arrive at net recognized revenues.The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate.In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly.We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received.For the three and six months ended June 30, 2012 and 2011, net positive revenue adjustments were $154,000, $375,000, $150,000 and $181,000, respectively.Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make positive or negative adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations.

154000 375000 150000 181000

Cash and Cash Equivalents .We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.

Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable market inputs such as quoted prices in active markets; Level 2: Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

Concentration of Credit Risks .Cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits.We have not experienced any significant losses on our deposits of cash and cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for products and services.An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals.The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments.Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts.We also review the age of receivables by payor class to assess our allowance at each period end.The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant.Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.

Stock-Based Compensation .The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award) which is generally three years.The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate.We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.Stock-based compensation expense for all periods presented attributable to our functional expense categories were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2012 2011 2012 2011 Cost of products and services $ 1 $ 16 $ 4 $ 32 Research and development 2 18 6 37 Sales and marketing (7 ) 17 4 34 General and administrative 85 318 240 607 Discontinued operations - (5 ) - (32 ) Total non-cash stock compensation $ 81 $ 364 $ 254 $ 678

Net Loss Per Share .Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented.Options and warrants to purchase common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share.The following table presents a reconciliation of basic and diluted loss per share from continuing operations for all periods presented (in thousands, except share and per-share data): Three Months Ended June 30, Six Months Ended June 30, 2012 2011 2012 2011 Numerator: Loss from continuing operations applicable to common shareholders $ (2,033 ) $ (1,889 ) $ (4,401 ) $ (3,872 ) Denominator: Weighted-average common shares outstanding 10,704,121 10,466,912 10,704,121 9,051,518 Basic and diluted loss per share from continuing operations $ (0.19 ) $ (0.18 ) $ (0.41 ) $ (0.43 ) Common stock options 2,019,536 2,336,018 2,019,536 2,336,018 Common stock warrants 2,807,244 4,894,570 2,807,244 4,894,570 Excluded potentially dilutive securities 4,826,780 7,230,588 4,826,780 7,230,588

Segments. We have determined that we operate in one segment for financial reporting purposes.

Reclassifications .Certain prior period amounts, including royalty revenues, have been reclassified to conform with the current period presentation.

Recent and Adopted Accounting Pronouncements .In July 2011, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting standards related to the revenue recognition practices of health care entities that recognize significant amounts of patient service revenues at the time services are rendered even though the entity does not assess the patient's ability to pay for those services.The amendment requires such entities to classify its provision for bad debts related to such revenues as a reduction from patient service revenues rather than as an operating expense as well as enhanced disclosures about an entity's policy for recognizing revenue and bad debt expense for patient service transactions along with quantitative information about the effects of changes in the assessment of collectability of patient service revenue.This amendment was effective for us beginning January 1, 2012.Given that we do not recognize significant amounts of patient service revenues from individual payments but primarily from contracted and non-contracted third-party payors, we do not believe this standard is applicable to us and therefore its adoption did not result in a material impact on our consolidated financial position, results of operations or cash flows. In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income.This standard revises the manner in which entities present comprehensive income in their financial statements and removes the option to present items of other comprehensive income in the statement of changes in shareholders' equity.This standard requires an entity to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements of net income and other comprehensive income.The adoption of this standard did not result in a material impact on our consolidated financial position, results of operations or cash flows.

<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Three Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Six Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" width="48%">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cost of products and services </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 16 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 4 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 32 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Research and development </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 2 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 18 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 6 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 37 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Sales and marketing </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> (7 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left"> ) </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 17 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 4 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 34 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> General and administrative </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 85 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 318 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 240 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 607 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Discontinued operations </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> (5 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> (32 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px"> ) </td> </tr> <tr> <td valign="bottom" width="48%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> Total non-cash stock compensation </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 81 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 364 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 254 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 678 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table>

1000

16000

4000

32000

2000

18000

6000

37000

-7000

17000

4000

34000

85000

318000

240000

607000

-5000

-32000

81000

364000

254000

678000

<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Three Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Six Months Ended </div>June 30, </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2012 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> 2011 </div> </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Numerator: </div> </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> <td valign="bottom">   </td> <td colspan="2" valign="bottom">   </td> <td nowrap="nowrap" valign="bottom" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> Loss from continuing operations applicable to common shareholders </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (2,033 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (1,889 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (4,401 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (3,872 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Denominator: </div> </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Weighted-average common shares outstanding </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,704,121 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,466,912 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 10,704,121 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 9,051,518 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: -9pt; DISPLAY: block; MARGIN-LEFT: 18pt; MARGIN-RIGHT: 0pt" align="left"> Basic and diluted loss per share from continuing operations </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.19 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.18 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.41 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> (0.43 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px"> ) </td> </tr> <tr> <td valign="bottom" width="52%">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Common stock options </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,019,536 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,336,018 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,019,536 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="TEXT-ALIGN: right"> 2,336,018 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Common stock warrants </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 2,807,244 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 4,894,570 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 2,807,244 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 4,894,570 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="52%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Excluded potentially dilutive securities </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 4,826,780 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 7,230,588 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 4,826,780 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="9%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 7,230,588 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table>

2019536

2336018

2019536

2336018

2807244

4894570

2807244

4894570

4826780

7230588

4826780

7230588

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> 4.     FAIR VALUE MEASUREMENTS </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> The following table summarizes, for each major category of financial assets measured on a recurring basis, the respective fair value at June 30, 2012 and December 31, 2011 and the classification by level of input within the fair value hierarchy defined above (in thousands): </div> <table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="10" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Fair Value Measurements at </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> June 30, 2012 </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Total </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 1 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 2 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 3 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Assets: </div> </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cash equivalents </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 2,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 2,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table> <table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="10" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Fair Value Measurements at </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> December 31, 2011 </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Total </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 1 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 2 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 3 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Assets: </div> </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cash equivalents </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 5,771 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 5,771 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table>

<table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="10" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Fair Value Measurements at </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> June 30, 2012 </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Total </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 1 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 2 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 3 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Assets: </div> </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cash equivalents </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 2,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 2,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table><table cellpadding="0" cellspacing="0" width="90%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="48%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="10" valign="bottom" width="37%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Fair Value Measurements at </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> December 31, 2011 </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Total </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 1 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 2 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Level 3 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="48%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Assets: </div> </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> </tr> <tr> <td align="left" valign="bottom" width="48%" style="PADDING-BOTTOM: 4px; TEXT-INDENT: 9pt"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 9pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Cash equivalents </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 5,771 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 5,771 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left"> $ </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> </tr> </table>

2572000

5771000

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> 5.     SHAREHOLDERS’ EQUITY </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Equity Financings </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> There were no equity financing transactions in the periods ended June 30, 2012. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> On April 7, 2011 (the “Closing Date”), we completed a private placement transaction (the “Private Placement”) with accredited investors in which we sold $6.76 million of newly-issued shares of our common stock and common stock purchase warrants.  Under the terms of the Private Placement, we sold 3.08 million units for $2.193125 per unit.  Each unit consisted of one share of CombiMatrix common stock and one warrant to purchase 0.425 shares of common stock at an exercise price of $2.14 per share.  The unit price reflects the market value of our common stock as determined by Nasdaq rules plus $0.053125 for the warrant component.  The warrants may be exercised beginning six months after the Closing Date and have a term of five years.  The proceeds of the transaction, net of legal costs, will be used to fund growth initiatives and for general working capital purposes. No investment banking or advisory fees were paid by the Company.  Attorney’s fees and related costs were approximately $122,000, bringing the net proceeds from the Private Placement to $6.64 million. </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Warrants </div> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 18pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"> Outstanding warrants to purchase CombiMatrix stock are as follows: </div> <table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"> <tr> <td valign="bottom" width="29%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="6" valign="bottom" width="24%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Shares of Common Stock </div>Issuable from Warrants </div>Outstanding as of </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="3" valign="bottom" width="12%" style="PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td colspan="3" valign="bottom" width="31%" style="PADDING-BOTTOM: 2px">   </td> </tr> <tr> <td align="left" valign="bottom" width="29%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Date of Issue </div> </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> June 30, </div>2012 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="2" valign="bottom" width="11%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> December 31, </div>2011 </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td colspan="3" valign="bottom" width="12%" style="BORDER-BOTTOM: black 2px solid"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"> Exercise </div>Price </div> </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td colspan="3" valign="bottom" width="31%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center"> Expiration </td> </tr> <tr> <td valign="bottom" width="29%">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="2" valign="bottom" width="11%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td colspan="3" valign="bottom" width="12%">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%">   </td> <td valign="bottom" width="11%">   </td> <td valign="bottom" width="10%">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> April 2011 </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1,310,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1,310,572 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> $2.14 </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%">   </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center"> April 2016 </td> <td valign="bottom" width="10%">   </td> </tr> <tr> <td align="left" valign="bottom" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> October 2009 </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 30,000 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 30,000 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> $7.78 </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%">   </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center"> October 2014 </td> <td valign="bottom" width="10%">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> May 2009 </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 29,688 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 29,688 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> $7.50 </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> - </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left"> $9.00 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right">  May 2014 </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center"> - </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: left"> <div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"> June 2014 </div> </td> </tr> <tr> <td align="left" valign="bottom" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> May 2009 </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1,100,000 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 1,100,000 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> $9.00 </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%">   </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center"> May 2014 </td> <td valign="bottom" width="10%">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="29%"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> July 2008 </div> </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 336,984 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td align="right" valign="bottom" width="1%">   </td> <td valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="TEXT-ALIGN: right"> 336,984 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="1%">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right"> $11.87 </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> - </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left"> $13.65 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%">   </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center"> July 2013 </td> <td valign="bottom" width="10%">   </td> </tr> <tr> <td align="left" valign="bottom" width="29%" style="PADDING-BOTTOM: 2px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> May 2007 </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> - </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right"> 959,390 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: center"> $5.50 </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 2px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">   </td> <td valign="bottom" width="11%" style="TEXT-ALIGN: center; PADDING-BOTTOM: 2px"> May 2012 </td> <td valign="bottom" width="10%" style="PADDING-BOTTOM: 2px">   </td> </tr> <tr style="background-color: #C0FFFF;"> <td align="left" valign="bottom" width="29%" style="PADDING-BOTTOM: 4px"> <div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"> Total </div> </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 2,807,244 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td align="right" valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left">   </td> <td valign="bottom" width="10%" style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right"> 3,766,634 </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="1%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="2%" style="TEXT-ALIGN: left">   </td> <td valign="bottom" width="5%" style="TEXT-ALIGN: right; PADDING-BOTTOM: 4px">   </td> <td nowrap="nowrap" valign="bottom" width="1%" style="TEXT-ALIGN: left; PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="10%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="11%" style="PADDING-BOTTOM: 4px">   </td> <td valign="bottom" width="10%" style="PADDING-BOTTOM: 4px">   </td> </tr> </table>

6760000

3080000

2.193125

0.425

2.14 0.053125

122000

6640000

1310572

2.14

30000

7.78

29688

7.50 9.00

1100000

9.00

336984

11.87 13.65

959390

5.50

2807244

3766634

0.125 1500000 25000

25000

50000

25000

50000

EX-101.SCH 7 cbmx-20120630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Disclosure - Note 1 - Overview and Background link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Note 3 - Restructuring link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Note 4 - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Note 5 - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Note 6 - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Note 4 - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Note 5 - Shareholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Note 1 - Overview and Background (Detail) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) - Stock-Based Compensation by Functional Expense Categories link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) - Reconciliation of Basic and Diluted Loss Per Share link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Note 3 - Restructuring (Detail) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Note 4 - Fair Value Measurements (Detail) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Note 4 - Fair Value Measurements (Detail) - Financial Assets Measured on a Recurring Basis link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Note 5 - Shareholders' Equity (Detail) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Note 5 - Shareholders' Equity (Detail) - Outstanding Warrants link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Note 6 - Commitments and Contingencies (Detail) link:presentationLink link:definitionLink link:calculationLink 000 - Disclosure - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.LAB 8 cbmx-20120630_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Consolidated Balance Sheets (Current Period Unaudited) Consolidated Balance Sheets (Current Period Unaudited) [Abstract] ASSETS ASSETS [Abstract] Current assets: Current assets: [Abstract] Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $464 and $333 Supplies Prepaid expenses and other assets Total current assets Property and equipment, net Investments in unconsolidated subsidiaries Patents and licenses, net Total assets LIABILITIES AND SHAREHOLDERS' EQUITY LIABILITIES AND SHAREHOLDERS' EQUITY [Abstract] Current liabilities: Current liabilities: [Abstract] Accounts payable, accrued expenses and other Current portion, capital lease obligations Total current liabilities Capital lease obligations, net of current portion Total liabilities Commitments and contingencies Shareholders' equity: Shareholders' equity: [Abstract] Preferred stock; $0.001 par value; 5,000,000 shares authorized; none issued and outstanding Common stock; $0.001 par value; 25,000,000 shares authorized; 10,704,121 shares issued and outstanding, respectively Additional paid-in capital Accumulated net losses Total shareholders' equity Total liabilities and shareholders' equity Allowance for doubtful accounts (in Dollars) Preferred stock, par value (in Dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in Dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Consolidated Statements of Operations (Unaudited) Consolidated Statements of Operations (Unaudited) [Abstract] Revenues Revenues [Abstract] Services Royalty Total revenues Operating expenses: Operating expenses: [Abstract] Cost of services Research and development Sales and marketing General and administrative Patent amortization and royalties Total operating expenses Operating loss Other income (expense): Other income (expense): [Abstract] Interest income Interest expense Total other expense Net loss from continuing operations Income from discontinued operations Net loss Basic and diluted net loss per share from continuing operations (in Dollars per share) Basic and diluted net income per share from discontinued operations (in Dollars per share) Basic and diluted net loss per share (in Dollars per share) Basic and diluted weighted average common shares outstanding (in Shares) Consolidated Statements of Cash Flows (Unaudited) Consolidated Statements of Cash Flows (Unaudited) [Abstract] Operating activities: Operating activities: [Abstract] Net loss Adjustments to reconcile net loss to net cash flows from operating activities: Adjustments to reconcile net loss to net cash flows from operating activities: [Abstract] Depreciation and amortization Non-cash stock compensation Provision for bad debts Changes in assets and liabilities: Changes in assets and liabilities: [Abstract] Accounts receivable Supplies, prepaid expenses and other assets Accounts payable, accrued expenses and other Net cash flows from operating activities Investing activities: Investing activities: [Abstract] Purchases of property and equipment Net cash flows from investing activities Financing activities: Financing activities: [Abstract] Net proceeds from issuance of common stock, net Repayment of capital lease obligations Net cash flows from financing activities (Decrease) increase in cash and cash equivalents Cash and cash equivalents, beginning Cash and cash equivalents, ending Non-cash financing activities: Non-cash financing activities: [Abstract] Property and equipment purchased under capital lease Note 1 - Overview and Background Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Note 2 - Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Note 3 - Restructuring Restructuring and Related Activities Disclosure [Text Block] Note 4 - Fair Value Measurements Fair Value Disclosures [Text Block] Note 5 - Shareholders' Equity Stockholders' Equity Note Disclosure [Text Block] Note 6 - Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Significant Accounting Policies (Abstract) Significant Accounting Policies Use of Estimates, Policy [Policy Text Block] Consolidation, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy [Policy Text Block] Concentration Risk Disclosure [Text Block] Receivables, Policy [Policy Text Block] Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] Reclassification, Policy [Policy Text Block] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule of Earnings Per Share Reconciliation [Table Text Block] Fair Value, Assets Measured on Recurring Basis [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Stock-Based Compensation by Functional Expense Categories Stock-Based Compensation by Functional Expense Categories [Abstract] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Segment, Operating Activities [Domain] Non-cash stock compensation Reconciliation of Basic and Diluted Loss Per Share Reconciliation of Basic and Diluted Loss Per Share [Abstract] Antidilutive Securities, Name [Domain] Numerator: Numerator: [Abstract] Loss from continuing operations applicable to common shareholders (in Dollars) Denominator: Denominator: [Abstract] Weighted-average common shares outstanding Basic and diluted loss per share from continuing operations (in Dollars per share) Excluded potentially dilutive securities Financial Assets Measured on a Recurring Basis Financial Assets Measured on a Recurring Basis [Abstract] Fair Value, Measurements, Fair Value Hierarchy [Domain] Assets: Assets: [Abstract] Cash equivalents Outstanding Warrants Outstanding Warrants [Abstract] EquityIssuedSinceInceptionByIssuance [Domain] Range [Domain] Shares of Common Stock Issuable from Warrants Outstanding Exercise Price (in Dollars per share) Number of Markets Diagnostic Tests are Performed Cash and Cash Equivalents, at Carrying Value (in Dollars) Equity Method Investment, Ownership Percentage Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Net Revenue Adjustments (in Dollars) Class of Warrant or Right [Domain] Standard [Domain] Proceeds from Issuance or Sale of Equity (in Dollars) Stockholders' Equity, Other Shares (in Shares) Sale Price Per Share of Stock Unit Common Stock, Shares, Issued (in Shares) Investment Warrants, Exercise Price Payments of Stock Issuance Costs (in Dollars) Litigation Settlement Percentage Maximum Annual Litigation Payment Minimum Quarterly Litigation Payment Royalty Expense Scenario [Axis] Segment, Discontinued Operations [Member] Fair Value, Hierarchy [Axis] Equity Issued Since Inception by Issuance [Axis] (Deprecated 2012-01-31) Research and Development Expense [Member] Warrant [Member] Class of Warrant or Right [Axis] Antidilutive Securities [Axis] Fair Value, Inputs, Level 2 [Member] Cost of Sales [Member] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Scenario, Unspecified [Domain] Range [Axis] Stock Options [Member] Statement, Operating Activities Segment [Axis] Selling and Marketing Expense [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 3 [Member] Maximum [Member] Minimum [Member] General and Administrative Expense [Member] Standard [Axis] Standard [Axis] October 2009 [Member] October 2009 [Member] May 2009II [Member] May 2009 II [Member] Net [Member] Net [Member] Per Warrant [Member] Per Warrant [Member] Warrant Component [Member] Warrant Component [Member] May 2007 [Member] May 2007 [Member] May 2009 [Member] May 2009 [Member] Gross [Member] Gross [Member] July 2008 [Member] EX-101.DEF 9 cbmx-20120630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.PRE 10 cbmx-20120630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.CAL 11 cbmx-20120630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Fair Value Measurements

6 Months Ended

Jun. 30, 2012

Fair Value Disclosures [Text Block]

4. FAIR VALUE MEASUREMENTS

			Fair Value Measurements at
June 30, 2012	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	2,572	$	2,572	$	-	$	-

			Fair Value Measurements at
December 31, 2011	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	5,771	$	5,771	$	-	$	-

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

EXCEL 14 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]F-6$U9F9D95\V9CDW7S0T.3-?.3,U-E]B.#(R M9#$U,61C,V0B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;G-O;&ED871E9%]3=&%T96UE;G1S7V]F7T-A M#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO=&5?,E]3=6UM87)Y7V]F7U-I9VYI9FEC M86YT7SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,U]297-T#I%>&-E;%=O#I%>&-E;%=O5\\+W@Z3F%M93X-"B`@("`\>#I7;W)K5]O9E]3:6=N:69I8V%N=%\Q M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DYO=&5?-5]3:&%R96AO;&1E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DYO M=&5?,5]/=F5R=FEE=U]A;F1?0F%C:V=R;W5N9#$\+W@Z3F%M93X-"B`@("`\ M>#I7;W)K5]O9E]3:6=N M:69I8V%N=%\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E M;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/DYO=&5?,E]3=6UM87)Y7V]F M7U-I9VYI9FEC86YT7S0\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/DYO=&5?-E]# M;VUM:71M96YT#I7;W)K M#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F M-6$U9F9D95\V9CDW7S0T.3-?.3,U-E]B.#(R9#$U,61C,V0-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C5A-69F9&5?-F8Y-U\T-#DS7SDS-39? M8C@R,F0Q-3%D8S-D+U=O'0O:'1M;#L@8VAA2!);F9O2!);F9O2!296=I2!#;VUM;VX@4W1O8VLL M(%-H87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!& M:6QE'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2!796QL+6MN M;W=N(%-E87-O;F5D($ES'0^3F\\'0^2G5N(#,P+`T*"0DR,#$R/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,CQS<&%N/CPO'0^43(\'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6%B;&4L(&%C8W)U960@97AP96YS97,@ M86YD(&]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`V M,#QS<&%N/CPO'0^)FYB'0^)FYBF5D M.R`Q,"PW,#0L,3(Q('-H87)E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]F-6$U9F9D95\V9CDW M7S0T.3-?.3,U-E]B.#(R9#$U,61C,V0-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO9C5A-69F9&5?-F8Y-U\T-#DS7SDS-39?8C@R,F0Q-3%D8S-D M+U=O'0O M:'1M;#L@8VAAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$;G5M<#XU+#`P,"PP,#`\'1087)T7V8U835F9F1E7S9F.3=?-#0Y,U\Y,S4V7V(X,C)D,34Q9&,S M9`T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]F-6$U9F9D95\V9CDW M7S0T.3-?.3,U-E]B.#(R9#$U,61C,V0O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&-E<'0@4VAA6%L='D\+W1D/@T*("`@ M("`@("`\=&0@8VQA'!E;G-E'!E;G-E*3H\+W-T M3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]F-6$U9F9D95\V9CDW7S0T.3-?.3,U-E]B.#(R9#$U,61C M,V0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C5A-69F9&5?-F8Y M-U\T-#DS7SDS-39?8C@R,F0Q-3%D8S-D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4L(&%C8W)U960@97AP96YS M97,@86YD(&]T:&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU M-CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M M96YT('!U7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&IU3X-"B`@(`T* M("`@("`@/&9O;G0@2!O9B!!8V%C M:6$@4F5S96%R8V@@0V]R<&]R871I;VX-"B`@(`T*("`@("`@*"8C.#(R,#M! M8V%C:6$F(S@R,C$[*2XF(S$V,#LF(S$V,#M);B!$96-E;6)E&-H86YG92!#;VUM:7-S:6]N("@F(S@R,C`[4T5#)B,X,C(Q.RD@:6X@;W)D M97(@=&\@2!T6UB;VPZ#0H@("`@(`T*("`@("`@)B,X,C(P.T-" M35@F(S@R,C$[*2XF(S$V,#LF(S$V,#M!3PO M9F]N=#X-"B`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@3X-"B`@(`T*("`@("`@/&9O;G0@7-I2]O;F-O;&]G M>0T*("`@("`-"B`@("`@(&=E;F]M:6-S+B8C,38P.R8C,38P.T--1%@@<')O M=FED97,@:71S('-E0T*("`-"B`@("`@('1H2UC;VUP87)A=&EV92!G96YO;6EC(&AY8G)I M9&EZ871I;VX-"B`@("`@#0H@("`@("`H)B,X,C(P.V%#1T@F(S@R,C$[*2P@ M=VAI8V@@96YA8FQE6)R:61I>F%T:6]N("@F(S@R,C`[1DE32"8C.#(R,3LI(&%N M9`T*("`@#0H@("`@("!'+4)A;F0@0VAR;VUO7-I2!O;B!R97-E87)C:"P-"B`@#0H@("`@("!D979E;&]P;65N="!A;F0@8V]M M;65R8VEA;&EZ871I;VX@;V8@=&AE($-O;7!A;GDF(S@R,3<[6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E. M1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[ M($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY4:&4-"B`@ M(`T*("`@("`@86-C;VUP86YY:6YG(&-O;G-O;&ED871E9"!F:6YA;F-I86P@ M2!A8V-E<'1E9"!A8V-O=6YT:6YG M#0H@("`@#0H@("`@("!P2!G96YE2!A8V-O=6YT:6YG('!R:6YC:7!L97,-"B`@("`- M"B`@("`@(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E M65A6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$ M25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4 M.B`P<'0G(&%L:6=N/3-$:G5S=&EF>3X-"B`@#0H@("`@("`\9F]N="!S='EL M93TS1"=&3TY4+5-464Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@;F]R;6%L)SY,:7%U:61I='D-"B`@("`@#0H@("`@("!A M;F0@4FES:W,\+V9O;G0^#0H@("`@#0H@("`@/"]D:78^/&)R+SX\9&EV('-T M>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,3AP=#L@ M1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=( M5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY790T*("`-"B`@("`@(&AA=F4@ M82!H:7-T;W)Y(&]F(&EN8W5R3X-"B`@(`T*("`@("`@/&9O;G0@2!T;R!E>&5C=71E(&]U2!T;PT*("`@#0H@("`@("!C;VYT:6YU92!A M6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@ M("`@(&]R9&5R(&9O2P@=V4@;6%Y(&)E(')E<75I'1E'1E2!O6QE/3-$)TQ)3D4M M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO M8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG M;CTS1&IU6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SY/=7(-"B`@(`T*("`@("`@8G5S:6YE6QE/3-$)T9/3E0M M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E3X-"B`@("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SYM M87)K970-"B`@("`-"B`@("`@("`@("`@("`@86-C97!T86YC92!O9B!O=7(@ M<')O9'5C=',@86YD('-E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E M3X- M"B`@("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SYT96-H;F]L;V=I8V%L#0H@#0H@("`@("`@("`@("`@(&%D M=F%N8V5S('1H870@;6%Y(&UA:V4@;W5R('!R;V1U8W1S(&%N9"!S97)V:6-E M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@ M#0H@("`@("`@("`@/"]T9#X-"B`@#0H@("`@("`@("`@/'1D('-T>6QE/3-$ M)U=)1%1(.B`Q.'!T)SX-"B`-"B`@("`@("`@("`@(#QD:78@6QE/3-$)T9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R<^#0H@("`@#0H@("`@ M("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q.2XR<'0G/@T*("`@#0H@("`@ M("`@("`@("`\9&EV/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!4:6UE6QE/3-$)U1%6%0M24Y$14Y4.B`P<'0[($U!4D=) M3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)SX-"B`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)V1I6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+V1I=CX-"B`@("`@#0H@("`@("`@("`@/"]T9#X- M"B`@#0H@("`@("`@("`@/'1D('-T>6QE/3-$)U=)1%1(.B`Q.'!T)SX-"B`- M"B`@("`@("`@("`@(#QD:78@3X-"B`@#0H@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!4:6UE2!R87!I9"!T96-H;F]L;V=I8V%L M(&%D=F%N8V5S+"!F2!A;F0-"B`@(`T*("`@("`@8VQA2!R97-U;'0@9G)O;2!T M:&4@;6%T=&5R3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]F-6$U9F9D95\V9CDW7S0T.3-?.3,U-E]B.#(R M9#$U,61C,V0-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C5A-69F M9&5?-F8Y-U\T-#DS7SDS-39?8C@R,F0Q-3%D8S-D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/&1I=B!S='EL93TS M1"=,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q! M63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T M)R!A;&EG;CTS1&IU3X- M"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E34$Q!63H@ M:6YL:6YE)SY52!A;F0@;W5R('=H;VQL>2!O=VYE9"!A;F0@;6%J;W)I='DM;W=N960- M"B`@("`-"B`@("`@('-U8G-I9&EA2!O=VYE2!M971H;V0N)B,Q-C`[)B,Q-C`[5&AE#0H@(`T*("`@ M("`@8V]S="!M971H;V0@:7,@=7-E9"!W:&5R92!W92!M86EN=&%I;B!O=VYE M&ES=',L("AI:2D@9&5L:79E6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY3 M97)V:6-E#0H@(`T*("`@("`@6]R'!E8W1E9"!T;R!B92!C;VQL96-T960@9G)O;0T*("`@#0H@("`@("!N;VXM M8V]N=')A8W1E9"!P87EO6]R6]R(&]R('!A>6]R#0H@(`T*("`@ M("`@9W)O=7`L(&%S(&%P<')O<')I871E+B8C,38P.R8C,38P.TEN(&5A8V@@ M2XF(S$V,#LF(S$V,#M790T* M("`-"B`@("`@(&%L6UE;G1S#0H@#0H@("`@("!T:&%T(&5X8V5E M9"!A;6]U;G1S(&EN:71I86QL>2!R96-O9VYI>F5D+"!I;B!T:&4@<&5R:6]D M('1H90T*(`T*("`@("`@<&%Y;65N=',@87)E(')E8V5I=F5D+B8C,38P.R8C M,38P.T9O`T*("`@("`-"B`@("`@(&UO;G1H M2XF(S$V,#LF(S$V,#M"96-A=7-E(&$@2!L:7%U:60L('-H;W)T M+71E6QE/3-$)U=)1%1(.B`Q.'!T)SX-"B`@#0H@("`@("`@("`@("`@(#QD:78@ M6QE/3-$)V1I6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)SY/8G-E6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!, M05DZ(&)L;V-K.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P M="<^#0H@(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[ M(&9O;G0M9F%M:6QY.B!3>6UB;VPL('-E0T*("`@#0H@("`@("`@("`@("`@("`@;W(@:6YD M:7)E8W1L>3L@86YD/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO9&EV M/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@/"]T M6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%1%6%0M24Y$14Y4.B`P<'0[($1)4U!,05DZ(&)L;V-K M.R!-05)'24XM3$5&5#H@,'!T.R!-05)'24XM4DE'2%0Z(#!P="<^#0H@(`T* M("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q M,'!T)SX\9F]N="!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M M:6QY.B!3>6UB;VPL('-E6QE/3-$)T9/3E0M4U193$4Z(&ET86QI8SL@1$E3 M4$Q!63H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0G/D-O;F-E;G1R871I;VX- M"B`-"B`@("`@(&]F($-R961I="!2:7-K2P@870@=&EM97,L(&5X8V5E9"!F961E2!S:6=N:69I8V%N="!L;W-S97,@;VX@;W5R M(&1E<&]S:71S#0H@#0H@("`@("!O9B!C87-H(&%N9"!C87-H(&5Q=6EV86QE M;G1S+CPO9F]N=#X-"B`@("`-"B`@("`\+V1I=CX\8G(O/CQD:78@3X-"B`@(`T*("`@("`@/&9O;G0@6QE/3-$)T9/3E0M4U19 M3$4Z(&ET86QI8SL@1$E34$Q!63H@:6YL:6YE)SY!8V-O=6YT&AA=7-T960N($%D9&ET:6]N0T*(`T*("`@("`@2X\+V9O;G0^#0H@(`T*("`@(#PO9&EV/CQB'!E;G-E+`T*("`@#0H@("`@("!O;B!A('-T65E)B,X,C$W.W,@2!T:&4@ M=F5S=&EN9R!P97)I;V0@;V8@=&AE(&5Q=6ET>0T*("`@("`-"B`@("`@(&%W M87)D*2!W:&EC:"!I65AF5D M(&]N;'D@9F]R('1H;W-E(&%W87)D'!E8W1E9"!T;R!V M97-T#0H@("`@(`T*("`@("`@=7-I;F<@86X@97-T:6UA=&5D(&9O"<^#0H@("`@#0H@("`@("`@("`@("`@("8C,38P.PT*("`@ M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)TQ)3D4M2$5)1TA4 M.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%2 M1TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N M=&5R/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^2G5N M90T*("`@#0H@("`@("`@("`@("`@(#,P+#PO9F]N=#X-"B`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@ M8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"B`@#0H@("`@ M("`@("`@("`@(#QD:78@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4VEX#0H@("`@#0H@ M("`@("`@("`@("`@("`@36]N=&AS($5N9&5D/"]F;VYT/CPO9F]N=#X-"B`@ M("`@#0H@("`@("`@("`@("`@(#PO9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^2G5N90T*("`@#0H@ M("`@("`@("`@("`@(#,P+#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^ M#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!& M3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@(`T*("`@("`@("`@("`@ M("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%2 M1TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[ M/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q M,CPO9F]N=#X-"B`-"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT M/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO M=&0^#0H@("`@#0H@("`@("`@("`@/"]T6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&-O M;'-P86X],T0R('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)3X-"B`@(`T* M("`@("`@("`@("`@("`F(S$V,#L-"B`@("`@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI M9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4+4%,24=..B!L M969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@ M("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#$Q)3X-"B`@(`T*("`@("`@("`@("`@("`F(S$V,#L-"B`@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)V)A8VMG6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F M;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ/"]F;VYT/@T*("`-"B`@("`@ M("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T* M("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@ M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXQ-CPO9F]N=#X-"B`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY297-E87)C:`T*("`@#0H@ M("`@("`@("`@("`@("`@86YD(&1E=F5L;W!M96YT/"]F;VYT/@T*("`@("`- M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!A;&EG;CTS1')I9VAT('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E/@T*("`@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"=415A4+4%,24=..B!R:6=H="<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0G/@T*("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXS-SPO9F]N=#X-"B`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`- M"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@("`@(#QT6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T* M("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S M='EL93TS1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXQ-SPO9F]N=#X-"B`@ M(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT/"]F;VYT/@T*("`- M"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@;F]W M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS M1"=415A4+4%,24=..B!R:6=H="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&%L:6=N/3-$6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXV,#<\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$)V)A8VMG6QE/3-$)U!!1$1) M3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S M='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P M)2!S='EL93TS1"="3U)$15(M0D]45$]-.B!B;&%C:R`R<'@@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@ M#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9#L@5$58 M5"U!3$E'3CH@;&5F="<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXM/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@("`\=&0@;F]W6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#)P>"!S;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,S(\+V9O;G0^#0H@("`@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=4 M15A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@#0H@ M("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@ M1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T M)SXI/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@ M("`@("`@/"]T6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@.7!T M.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5)) M1TA4.B`P<'0G/@T*(`T*("`@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY4;W1A;`T*("`@("`-"B`@("`@("`@("`@ M("`@("!N;VXM8V%S:"!S=&]C:R!C;VUP96YS871I;VX\+V9O;G0^#0H@(`T* M("`@("`@("`@("`@("`\+V1I=CX-"B`@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXD/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@ M("`@#0H@("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,3`E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`@#0H@("`@("`@("`@("`@(#QF M;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXS-C0\+V9O;G0^#0H@ M("`@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S M='EL93TS1"=415A4+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@-'!X M)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494 M.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU2!D:79I9&EN9R!T:&4@;F5T(&QO6QE/3-$)T9/3E0M1D%- M24Q9.B!T:6UE6QE M/3-$)U1%6%0M04Q)1TXZ(&-E;G1E"<^ M#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^/&9O;G0@"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1"=415A4+4%,24=..B!C96YT97([(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI M9#L@5$585"U!3$E'3CH@8V5N=&5R)SX-"B`@("`@#0H@("`@("`@("`@("`@ M(#QD:78@6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^4VEX#0H@("`@#0H@("`@("`@("`@ M("`@("`@36]N=&AS($5N9&5D/"]F;VYT/CPO9F]N=#X-"B`@("`@#0H@("`@ M("`@("`@("`@(#PO9&EV/CQF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^2G5N90T*("`@#0H@("`@("`@("`@ M("`@(#,P+#PO9F]N=#X-"B`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@;F]W6QE/3-$)U!!1$1)3D"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^,C`Q,3PO9F]N=#X-"B`- M"B`@("`@("`@("`@("`@/"]D:78^#0H@(`T*("`@("`@("`@("`@/"]T9#X- M"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N M/3-$8F]T=&]M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q M-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@8V]L6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^#0H@("`@ M(`T*("`@("`@("`@("`@("`\9&EV('-T>6QE/3-$)TQ)3D4M2$5)1TA4.B`Q M+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE. M+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$8V5N=&5R M/@T*("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@"<^#0H@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q M-C`[/"]F;VYT/@T*("`@("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@ M("`@("`@("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)U!!1$1) M3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P M=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M(&-O;'-P86X],T0R('9A;&EG;CTS1&)O='1O;3X-"B`-"B`@("`@("`@("`@ M("`@)B,Q-C`[#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@("`-"B`@("`@("`@ M("`@("`@/&9O;G0@6QE/3-$)U!! M1$1)3D6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,BPP,S,\+V9O;G0^#0H@(`T*("`@ M("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`] M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXI/"]F;VYT/@T*("`-"B`@("`@("`@ M("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@("`\=&0@86QI9VX],T1R:6=H M="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=0041$24Y' M+4)/5%1/33H@-'!X)SX-"B`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@ M("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS M1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L M86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@ M("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD M/"]F;VYT/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@ M("`@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)U!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXH,RPX-S(\ M+V9O;G0^#0H@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY796EG:'1E9"UA=F5R M86=E#0H@#0H@("`@("`@("`@("`@("`@8V]M;6]N('-H87)E6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN M;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I% M.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T* M("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS M1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[ M(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O M;G0@6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$ M25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXQ,"PT-C8L.3$R/"]F;VYT/@T*(`T*("`@("`@ M("`@("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(&QE9G0G M/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K M(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS M1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I M9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B M;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`-"B`@("`@("`@("`@("`@ M/&9O;G0@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9 M.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\ M+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W M:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*(`T* M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T*("`@("`-"B`@ M("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`@("`-"B`@("`@ M("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SX-"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX- M"B`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G M/@T*(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I M;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY#;VUM;VX-"B`-"B`@("`@("`@("`@("`@ M("!S=&]C:R!O<'1I;VYS/"]F;VYT/@T*("`@#0H@("`@("`@("`@("`@(#PO M9&EV/@T*("`-"B`@("`@("`@("`@(#PO=&0^#0H@("`@#0H@("`@("`@("`@ M("`\=&0@86QI9VX],T1R:6=H="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)3X-"B`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXR+#`Q.2PU,S8\ M+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@("`@ M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D]. M5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF M(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@ M("`@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M("`@("`-"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/@T* M(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI M;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1) M4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@ M1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@ M("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O M;2!W:61T:#TS1#DE('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SX-"B`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXR+#,S-BPP,3@\+V9O;G0^#0H@("`@(`T*("`@("`@("`@ M("`@/"]T9#X-"B`@("`-"B`@("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R M87`@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@ M("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T*("`@("`@ M("`@(#QT6QE/3-$)U!!1$1)3D"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N M/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N M="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE M6QE/3-$)T1)4U!,05DZ M(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U3 M25I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D M/@T*("`@(`T*("`@("`@("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-0 M3$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V M,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@ M("`@("`@/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@ M("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/ M3E0M1D%-24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@(#PO='(^#0H@(`T* M("`@("`@("`@(#QT6QE/3-$ M)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA M;CL@1D].5"U325I%.B`Q,'!T)SY%>&-L=61E9`T*("`@#0H@("`@("`@("`@ M("`@("`@<&]T96YT:6%L;'D@9&EL=71I=F4@6QE/3-$)U!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!,05DZ(&EN;&EN M93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q M,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@ M(`T*("`@("`@("`@("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1% M6%0M04Q)1TXZ(&QE9G0G/@T*("`@#0H@("`@("`@("`@("`@(#QF;VYT('-T M>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@#0H@ M("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#DE('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ M(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT)SX-"B`@("`- M"B`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O M;G0^#0H@#0H@("`@("`@("`@("`\+W1D/@T*("`@(`T*("`@("`@("`@("`@ M/'1D(&%L:6=N/3-$"<^#0H@(`T*("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXT+#@R-BPW M.#`\+V9O;G0^#0H@("`@(`T*("`@("`@("`@("`@/"]T9#X-"B`@("`-"B`@ M("`@("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@"<^#0H@(`T*("`@("`@("`@("`@("`\9F]N="!S='EL M93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)U!! M1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4 M+4E.1$5.5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P M<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,3AP=#L@1$E3 M4$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@ M,'!T)R!A;&EG;CTS1&IU6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2 M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX\9F]N="!S='EL93TS1"=&3TY4+5-4 M64Q%.B!I=&%L:6,[($1)4U!,05DZ(&EN;&EN92<^4F5C;&%S2!R979E;G5E M0T*(`T*("`@("`@,C`Q,2P@=&AE($9I M;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD87)DF4@ M2!F;W(@=&AO2!I=',@<')O=FES:6]N(&9O28C.#(Q-SMS('!O;&EC>2!F;W(-"B`@("`-"B`@("`@ M(')E8V]G;FEZ:6YG(')E=F5N=64@86YD(&)A9"!D96)T(&5X<&5N2`Q+"`R,#$R+B8C,38P.R8C,38P.T=I=F5N#0H@("`@(`T*("`@("`@ M=&AA="!W92!D;R!N;W0@6UE;G1S(&)U="!P6]R6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5. M5#H@,3AP=#L@1$E34$Q!63H@8FQO8VL[($U!4D=)3BU,1494.B`P<'0[($U! M4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS1&IU6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SY);@T*("`-"B`@ M("`@($IU;F4@,C`Q,2P@=&AE($9!4T(@:7-S=65D(&%N(&%M96YD;65N="!T M;R!T:&4@86-C;W5N=&EN9PT*("`@(`T*("`@("`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%]F-6$U9F9D95\V9CDW7S0T.3-?.3,U-E]B.#(R9#$U,61C,V0- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9C5A-69F9&5?-F8Y-U\T M-#DS7SDS-39?8C@R,F0Q-3%D8S-D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R6QE/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!4 M15A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z M(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$;&5F=#X-"B`-"B`@ M("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U) M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=% M24=(5#H@8F]L9"<^,RXF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#LF(S$V,#M2 M15-44E5#5%5224Y'/"]F;VYT/@T*("`-"B`@("`\+V1I=CX\8G(O/CQD:78@ M3X-"B`@(`T*("`@("`@/&9O;G0@ M2!O M;B!O=7(@9&EA9VYO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5S+"!F;W(@96%C:"!M86IO2!O9@T*(`T*("`@("`@9FEN86YC:6%L(&%S2!D969I;F5D(&%B;W9E("AI;B!T:&]U6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1) M3D6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P M>"!S;VQI9"<^#0H@("`@(`T*("`@("`@("`@("`@("`@(#QD:78@"<^#0H@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)TQ)3D4M2$5) M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-03$%9.B!B;&]C:SL@ M34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P<'0G(&%L:6=N/3-$ M;&5F=#X-"B`@(`T*("`@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)U!!1$1) M3D6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^5&]T86P\+V9O;G0^#0H@("`@#0H@("`@("`@("`@("`@("`@ M/"]D:78^#0H@("`@#0H@("`@("`@("`@("`@(#PO=&0^#0H@#0H@("`@("`@ M("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@"<^#0H@("`@#0H@("`@("`@("`@("`@("`@/&9O;G0@"<^#0H@("`@(`T*("`@("`@("`@ M("`@("`@(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U& M04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4 M+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT/@T*("`-"B`@("`@("`@("`@ M("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D(&-O;'-P86X],T0R('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$Q)2!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B!B;&%C:R`R<'@@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D6QE/3-$)T1)4U!, M05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R;VUA;CL@1D]. M5"U325I%.B`Q,'!T.R!&3TY4+5=%24=(5#H@8F]L9"<^)B,Q-C`[/"]F;VYT M/@T*("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@ M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$)U!!1$1) M3D6QE M/3-$)TQ)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,'!T.R!$25-0 M3$%9.B!B;&]C:SL@34%21TE.+4Q%1E0Z(#!P=#L@34%21TE.+5))1TA4.B`P M<'0G(&%L:6=N/3-$8V5N=&5R/@T*("`@("`-"B`@("`@("`@("`@("`@("`@ M(#QF;VYT('-T>6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T.R!&3TY4+5=%24=( M5#H@8F]L9"<^3&5V96P-"B`-"B`@("`@("`@("`@("`@("`@(#(\+V9O;G0^ M#0H@("`-"B`@("`@("`@("`@("`@("`\+V1I=CX-"B`@("`-"B`@("`@("`@ M("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1"=415A4 M+4%,24=..B!L969T.R!0041$24Y'+4)/5%1/33H@,G!X)SX-"B`@("`-"B`@ M("`@("`@("`@("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[ M($9/3E0M1D%-24Q9.B!T:6UE6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#)P>"!S;VQI9"<^ M#0H@("`@#0H@("`@("`@("`@("`@("`@/&1I=B!S='EL93TS1"=,24Y%+4A% M24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#!P=#L@1$E34$Q!63H@8FQO8VL[ M($U!4D=)3BU,1494.B`P<'0[($U!4D=)3BU224=(5#H@,'!T)R!A;&EG;CTS M1&-E;G1E"<^#0H@("`@#0H@("`@("`@("`@("`@ M("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SY!6QE M/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE=R!R M;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`-"B`@ M("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D('9A;&EG M;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`-"B`@("`@("`@("`@("`@("`\ M9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9.B!T M:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S(&YE M=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@("`- M"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`-"B`@("`@("`@("`@("`@ M("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%-24Q9 M.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I;65S M(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^#0H@ M("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@("`@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/@T*("`-"B`@("`@("`@("`@ M("`@("`\9F]N="!S='EL93TS1"=$25-03$%9.B!I;FQI;F4[($9/3E0M1D%- M24Q9.B!T:6UE6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ('1I M;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXF(S$V,#L\+V9O;G0^ M#0H@("`-"B`@("`@("`@("`@("`@/"]T9#X-"B`-"B`@("`@("`@("`@(#PO M='(^#0H@("`@#0H@("`@("`@("`@("`\='(^#0H@("`-"B`@("`@("`@("`@ M("`@/'1D(&%L:6=N/3-$;&5F="!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T M."4@#L@5$585"U)3D1%3E0Z M(#EP="<^#0H@(`T*("`@("`@("`@("`@("`@(#QD:78@"<^#0H@("`@ M#0H@("`@("`@("`@("`@("`@/&9O;G0@6QE/3-$)T1)4U!,05DZ(&EN;&EN93L@1D].5"U&04U)3%DZ M('1I;65S(&YE=R!R;VUA;CL@1D].5"U325I%.B`Q,'!T)SXD/"]F;VYT/@T* M("`@(`T*("`@("`@("`@("`@("`\+W1D/@T*(`T*("`@("`@("`@("`@("`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E('-T>6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#1P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT M)SX-"B`@#0H@("`@("`@("`@("`@("`@/&9O;G0@"<^#0H@("`@#0H@("`@("`@ M("`@("`@("`@/&9O;G0@ XML 15 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Restructuring	6 Months Ended
Jun. 30, 2012
Restructuring and Related Activities Disclosure [Text Block]	3. RESTRUCTURING On April 19, 2010, we announced a Restructuring Plan intended to focus our Company on our diagnostic services business while shutting down our CustomArray business. Certain activities relating to completion of our former Department of Defense contracts continued into the first six months of 2011. There have been no activities from discontinued operations subsequent to June 30, 2011.

Note 3 - Restructuring

6 Months Ended

Jun. 30, 2012

Restructuring and Related Activities Disclosure [Text Block]

3. RESTRUCTURING

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details

XML 16 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Current Period Unaudited) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
ASSETS
Cash and cash equivalents	$ 3,159	$ 6,385
Accounts receivable, net of allowance for doubtful accounts of $464 and $333	985	1,462
Supplies	298	476
Prepaid expenses and other assets	145	259
Total current assets	4,587	8,582
Property and equipment, net	504	607
Investments in unconsolidated subsidiaries	127	127
Patents and licenses, net	99	132
Total assets	5,317	9,448
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable, accrued expenses and other	1,060	1,004
Current portion, capital lease obligations	114	115
Total current liabilities	1,174	1,119
Capital lease obligations, net of current portion	140	179
Total liabilities	1,314	1,298
Commitments and contingencies
Preferred stock; $0.001 par value; 5,000,000 shares authorized; none issued and outstanding	0	0
Common stock; $0.001 par value; 25,000,000 shares authorized; 10,704,121 shares issued and outstanding, respectively	11	11
Additional paid-in capital	66,353	66,099
Accumulated net losses	(62,361)	(57,960)
Total shareholders' equity	4,003	8,150
Total liabilities and shareholders' equity	$ 5,317	$ 9,448

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Overview and Background

6 Months Ended

Jun. 30, 2012

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1. OVERVIEW AND BACKGROUND

Description of the Company

Basis of Presentation

Liquidity and Risks

We have a history of incurring net losses and net operating cash flow deficits. We are also deploying new technologies and continue to develop commercial tests and products.

Our business operations are also subject to certain risks and uncertainties, including:

market acceptance of our products and services;

technological advances that may make our products and services obsolete or less competitive;

increases in operating costs, including costs for supplies, personnel and equipment;

the availability and cost of capital; and

government regulation that may restrict our business.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

XML 18 R22.htm IDEA: XBRL DOCUMENT

Note 5 - Shareholders' Equity (Detail) - Outstanding Warrants (USD $)	6 Months Ended
	Jun. 30, 2012	Dec. 31, 2011
Shares of Common Stock Issuable from Warrants Outstanding	2,807,244	3,766,634
Exercise Price (in Dollars per share)	$ 2.14
April 2011 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,310,572	1,310,572
Exercise Price (in Dollars per share)	$ 2.14
October 2009 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	30,000	30,000
Exercise Price (in Dollars per share)	$ 7.78
May 2009 [Member] \| Minimum [Member]
Exercise Price (in Dollars per share)	$ 7.50
May 2009 [Member] \| Maximum [Member]
Exercise Price (in Dollars per share)	$ 9.00
May 2009 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	29,688	29,688
May 2009 II [Member]
Shares of Common Stock Issuable from Warrants Outstanding	1,100,000	1,100,000
Exercise Price (in Dollars per share)	$ 9.00
July 2008 [Member] \| Minimum [Member]
Exercise Price (in Dollars per share)	$ 11.87
July 2008 [Member] \| Maximum [Member]
Exercise Price (in Dollars per share)	$ 13.65
July 2008 [Member]
Shares of Common Stock Issuable from Warrants Outstanding	336,984	336,984
May 2007 [Member]
Shares of Common Stock Issuable from Warrants Outstanding		959,390
Exercise Price (in Dollars per share)	$ 5.50

XML 19 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 20 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2012

Significant Accounting Policies [Text Block]

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles (“GAAP”) in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Principles of Consolidation. The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries. Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method. Material intercompany transactions and balances have been eliminated in consolidation. Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method. The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.

Cash and Cash Equivalents. We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.

Level 1: Observable market inputs such as quoted prices in active markets;

Level 2: Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and

Level 3: Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.

Concentration of Credit Risks. Cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits. We have not experienced any significant losses on our deposits of cash and cash equivalents.

Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for products and services. An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals. The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments. Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts. We also review the age of receivables by payor class to assess our allowance at each period end. The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant. Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations. Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor. Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.

Stock-Based Compensation. The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee’s requisite service period (generally the vesting period of the equity award) which is generally three years. The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. Stock-based compensation expense for all periods presented attributable to our functional expense categories were as follows (in thousands):

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012		2011

Cost of products and services	$	1		$	16		$	4	$	32
Research and development		2			18			6		37
Sales and marketing		(7	)		17			4		34
General and administrative		85			318			240		607
Discontinued operations		-			(5	)		-		(32	)
Total non-cash stock compensation	$	81		$	364		$	254	$	678

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Numerator:
Loss from continuing operations applicable to common shareholders	$	(2,033	)	$	(1,889	)	$	(4,401	)	$	(3,872	)
Denominator:
Weighted-average common shares outstanding		10,704,121			10,466,912			10,704,121			9,051,518
Basic and diluted loss per share from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.41	)	$	(0.43	)

Common stock options		2,019,536			2,336,018			2,019,536			2,336,018
Common stock warrants		2,807,244			4,894,570			2,807,244			4,894,570
Excluded potentially dilutive securities		4,826,780			7,230,588			4,826,780			7,230,588

Segments. We have determined that we operate in one segment for financial reporting purposes.

Reclassifications. Certain prior period amounts, including royalty revenues, have been reclassified to conform with the current period presentation.

Recent and Adopted Accounting Pronouncements. In July 2011, the Financial Accounting Standards Board (“FASB”) issued an amendment to the accounting standards related to the revenue recognition practices of health care entities that recognize significant amounts of patient service revenues at the time services are rendered even though the entity does not assess the patient’s ability to pay for those services. The amendment requires such entities to classify its provision for bad debts related to such revenues as a reduction from patient service revenues rather than as an operating expense as well as enhanced disclosures about an entity’s policy for recognizing revenue and bad debt expense for patient service transactions along with quantitative information about the effects of changes in the assessment of collectability of patient service revenue. This amendment was effective for us beginning January 1, 2012. Given that we do not recognize significant amounts of patient service revenues from individual payments but primarily from contracted and non-contracted third-party payors, we do not believe this standard is applicable to us and therefore its adoption did not result in a material impact on our consolidated financial position, results of operations or cash flows.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 21 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $) In Thousands, except Share data, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011
Allowance for doubtful accounts (in Dollars)	$ 464	$ 333
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	25,000,000	25,000,000
Common stock, shares issued	10,704,121	10,704,121
Common stock, shares outstanding	10,704,121	10,704,121

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References+ Details

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References+ Details

XML 22 R17.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners	20.00%		20.00%
Net Revenue Adjustments (in Dollars)	$ 154,000	$ 150,000	$ 375,000	$ 181,000
Minimum [Member]
Equity Method Investment, Ownership Percentage	20.00%		20.00%
Maximum [Member]
Equity Method Investment, Ownership Percentage	50.00%		50.00%

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References+ Details

XML 23 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2012	Aug. 06, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	CombiMatrix Corp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		10,704,121
Amendment Flag	false
Entity Central Index Key	0001383183
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Jun. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q2

XML 24 R18.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Detail) - Stock-Based Compensation by Functional Expense Categories (USD $) In Thousands, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Non-cash stock compensation	$ 81	$ 364	$ 254	$ 678
Cost of Sales [Member]
Non-cash stock compensation	1	16	4	32
Research and Development Expense [Member]
Non-cash stock compensation	2	18	6	37
Selling and Marketing Expense [Member]
Non-cash stock compensation	(7)	17	4	34
General and Administrative Expense [Member]
Non-cash stock compensation	85	318	240	607
Segment, Discontinued Operations [Member]
Non-cash stock compensation		$ (5)		$ (32)

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References+ Details

XML 25 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Revenues
Services	$ 1,252	$ 1,209	$ 2,496	$ 2,122
Royalty	54	25	79	50
Total revenues	1,306	1,234	2,575	2,172
Operating expenses:
Cost of services	677	693	1,336	1,323
Research and development	342	321	792	660
Sales and marketing	679	671	1,552	1,228
General and administrative	1,569	1,369	3,143	2,695
Patent amortization and royalties	66	66	142	131
Total operating expenses	3,333	3,120	6,965	6,037
Operating loss	(2,027)	(1,886)	(4,390)	(3,865)
Other income (expense):
Interest income		1	1	2
Interest expense	(6)	(4)	(12)	(9)
Total other expense	(6)	(3)	(11)	(7)
Net loss from continuing operations	(2,033)	(1,889)	(4,401)	(3,872)
Income from discontinued operations		205		236
Net loss	$ (2,033)	$ (1,684)	$ (4,401)	$ (3,636)
Basic and diluted net loss per share from continuing operations (in Dollars per share)	$ (0.19)	$ (0.18)	$ (0.41)	$ (0.43)
Basic and diluted net income per share from discontinued operations (in Dollars per share)		$ 0.02		$ 0.03
Basic and diluted net loss per share (in Dollars per share)	$ (0.19)	$ (0.16)	$ (0.41)	$ (0.40)
Basic and diluted weighted average common shares outstanding (in Shares)	10,704,121	10,466,912	10,704,121	9,051,518

XML 26 R12.htm IDEA: XBRL DOCUMENT

Accounting Policies, by Policy (Policies)	6 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2012
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. The preparation of financial statements in conformity with generally accepted accounting principles ("GAAP") in the United States of America requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation .The accompanying consolidated financial statements include the accounts of the Company and our wholly owned and majority-owned subsidiaries.Investments for which we possess the power to direct or cause the direction of the management and policies, either through majority ownership or other means, are accounted for under the consolidation method.Material intercompany transactions and balances have been eliminated in consolidation.Investments in companies in which we maintain an ownership interest of 20% to 50% or exercise significant influence over operating and financial policies are accounted for under the equity method.The cost method is used where we maintain ownership interests of less than 20% and do not exercise significant influence over the investee.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition . We recognize revenue when (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been performed, (iii) amounts are fixed or determinable and (iv) collectability of amounts is reasonably assured. Service revenues from providing diagnostic tests are recognized when the testing process is complete and test results are reported to the ordering physician or clinic.These diagnostic services are billed to various payors, including commercial insurance companies, healthcare institutions, government payors including Medicare and Medicaid and individuals.We report revenues from contracted payors based on a contractual rate, or in the case of Medicare and Medicaid, published fee schedules for our tests.We report revenues from non-contracted payors based on the amount expected to be collected.The difference between the amount billed and the amount expected to be collected from non-contracted payors is recorded as a contractual allowance to arrive at net recognized revenues.The expected revenues from non-contracted payors are based on the historical collection experience of each payor or payor group, as appropriate.In each reporting period, we review our historical collection experience for non-contracted payors and adjust our expected revenues for current and subsequent periods accordingly.We also recognize additional revenue from actual cash payments that exceed amounts initially recognized, in the period the payments are received.For the three and six months ended June 30, 2012 and 2011, net positive revenue adjustments were $154,000, $375,000, $150,000 and $181,000, respectively.Because a substantial portion of our revenues is from non-contracted third-party payors, it is likely that we will be required to make positive or negative adjustments to accounting estimates with respect to contractual allowances in the future, which may positively or adversely affect our results of operations.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents .We consider all highly liquid, short-term investments with original maturities of three months or less when purchased to be cash equivalents.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements. We measure fair value as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants.As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.We utilize a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1: Observable market inputs such as quoted prices in active markets; Level 2: Observable market inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and Level 3: Unobservable inputs where there is little or no market data, which require the reporting entity to develop its own assumptions.
Concentration Risk Disclosure [Text Block]	Concentration of Credit Risks .Cash equivalents are invested in deposits with certain financial institutions and may, at times, exceed federally insured limits.We have not experienced any significant losses on our deposits of cash and cash equivalents.
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts. Accounts receivable are stated at principal amounts and are primarily comprised of amounts contractually due from customers for products and services.An allowance for doubtful accounts is recorded for estimated uncollectible amounts due from various payor groups such as commercial insurance companies, healthcare institutions, government payors and individuals.The process for estimating the allowance for doubtful accounts involves significant assumptions and judgments.Specifically, the allowance for doubtful accounts is adjusted periodically and is principally based upon specific identification of past due or disputed accounts.We also review the age of receivables by payor class to assess our allowance at each period end.The payment realization cycle for certain governmental and commercial insurance payors can be lengthy, involving denial, appeal and adjudication processes, and is subject to periodic adjustments that may be significant.Accounts receivable are periodically written off when identified as uncollectible and deducted from the allowance for doubtful accounts after appropriate collection efforts have been exhausted. Additions to the allowance for doubtful accounts are charged to bad debt expense as a component of general and administrative expenses in the consolidated statements of operations.Collection of governmental, private health insurer, and client receivables are generally a function of providing complete and correct billing information to the insurers and clients within the filing deadlines required by each payor.Collection of receivables due from patients and clients is generally subject to increased credit risk due to credit-worthiness or inability to pay.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation .The compensation cost for all stock-based awards is measured at the grant date, based on the fair value of the award, and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award) which is generally three years.The fair value of each option award is estimated on the date of grant using a Black-Scholes option valuation model.Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate.We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized.Stock-based compensation expense for all periods presented attributable to our functional expense categories were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2012 2011 2012 2011 Cost of products and services $ 1 $ 16 $ 4 $ 32 Research and development 2 18 6 37 Sales and marketing (7 ) 17 4 34 General and administrative 85 318 240 607 Discontinued operations - (5 ) - (32 ) Total non-cash stock compensation $ 81 $ 364 $ 254 $ 678
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share .Basic and diluted net loss per share has been computed by dividing the net loss by the weighted average number of common shares issued and outstanding during the periods presented.Options and warrants to purchase common stock are anti-dilutive and therefore are not included in the determination of the diluted net loss per share.The following table presents a reconciliation of basic and diluted loss per share from continuing operations for all periods presented (in thousands, except share and per-share data): Three Months Ended June 30, Six Months Ended June 30, 2012 2011 2012 2011 Numerator: Loss from continuing operations applicable to common shareholders $ (2,033 ) $ (1,889 ) $ (4,401 ) $ (3,872 ) Denominator: Weighted-average common shares outstanding 10,704,121 10,466,912 10,704,121 9,051,518 Basic and diluted loss per share from continuing operations $ (0.19 ) $ (0.18 ) $ (0.41 ) $ (0.43 ) Common stock options 2,019,536 2,336,018 2,019,536 2,336,018 Common stock warrants 2,807,244 4,894,570 2,807,244 4,894,570 Excluded potentially dilutive securities 4,826,780 7,230,588 4,826,780 7,230,588
Segment Reporting, Policy [Policy Text Block]	Segments. We have determined that we operate in one segment for financial reporting purposes.
Reclassification, Policy [Policy Text Block]	Reclassifications .Certain prior period amounts, including royalty revenues, have been reclassified to conform with the current period presentation.
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	Recent and Adopted Accounting Pronouncements .In July 2011, the Financial Accounting Standards Board ("FASB") issued an amendment to the accounting standards related to the revenue recognition practices of health care entities that recognize significant amounts of patient service revenues at the time services are rendered even though the entity does not assess the patient's ability to pay for those services.The amendment requires such entities to classify its provision for bad debts related to such revenues as a reduction from patient service revenues rather than as an operating expense as well as enhanced disclosures about an entity's policy for recognizing revenue and bad debt expense for patient service transactions along with quantitative information about the effects of changes in the assessment of collectability of patient service revenue.This amendment was effective for us beginning January 1, 2012.Given that we do not recognize significant amounts of patient service revenues from individual payments but primarily from contracted and non-contracted third-party payors, we do not believe this standard is applicable to us and therefore its adoption did not result in a material impact on our consolidated financial position, results of operations or cash flows. In June 2011, the FASB issued an amendment to the accounting standards related to the presentation of comprehensive income.This standard revises the manner in which entities present comprehensive income in their financial statements and removes the option to present items of other comprehensive income in the statement of changes in shareholders' equity.This standard requires an entity to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements of net income and other comprehensive income.The adoption of this standard did not result in a material impact on our consolidated financial position, results of operations or cash flows.

XML 27 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies

6 Months Ended

Jun. 30, 2012

Commitments and Contingencies Disclosure [Text Block]

6. COMMITMENTS AND CONTINGENCIES

Human Resources

Litigation

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 28 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Detail) (USD $)	3 Months Ended		6 Months Ended
Note 6 - Commitments and Contingencies (Detail) (USD $)	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Litigation Settlement Percentage	12.50%		12.50%
Maximum Annual Litigation Payment	$ 1,500,000		$ 1,500,000
Minimum Quarterly Litigation Payment	25,000		25,000
Royalty Expense	$ 25,000	$ 25,000	$ 50,000	$ 50,000

XML 29 R19.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Detail) - Reconciliation of Basic and Diluted Loss Per Share (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2012	Jun. 30, 2011
Numerator:
Loss from continuing operations applicable to common shareholders (in Dollars)	$ (2,033)	$ (1,889)	$ (4,401)	$ (3,872)
Denominator:
Weighted-average common shares outstanding	10,704,121	10,466,912	10,704,121	9,051,518
Basic and diluted loss per share from continuing operations (in Dollars per share)	$ (0.19)	$ (0.18)	$ (0.41)	$ (0.43)
Excluded potentially dilutive securities	4,826,780	7,230,588	4,826,780	7,230,588
Stock Options [Member]
Denominator:
Excluded potentially dilutive securities	2,019,536	2,336,018	2,019,536	2,336,018
Warrant [Member]
Denominator:
Excluded potentially dilutive securities	2,807,244	4,894,570	2,807,244	4,894,570

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Amount of income (loss) from continuing operations attributable to the parent. Also defined as revenue less expenses and taxes from ongoing operations before extraordinary items but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4613673-111683

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.13)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph b(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+ References+ Details

XML 30 R15.htm IDEA: XBRL DOCUMENT

Note 5 - Shareholders' Equity (Tables)

6 Months Ended

Jun. 30, 2012

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

	Shares of Common Stock Issuable from Warrants Outstanding as of
Date of Issue	June 30, 2012		December 31, 2011		Exercise Price			Expiration

April 2011		1,310,572		1,310,572		$2.14			April 2016
October 2009		30,000		30,000		$7.78			October 2014
May 2009		29,688		29,688	$7.50	-	$9.00	May 2014	-	June 2014
May 2009		1,100,000		1,100,000		$9.00			May 2014
July 2008		336,984		336,984	$11.87	-	$13.65		July 2013
May 2007		-		959,390		$5.50			May 2012
Total		2,807,244		3,766,634

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

XML 31 R13.htm IDEA: XBRL DOCUMENT

Note 2 - Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2012

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012		2011

Cost of products and services	$	1		$	16		$	4	$	32
Research and development		2			18			6		37
Sales and marketing		(7	)		17			4		34
General and administrative		85			318			240		607
Discontinued operations		-			(5	)		-		(32	)
Total non-cash stock compensation	$	81		$	364		$	254	$	678

Schedule of Earnings Per Share Reconciliation [Table Text Block]

	Three Months Ended June 30,						Six Months Ended June 30,
	2012			2011			2012			2011
Numerator:
Loss from continuing operations applicable to common shareholders	$	(2,033	)	$	(1,889	)	$	(4,401	)	$	(3,872	)
Denominator:
Weighted-average common shares outstanding		10,704,121			10,466,912			10,704,121			9,051,518
Basic and diluted loss per share from continuing operations	$	(0.19	)	$	(0.18	)	$	(0.41	)	$	(0.43	)

Common stock options		2,019,536			2,336,018			2,019,536			2,336,018
Common stock warrants		2,807,244			4,894,570			2,807,244			4,894,570
Excluded potentially dilutive securities		4,826,780			7,230,588			4,826,780			7,230,588

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References+ Details

XML 32 R14.htm IDEA: XBRL DOCUMENT

Note 4 - Fair Value Measurements (Tables)

6 Months Ended

Jun. 30, 2012

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Fair Value Measurements at
June 30, 2012	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	2,572	$	2,572	$	-	$	-

			Fair Value Measurements at
December 31, 2011	Total		Level 1		Level 2		Level 3
Assets:
Cash equivalents	$	5,771	$	5,771	$	-	$	-

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References+ Details

XML 33 R16.htm IDEA: XBRL DOCUMENT

Note 1 - Overview and Background (Detail) (USD $) In Thousands, unless otherwise specified	Jun. 30, 2012	Dec. 31, 2011	Jun. 30, 2011	Dec. 31, 2010
Number of Markets Diagnostic Tests are Performed	2
Cash and Cash Equivalents, at Carrying Value (in Dollars)	$ 3,159	$ 6,385	$ 9,988	$ 6,556

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

XML 34 R21.htm IDEA: XBRL DOCUMENT

Note 5 - Shareholders' Equity (Detail) (USD $)	6 Months Ended
Note 5 - Shareholders' Equity (Detail) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Stockholders' Equity, Other Shares (in Shares)	3,080,000
Sale Price Per Share of Stock Unit	$ 2.193125
Common Stock, Shares, Issued (in Shares)	10,704,121	10,704,121
Investment Warrants, Exercise Price	$ 2.14
Payments of Stock Issuance Costs (in Dollars)	$ 122,000
Per Warrant [Member]
Common Stock, Shares, Issued (in Shares)	0.425
Gross [Member]
Proceeds from Issuance or Sale of Equity (in Dollars)	6,760,000
Warrant Component [Member]
Sale Price Per Share of Stock Unit	$ 0.053125
Net [Member]
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 6,640,000

- Definition

The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.

+ References+ Details

XML 35 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	6 Months Ended
	Jun. 30, 2012	Jun. 30, 2011
Operating activities:
Net loss	$ (4,401)	$ (3,636)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation and amortization	175	160
Non-cash stock compensation	254	678
Provision for bad debts	278	117
Changes in assets and liabilities:
Accounts receivable	199	(303)
Supplies, prepaid expenses and other assets	292	(153)
Accounts payable, accrued expenses and other	56	16
Net cash flows from operating activities	(3,147)	(3,121)
Investing activities:
Purchases of property and equipment	(20)	(50)
Net cash flows from investing activities	(20)	(50)
Financing activities:
Net proceeds from issuance of common stock, net		6,638
Repayment of capital lease obligations	(59)	(35)
Net cash flows from financing activities	(59)	6,603
(Decrease) increase in cash and cash equivalents	(3,226)	3,432
Cash and cash equivalents, beginning	6,385	6,556
Cash and cash equivalents, ending	3,159	9,988
Non-cash financing activities:
Property and equipment purchased under capital lease	$ 19	$ 71

XML 36 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Shareholders' Equity

6 Months Ended

Jun. 30, 2012

Stockholders' Equity Note Disclosure [Text Block]

5. SHAREHOLDERS’ EQUITY

Equity Financings

There were no equity financing transactions in the periods ended June 30, 2012.

Warrants

Outstanding warrants to purchase CombiMatrix stock are as follows:

	Shares of Common Stock Issuable from Warrants Outstanding as of
Date of Issue	June 30, 2012		December 31, 2011		Exercise Price			Expiration

April 2011		1,310,572		1,310,572		$2.14			April 2016
October 2009		30,000		30,000		$7.78			October 2014
May 2009		29,688		29,688	$7.50	-	$9.00	May 2014	-	June 2014
May 2009		1,100,000		1,100,000		$9.00			May 2014
July 2008		336,984		336,984	$11.87	-	$13.65		July 2013
May 2007		-		959,390		$5.50			May 2012
Total		2,807,244		3,766,634

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section B

-Paragraph 7, 11A

-Chapter 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

+ Details

XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 63 116 1 false 20 0 false 4 false false R1.htm 000 - Disclosure - Document And Entity Information Sheet http://www.combimatrix.com/role/DocumentAndEntityInformation Document And Entity Information true false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.combimatrix.com/role/ConsolidatedBalanceSheet Consolidated Balance Sheets (Current Period Unaudited) false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.combimatrix.com/role/ConsolidatedBalanceSheet_Parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.combimatrix.com/role/ConsolidatedIncomeStatement Consolidated Statements of Operations (Unaudited) false false R5.htm 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.combimatrix.com/role/ConsolidatedCashFlow Consolidated Statements of Cash Flows (Unaudited) false false R6.htm 005 - Disclosure - Note 1 - Overview and Background Sheet http://www.combimatrix.com/role/Note Note 1 - Overview and Background false false R7.htm 006 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://www.combimatrix.com/role/Note0 Note 2 - Summary of Significant Accounting Policies false false R8.htm 007 - Disclosure - Note 3 - Restructuring Sheet http://www.combimatrix.com/role/Note00 Note 3 - Restructuring false false R9.htm 008 - Disclosure - Note 4 - Fair Value Measurements Sheet http://www.combimatrix.com/role/Note000 Note 4 - Fair Value Measurements false false R10.htm 009 - Disclosure - Note 5 - Shareholders' Equity Sheet http://www.combimatrix.com/role/Note0000 Note 5 - Shareholders' Equity false false R11.htm 010 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.combimatrix.com/role/Note00000 Note 6 - Commitments and Contingencies false false R12.htm 011 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.combimatrix.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) false false R13.htm 012 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://www.combimatrix.com/role/NoteTables Note 2 - Summary of Significant Accounting Policies (Tables) false false R14.htm 013 - Disclosure - Note 4 - Fair Value Measurements (Tables) Sheet http://www.combimatrix.com/role/NoteTables0 Note 4 - Fair Value Measurements (Tables) false false R15.htm 014 - Disclosure - Note 5 - Shareholders' Equity (Tables) Sheet http://www.combimatrix.com/role/NoteTables00 Note 5 - Shareholders' Equity (Tables) false false R16.htm 015 - Disclosure - Note 1 - Overview and Background (Detail) Sheet http://www.combimatrix.com/role/NoteDetail Note 1 - Overview and Background (Detail) false false R17.htm 016 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) Sheet http://www.combimatrix.com/role/NoteDetail0 Note 2 - Summary of Significant Accounting Policies (Detail) false false R18.htm 017 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) - Stock-Based Compensation by Functional Expense Categories Sheet http://www.combimatrix.com/role/StockBasedCompensationbyFunctionalExpenseCategoriesTable Note 2 - Summary of Significant Accounting Policies (Detail) - Stock-Based Compensation by Functional Expense Categories false false R19.htm 018 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Detail) - Reconciliation of Basic and Diluted Loss Per Share Sheet http://www.combimatrix.com/role/ReconciliationofBasicandDilutedLossPerShareTable Note 2 - Summary of Significant Accounting Policies (Detail) - Reconciliation of Basic and Diluted Loss Per Share false false R20.htm 021 - Disclosure - Note 4 - Fair Value Measurements (Detail) - Financial Assets Measured on a Recurring Basis Sheet http://www.combimatrix.com/role/FinancialAssetsMeasuredonaRecurringBasisTable Note 4 - Fair Value Measurements (Detail) - Financial Assets Measured on a Recurring Basis false false R21.htm 022 - Disclosure - Note 5 - Shareholders' Equity (Detail) Sheet http://www.combimatrix.com/role/NoteDetail0000 Note 5 - Shareholders' Equity (Detail) false false R22.htm 023 - Disclosure - Note 5 - Shareholders' Equity (Detail) - Outstanding Warrants Sheet http://www.combimatrix.com/role/OutstandingWarrantsTable Note 5 - Shareholders' Equity (Detail) - Outstanding Warrants false false R23.htm 024 - Disclosure - Note 6 - Commitments and Contingencies (Detail) Sheet http://www.combimatrix.com/role/NoteDetail00000 Note 6 - Commitments and Contingencies (Detail) false false All Reports Book All Reports 'Shares' elements on report '022 - Disclosure - Note 5 - Shareholders' Equity (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '024 - Disclosure - Note 6 - Commitments and Contingencies (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Process Flow-Through: Removing column 'Jun. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Process Flow-Through: 003 - Statement - Consolidated Statements of Operations (Unaudited) Process Flow-Through: 004 - Statement - Consolidated Statements of Cash Flows (Unaudited) cbmx-20120630.xml cbmx-20120630.xsd cbmx-20120630_cal.xml cbmx-20120630_def.xml cbmx-20120630_lab.xml cbmx-20120630_pre.xml true true ZIP 38 0001104659-12-057017-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-12-057017-xbrl.zip M4$L#!!0````(`.B#"D'PT%3CWWP``&FH!P`1`!P`8V)M>"TR,#$R,#8S,"YX M;6Q55`D``Y1O)5"4;R50=7@+``$$)0X```0Y`0``[%UK<^)&L_Y^JLY_T/%; ME=I4&:,+5WN7*M:7#8EM_-I.-CE?4D(:8$Z$1#22;?+K3\](`FDDP0B$`;^D M*KNL+M-/=S_3W3.29C[_3Z4B?4,VD"J5CD3_^^__ M^DR%7+J(BCB7GL>^U/5'DMR6E/JYW#ROMZ1?GR\E55;4X":XXVW@6M+;Q++) MEY.8('KXS'%'5566M2JVB:?;!CH)KCRG9W&!ZS$H0[SY#>QB@HRSD?-2#5(-&S(=H`O1/S\C MV\/>K#,_`(>P20\.,?1(!@4E%(FH>=G[Y:0C@SI:2U-:VN?JXK9X^]6%@.C0 M%+G8,9,BF1V\3N#.1D63/U>C8_.6%O<%.E9#):.6DDHK@=+*%3*@566_E58J MH+>F;*RT^N>-ZTR4[M2EEGQV]MGGH*CK74'\#KU>@W[\N;HX*DGQJY%MQJX- M&!(=6]-86MQ8RL)8^\B5A+&4`L922C)6+3#6S[I]>,Q2WIM9];BQ#HQ9PL8J MBUF-1*"6]]!$L4`MEQ2HFXF4O(^\2&2GF.5 MV\G2Z\\[;..)/[E#DP%RW]$"M*.CT00M-&''@L'".7J;6MC`7@!+,C%<2+!C M?SD)J_[S1]T>H>X;)B>=Z%!"E<_5S*8Z,?G5.8#=UX8R[Q;]C7/+`?LEKLN! M^47)JU__O'2(UQ\^Z18B!]=YZ&#/]"W4'U[#&,Z9(?2$W!=LH*>Q[J*O,#8V MZ<0(W*9[<&/7LAR#_>H/'Y'AC&S\#S(?F"6I&I2F[=="33(9-I%U63JN9634VN!7;KF!-N8>*Y.7[4],FH5HX0L][&KIUIN]72DU<>@ MU4[JJ'IN'76DU<>@U4XJJD9N176DU<>@U4YJJ^:2*02FTA4F]`YL^\CL3^F7 M3F#IQ1X/K-L'P3F51GFG5\+TPU MU[IK`UT())H@+\VR&^#HDS+1^[%E)U\>+9FB/K)EG]FRBZ2C+9F#/K)EG]FR MBR&1MF22^\B1G50F^9.U1X[L(4=V4H\TN2]S;W3L_J9;/NK98$9R2U^.5`YN M\GZNQ=?9_.=/((*^\CEC.B4]OD3K9?[?G`!;^*A7:R46>`@7#'DGQZVC=CDK M/&CMI-I')N^0R>6XM";G/\1V'1(;4^^W+^FR872.WS9UUPSY0HZ@_42W,MMINR=A\9:UQ_ZTY=;-'R M_L`>8%__[0.\'B$^,I^P;4#U82`VJ_N5':5K;L;\RZEY6(OFU.K)E2Z/3MNB MT\I:J+/6R`V91_=]N(*3G]3H&YX#RJFRW#Z8"F9--Z=4W>K\U3;":XL+KT?G M;=]YI879=FZ8/;KQHSYGJ*=7=YQQ;OZ8?D[H>7#SQ'5NQ?:CV[;JMK)";%W- M#;$)Q0YVZ=NM>[,(F!VNP[O[N)X_S<0Q+;6:[Y%II3#MG586WCW3^'FPT-2] MWL<>DW-J'M8\6)V?!SLZ;?_GP>KY\V!']WVXL,K/@_WL6U3YU@$](EK3RTE- MM[>4VS;B*C\!=O3:%KU66F#-G_E*:I4Q+CLZLR"2_^1162/_I2B>:(>ZR^BSKA M?KOGOSY=?:Y&!Z5%>_3^V+_CS3T@E]#O)$CLE4P3OX!3$UK36^[]"5UPPHD' M.Q$0"Y/SK23;OT*V,\%V="Y+!MLK^CP`G*'I0@K?UMS6"]U6V&9N%<[6.1"6 M-S:%:Q+=+]D:/9VV6;JYZ)U4G=!EK.E?M)^\Z!8PEW2]2]UU9]@>L;?!)7KS M(]W#F))&"BG%#J2V*Y9,9.");I$O)Q7MI*,I]3;T\,_50@([I>9>^Z\+-&QBQS8%;)J:3./_"&OI5N8G/CU1JU),PB+@OU"NMJFE8BZB=_"ND+ MD0W,J+9;"4!1DVF^B0A;H7VMV1`4]N"BJ8[-<+4SZ+%];XS<+B'((YMS1ZDE M.YZ`M)3M-T2XPE(J%U[705B6M6KU5C-)6E[LNH)7&*%5;ZF%!#^X#A1*WNS! M@EH9C$1#/-O#`2+6!@:HRS7.&?EBLJB\'JA5J4UN;@`J*)[OD#=VS)[]@HA' M+]TDD"AJ$D^.A%*@K$IAZT+IV3#(&F&(N`'3P'3!5\10&7QS'/,56]8F^3[9 MIT6DE8]QE>TT=3V062%@DSZG*5E!IU-4S`IUV[5:2T!,F)$?]!E-QW113L-P M8=QYB_4!MMC7XB5D)9EFQXS*2T!LE@O*`;V*+S(7'#<#?:E/L:=;MS#.0?V! MA4?!ZH4E&%>I<0.!98(R!BKKXEIE/X4?H!3"52X!E6;22$(N*Y=.BM(N#B'' M:/>.;910*\HB#EK(2H?LC>"M,EB3'X<7AAMD6NRBZ/57!)H%E.7PA:AJ,YD.F%; M3.[VP"ZQX5;`LBM(UX=RV:7KE2]`%K5E[_Z&CIYDF1_++I&6-=!>']P2VVT- M7/!(8D.KK8`4R%@5&0K@666H$O'T?8\^S*(CB.T:*2:H;&0;FFLI,II%'+N4 MT*XHR>*`:WDSV2M+N?5EOU]P%Q":57"6!+50:-\8:LF!74T%SR6RTB.JM7&M MZGLEXRHEG"MR4ZXI:K8W4R&T#$2KK%0JHO)"N@`L/GB6AJT$DRW'UC5-3(=C MNO6@8[-GAX.U#0)\HZ'5N2=*V3+X&:WB2%;-1S=D;GY3#,DC\G1L(S-:E;%K M&/[$MVAHNT)#^F[&!N:I-%2MD&_RR$>6DZQ*MYY![V(05CW\81-C12'$Y@!@!%ZJ35(STJMD+9NL*PRN MZ#QV87!/NH7((WI!MA]M:D56/*%2\Y8M3T_5U)-/%7*$97&J."PM;Z7L-"RY M_7ZP:GFOX*6>_=;:C?>#5<];#S@%2U'7=>*C,],M;Q9>6PJEZLG)QJ2$C2`( MTT>M;PN",%6XR=\2(0C3@HO2JR$$9Y9.B(H'%DUN<)DS:'U-P05"AU8K4[!X M<*@WZV4*+M#]FZJH8+JW87]('P^SY!/&AB?(/Z5XO=%LXHFM80!E<",&%N*9HJ;C6.X@3158_AJBNZJK'#7GD)7Y,JA6Q:C:?] M$HEEH1.FFZ;RHYMW0%<@/>W`=L*L:Z1&7>+H\G>]+RG"<85IKKBL(G`M;.(1 MKJF\-S;Q"%?G!QI+P)4`3#S"J6IK/6`K-@(NIXRJ-Y)\6R&T/(CB!9>V*XC" MY-.4FK8;B.)%7*-=WP!B=^*X'OXGW$>%?S6PG,B7K%"62^SP\ZMKXQ./?KO! M)QX!N7)E)<"R$!8H]I1-$,YW0PXI6@[M-/[#C)28S8"(%W2**F\3B#"1&NU& M?9M`Q,LT66NN"Z1G&\X$W3JD')945%G-P;*0M"D:8:I4E%:KL6TTPGRIU+1V M#G/+0R-,FHK6RJ/O$C2+CP."BR`8(1>.E%/!<._59XO*>N&_."CQ=/&.H,2K ME+5!!6=*'8GQ7T/$)736EB_,FMIVY(L3)/4Y2!+`V@B$V9#Z:&:)!>X=VTGV M\S*Y4$F2(5<8;Y6U4(FG`>T=48FG`^[UKV6P2L`EGAB:ZUEKD36"_23IJ]T^ MW!2F%<Z=\9:I'9I\E%W0ZQ7 MF!C!7IZ+![Y'O]=Z=A[1E`[(H+QF:YV4\ZA4KB]1:`-T M647`.R@N7LIH?`&Q-<7AMO*'.UPP2LC@9_-5!X@&Y7W6"#?J`@^YVC$SQ-Y6%2*,"9OE,:1>)7#F@5G7LLO43(F6H M7^L`]1,B?:!?33E`_80Z5:B?]@[Z+0_M[\%4^4Q6UTL\2U3>B<:BO@6-.3-VTSDJX0S8]7RD!:)"8V=HITS>BV`Z1%XI2\-M+OB.Y!C,SN"S!] MA.Y]NKIA?QCG=H'O(H08F_.%1$$DJ1Y7KB9"C`XUJ34:;47=5TV$&'\0/A'J M$4R3MEQ7ZO'JJ[@B"3VNT-0%"2P5T"?@L0>1Y+VAR0^+/'9FL-0`^N\X+I8K49B_J58R<.UC*! MF0N2K05/G%Q*:FFR`O"@;G/IZB57*/B[9Z<71"QIBCJU(-=JR>E!]T9@A6VJ MR:EI80&L`L8-5Q:\"C]2SUQAL!QSJ^W4K.8:6#(FYDO62)SG]54^$5-(D%'+ M5M0JQ4/UU%SE&DB$2+>I2L7RW!94HDO@ZF3,(IN)S*^S7R$G].SY2P9=P\,O MY7FFHBFU)C\3*`@@5AA*7S2^R4`GO=K[+6AIWCJ>"=C"WPG#.WN/C4T^U2@(MSO%X6<+C%0,AD MDU;1-@;]86RA@9*^?=!2)>1RL9G?ETU#7O6'MXX]>D;N)&?]N7+R$_>UH[CX MU!"V).CBY1O_T=[ZT'.H=8-M\-D6NB1G=7'Q@EVR(/`BG_>D'EZ*(^>^?\O< M-N"!;-./U?SFNS$1%XYAD\SQO-L M*BY*D2O_#IJ/WY[4)5Q6]P830[?^0+I['6P^)"RD$FU2M:RU#F^\#=9I"O;" M;'3]T8H);S%IG;@UNF`DDQKJQM)'PB88@G04R$LTT$EQYA+.N+K5LTWT]@N: M"4N08]MIY;;627,T],?\[2&Z:)Q/A,7^07RDV^&#CDL(]XZ%S>@AR`.$"6@@_#`M M+!-UBRV[R&IW^DZ!Y=`-N9X!X5>+#LY$X?Y@>1A735>WJX[?YQ+@VHO`OI MKOOXK7=?N;V^B:X(CSP&[<"AH'5)AZ1FAZ+^SX=AZ'`6_..'$?S_KS?S(C`. M_8_"&X(J"7QST=BVL(TNI)O^_7/EIGO7NX6#SW@"E?L]>I4>G8ENAV>?>O][ M#V__M^O&WWO5WJ7M_ M)7WM7O[R[;'_Z_T55;-*]8R9(&R1G0(/L3/P>^!6HY]%_:8VM^^X;7IN(2Q6 MNB2M3^L8)WBI1OKDC5'HCI:JRA=A7#V='U(NXJ=?4?Q,I([$.99=ZI-X&Y"] MXR<=WXV=_5%ZU8GDN'@$_=:R9AR_L6V$B*&:Q+;4-SR'[C.IM-MU"6[4I4NP M^M!Q;:Q+1DPY$,HU19?E[WU=:I4NH"Y+:4&TIT7B5##JP,ZFC!@B\EN@'I\`"21\" M-3'KO91TITE%`G>>926,TO/%KO-\$/Z?_[B%^$_'Q-B(PZALT1^G2Q+$@O%HZ MW6U9']D.`#=HK<],#V[0(>"Q)W0@?.K"B-O%45Y=I%7FKB%&EDE]-T(V@E8@ MC.C6C&`6M;/EI(.!-W8=?S1FX2*14=)UT4@6:=;I)Y2$KTBRZ)_S[L&]1IS.;0!%*)O M"-/2-MB>CU-U:/D.C&@-6E5ANT*PYR,3RHO*#^`QT, M&K5"2Z2\BH!P%MP6E+G8MIV7P)>"P2]9 M,+"B9:LBLS&`#O[P(=R9M!"C-3^4WD80AZ)/,](1A'[U[_J&YU.:!U4W7_,^ M)BZA[S;$*9P:`GK(-H.2D(#U\!`BJ^T!T5QD^A"+YQ^&0PXD'O1`'#ZGRLI5 MD/38U%A0!,\+EE"\TKP@,<(MXM+`)V!L0CALU!3T*0#!P7`(V1@J5#"\/F+# MHKQJ.!J5S.OP&,:T<9@OZ`P6"HK\._\O;'G(.96^ZV0,5WE1F)O'$"B"H="> M1>%LK-.!)[(#Y:&9>9REAG##8>4IIUTL%S!-Z>`"N71N+8I$7-D7LR)?'P+O M'=LW+.1X$/4AOABNPR(XA$5C;-,T$D1/BSC27W1NE090.E>P=/0!7$X#MBT,J5?M9`DXX`)\7G8['!\C,?Y\?AYG"[WC;"H#V);-.L- MW7<837(O9F`(='+(F[27\^U,Z=NM;E`FTS9=D[XU%$S9C(*%!2$0P!DZWV6R M2WRV)6(J-D'8`+%36AE!42VK*CA^5')I,JQTEF)2>)LVQG9<\Y=6N*(B&+ M,Q2I(4C;FE]_NP'P#4J4K` MRM45N\4[-;2^W/7!_^@Q5DP3IN`"!EHLP'LZBL05_2[?#ST?PX"`B=H[@,QI M/?YHV(.L]KP(6#)[K0SP6,,PSK0EVB1VIFPL0K:U\P-I`2\XYK]>-O)#9E[. M1W[DHD&`F9I"*F"`/\'0"\[DERQ)R\P5/UPWR3_T=AFL*8I(::`IF!I#&O0D MZ=CK"*>C(YSG0&ST2>Y'@I%H\\X%,XL,EYN":,-B^?G?,G&9YB.O/US@YU]% MWK1S7`H0<9NGBL6"V`,F3%]F^@/3%0K$1XR%!ORMD#[$C#8$3>#&VC+':(*? M7\FW001C^`C'?E@6KDDUSA:.;B^24'R;<0L?0\6Q8 M&+W2F&*@Y%:SG-T/V*TI'(/<%`K6-R%)^^(?GHM\$DF=>X<+S6$VX,%8'LW3 M9&"RR*U2(3[`/K)*F4Q?;=^D?"O/2F<]`H;[FIGG56.,8OR5F5)9&2DB>FQ$ M],4!T7\RN>."*0F;35Q_*E]TGX>+;`)#Y4DDK*!6 MJAQ*)G(S`=U$;;B?A*?*X0UH M_/+O*I4!Q#HD]N1N?94"@4EX&\KJ[8]R?"KMUHM:&O22(N%ZS&"V6F@5)G@% M3PF<20<<*]SU@6%,:^0`W"&,#<'J#N(4-(.H;"K3#2IH3=<[0]1`)&DL=<.M M")S9`\@VNG`N*)/IK6`X2%>'"$FE*'9N!=I*-'PV]@I!H%8^;GB MN(&Z)U5?TC9,^%Q,\\6L3O@?![\IIW#2`4;HI@V4*_]Z&)7]^KP<"%&/^9Z1 M]9)$%DA*MZW4RF-*""ERG;'(S.#^*LS4]SSFPAH%V+@2EJ1$3;HIA]1:,5%B M"\@2S/V3^1/$^G\DJ`\C3*T4QTFW^AP/5D;D`*34Y(W`1D*)_8'ARW0S*_$+ M8GYFTT6QRPF&\T]F"0[>:3_C$M,J?.+;Z`Q:$.OA_-KSGH*,^OG?L<*2^T6FW M_TO]N13L+1C'E?Y0\7Q95!*.2^Z%@7&795+H3S0DEH5\YL!J:#LWQL]/[V_^ M!4^?'7:S4E44J?3Y>%UUXZ]=V#.@7`4263I>%8DM<>-5:&NB_SF\.BUS2LNG MW,/E3$9MM*EZS;J9K1O<=CB@]#0='+]Q,#0AIH$_7HO:WA96.#C#7TKK=MHK MK-N,@'2UZSAOI6KA^8:%?2P*IBL537E5RHU#NQL'^L*HQD4F>B:ODL?RLT#_ ML/P04;]YUJ#;5&M`QH",`1D#,@89_J?I8*NX_1;_,^T[F0X4R01,CHS-OUBU M9="K-:9,N.^R4`2L8D\*ZX58*`IQM:M$Q@2DOD?&A(Q)#0$G8T+&9-O&)$YW M%RM"XG]8':?GT60BCJ=4ZFPFP0B6A\5]!LF,5)F1(S(C9$9J M"#B9$3(CVS8CI2KL^)_:\Y*[\+)V11Q2C+=AQ;G/F5L(JV'NSEJ!/ED!L@(U M!)RL`%F!;5N!6_^.!=Y84Y\6_PN2HU9I:DJI>A$=H,21`4N<0Q#=N=+21QF'WOGN'8:R2C+] M8%JDJ?0,6&88+Y@:HG&H&=CZ$J&/X/G@N:)R[6&FTM-'FO@$*^#B6B!9ZU8Q MWSPDS)MB*_N-T@RU$Q2G+HOSDV5:WC1[/AX;*YC34NI8'=#('NV6!SEEWEF= MHL+R'D\<$U?9:#\HH6DL6"U56J2*L[$<,'`D3UC`F>I1A6?PM*>YDQ*83%L! ML=[BI$IEU5GV;&R)M`7.RJ:'8['$;ZPYU"F`,'/*/:F6Y-K:5#V]>;G0DF3[ MHN8K.1L';\J>C2NVX0C8T!7504#9Q.=<5-3)>B[%\J3)0<`L1/Z,FU^<8WS2 MQTJ.]9OR^AUUF"MSM*7\W>)@;N9NF*P5P0-,HJH31P0Q";'=+)Z,B>!=A1I. M+,=T])6^,RN7TC[1J^X8FG:5M0;CA]?Q'7:R5QI/&Q?=8'7_><"^LP!/'66; M8$]@O$*+Y':NE7BN1W+[V=ONFU<+OJQP+H+[O.RK#V\]N,KS/AWX_*CXSA8.L(/KCGP^H'+0G>]0+$"NY7LY@ILJ(<[:?H#5AR.H05,*4?(`V2.N(O[4K&WN!`6?LQ\RRE MR%,)8WPK6M14#"'?BJ>4V]S@99LDO^1FP>8<3LL01Q*-K#,S"V/)^; M#B+.ZHMCKH?%^9U;823.O\NCNM*YLAWL&Y:83YYA/AT6VQ1&S!CR>ZGO0D;* M[>Q#QFJD6+A#,L]9F*G-FX@F^O@*+I`FG_Z`4#2@?A3.0J( MFSPZ%=@HK]*2=.%.I#R-<"^=5O3[2[EIV5X.STX"\%@B/A%G0J0:B[]E>D]E M<*G;0Z+;_"Q>Q#__!$TH/ M>/J5%Y8Z&Z\ZWM"-1'--#%8RH2!*8;8GAUS2^NNC#A_-6(FT]U+*-9B$?`*3 M'J)GVKTX(Y:=>WGBO.PZN%+(@4_($9R,BO1BELS@0F$HV38$5XLQ.@6Y?=2_ MDL:^[#U=0<1]ZSEEO#=^RG`IV"//3BB[D-T9TW::8ZP9XTE+T4JV:0@30MF,B%Q$"F&@K&2J#_`AB(/ MV.FCT#O'9GANT/'D'ISH$'OW$I3'Q=1$G&]`BM5(#C:LP"M3X(%2(D^Z6ZI&!$%&)`7*%8\+BWY"JE_Q!.^?Y&(E MT5"(ZE/A'R/JQSZK'#+O+">#R>/K8EM6#!BWD15V7K0ZKNYX5HX%RJTZ\>4@ M>:X\-WD'GHD?81O89DQ&A+9^1+; M%36R/35V-$B^*X(-T8Q?)(*E2V-F@^#,,-HYM.05`WR$II>!/;/@IRAN$IAD M?1,)8%7'L:NFY?G>07%J51-+TY5I3RK1HJKL1@N4FM%A2P9=`G4'++Q'C$Q' MUV2RI=#%T:*6B/2M8F9%FO(3342("P4-[/C"DNS2F:[KWZ.X%I761R.!^SEF M*+JA9'0\YF[ES&.BBRGGZD6):17:EUF+DN\HF[>(71/%"W3F\8400B@#QTP( M$<2`*)/BA\+L;L&-GXAV@>8$(&D2X(4059>;B.&*<7>Y$O)>&&0'$!<#H;ET M#DM$57!$[!VAB1#C)O*00P`8BRYBY:TQC+3_I85FE2@39PH M3CV/S-G\V`F1G0JE4(D^)/'5MP7MQ5P.>\!+B%.S+HZ)NZ(E^=]-5/G7X;?Q*#/^^<=L2?BQK#<;5%7W3MU-XQ&=J:N38I M0E)EB%M"ST1L'+T>AB,GL`^PP?0T-7H05Y1;R;C.7V(S$Q>THG&!2/,E[()E M\-BM:`=0E*[<1E6V(66:(Q0I3<60BH8O)4Q+&LK)C:VXEP%N*&4:SONE36^U M]XB94[7[&`7ZAHGD;6X_C+I(NW.E6_"V@7\V,A?FSL^<_93)&`8/BB0FJE[BBE\75DI60.=B*56661?4(X4J@3G\`2H=PD M"JQ1YAHCJSS!3.\I:H^Y40G4;^1]3/K"9J8A;X+^"A%KI.HOYF___,0KW\0# MHM=)LBKL1Q*4C MGMP&D7Z3(SX0&47T,0`,F MHV$,KE)\DRA424='T_1<<@>ISC#51$<2[2;7MGR9BR>RCGK=Y=+'32V7+I=X M5E5,SRDMK5_BJZG^+%00Z-^0KY>LH"%+.EBS4:CA\"S:=(6IV@KD\R^??OOV M&HS?,%QIY<<,6O:Q3%G'[T+I[`HD`5>I3@GX$UGI+U@%65V,;1B=`I;JC'_R MTYI+>P>8X10%S]IEBRUH;#W0ZJ)1P`'DA3\JG#(M30!7'*56,YH52&FYQCO] MM,:QGW6;JY/&FBNR5V2OR%X]L96>:Z^Z.VNO6O$EF5@H@4%0T6Y589"A#%IL MN%JJVA#+`Q,2XO(?63U4WGI._\GS%>IKU:=?GYHA/"5#2(:PZ?!(AO"IK/1< M0]AKCB'\X?D%4Z@C6$5MLL90=J-WN.$Z82C[D7M^;"_QOKGJ-CZ&RBFJ7;Q" MR3EFE^75#O&])$YQ?S?])^]@31*JU=V^5RC\2YO!1FZ'[,1^B'9'+CDG[!2O M%L9Z]H#93JBYU$A_VWOQJA4S*+B$JJ15G$BVF=C851MQ<=_S[`6C:?65ICQZ M;$Y;R44'K;A.8-:S_LTF%;=?.0/.2: M3*+$NJD3D>7"B"NQJY;4M)['U0BBG.T]7F$SC-S24_%PAW,M M3_Q-M7TG7P18+4YPI%=SI)ML\G`)%D9DSN'B$^DUWEBK&#AB6RPIMYU18@%/ MV''-3WPT79;K91N0YN4WKK#4[_-Y:=6&&,=6?$H/H#@E@I*J-GP@KA3!`[-Q MQ97@C)IS0J\JZ=16.,K"L#3[.:>NLUR=5E'GJ2GLU!Q-FU>V*8\&R@+:S)35 MAF]Y-W,>0SWLCH!7+*5(-'-+%,7FS\B^K=[*OIXP2XSDXL7)6:+J4\55.1!& M[Z+V2PZG06N\*BJ6;?B"W-:-)H"B7-%A8-5[F#N9/C%YB,)09#X2`[Y^E#DF M67VMFZR&$\5^8JO]EFD.LJ?JR;'1A10PO;PELJKRS MKUR]2)F%)&6DOH4(N\=L27*`G824Y0 MY,X]@`$3AQ2Q^+M\LU/VYEEU\$$1Q#,$26JA<=D>(!W%8F!\?XB\:>#>Q#S MD;KPJ%@\C8>(DHL'84I4%;?U*/`Z!&X8WLC%$!5$6;'Q_EO`]'C2)Q;*96#)6,)A4IKI-2183%J*S97 MF7,1<5&>@+62>1.G9A#\,"M[@+S#-SNX=7$7'S4=XRVQC,4]%SHGORB%A7"P M9.VD/QV[!B]2&,*A[N(#5_)31;H\RZIQRG!*+U7N)ZNOJDH5KV&O]DFSQ6KY M6K7X,(8O/$CY&AP_==;5D1M;=,L:RG4I3!0[/-T"[]ZY)JSLM37R$7/4D/B> MW,GI;$&_S?3W#EYG9"0G5[$=T\<::IE]#_@B[ZGW.8N%+-DVRI[8P54H$Z8F MY&78`,,-F2.Z+P551U%^IET;2L%+P`[B%5>,24=,>EA@5B-ALL:?SO:$2-\0F1Y;<4!LB^4QT%+[*V7(&JV+K<0@TUG<6T=\`##\+`&43)[93R_D)I MH/&*22UY%EYDZ`?B=DG,J:95DL8+87`AD`0^\I>/*9I<9I\MNY%VMO5]M/(> M6E6.5^U-Y';8!GX8^F/-Q(Y.=1/[?O[^_:=OOQV\N[RYN?SZVNA.'N9NT*UT MBZT>\1T=[=G]%-EG^!>CUGQTF?(%?8$%KZC/U[?/;'3["%Y"&`,"'C,S+N^M MQ^'ND8[%[RZOWG^X2K@Y0*.!/#5$,*'\M]P2++4'NL&^9154KF;3['%2L>'W MW:`S4K7?]%6>I/F`Y_?F[;IJ$:*`TYN<&!XWK%K67KLU=^NLMKYY_GU@3M2$ MY"\+Z=Q<5).[Q'4P;5\ACO,L6ZR#TLI'-F'=6':K-(4BIIF MR@^9P,0$=A?31BT[9YM`,G?+2@"V"MEHA2>!=9.=>4(M0JW=0*T.H=9^:1^A M%J'6WJ,6^5I[IGV$6H1:>X]:Y&OMA_9M/ITW0UZVE:6;GS!?\0K77,YM`NE, MB[.ZA=J(9L\5O%U;81)O$F\2;Q)O$N]=7&$2;Q+O_1/O.I%$;@X#B,;QG+)G M'X!0^,%KXW]=M#_"OU]FLT0MCKXOS/+12(5R;3$!4$1LO#XT75]^H*I;U".0=E?5<-7UFSHAW#A_GNL$:KU\T1Y&R3(F(V>; M30^E[]0EX@AZ"'H62=;CLCG(>!I'$$ M>/8>>'JZ0BV"GJ:D%BE;N/ULX17C#*]TJZY4DGWE1,]E;%Q6JX2%$H5DNW:` M/[M@P[0FC"P8.<^[H&`$0+L/0)U3I96+8*>W8>>#D'/UL6)(&AI%2,(VGT(HEK%;0L3`=#2 M"D8`M/L`U-,B$$%00U*-E#WBXK=]4)1!J2$:Q><6+.8J6;;#_M%.4[QUNP=B.%S&[,D_I3QBF)WVOHOEB MXS.4*Q&47=#C51C.1:Y_UAK6I\(\K55=A'MZJ[MA!A[L6B%!8^Y2V85P@)"/ MD(^0KZ*`?/>V?QJ(?$D)"/D*^IS-L/Y'M1T623T&_C M_EZ=;/.2AD?<\R.=WY6=X%4\YE@N8EH<\>E83>6K;YQ@^3 M,(\+G+/\\5NQ_+.1]O6Y%VPQ\`DP_:C@X1[A'MKJ_8]UA^:(^3;O@83 M\A'R$?*MK<2X3\C75`TFY"/D(^1;6UWSR0Z>\-IOY)N5?Y:?F2!,XF/X;1"\ MBG]K1&.6#("?@"_YP>Z9P@I M$1YQP+S%KX=C0^)U_##8?S"+_FV46X]J.0A_!W?)\=!?%K@43' MM[DQ@:>9!Z_03OAR(JNP2TB&/+@W@\#T0FZ$OC&)`@OFRA*R1#H=.0#?<`X$ MNYP[EA(8#P2T!&SHXQ?A_ST_A&6TW,B&R3B>H-1F(0O&CB>2\CCS$I>*BY'R M7SNI&QATZ+NN?R^8(52OP#3%%6Z81L`LW[,/RA)0?ZEQ<&&@#2&*GK' M-Z;5[4!&`#KGEE?#>.%XQ7'"D1]Q>"UO&>S!8I-0R1A2`@, M!M[PQ#Y'7LGBQ/]Z[=;JE&N9..#1I28[#TF$V(38A-C+O._:>:@LW"/()LC> MQI'TIQ-#-,3ZS$:D68O_"`[EC5)WA4:)#-`CEKO;[N@JJM=7D[FO\+D5I2+8 M(=C95=C158\2[.R$4A'L$.SL*NR0M[.S2D6P0["SJ[!#WLZN*56=U-4VNRG. M@;.GW1'Q6S3&>A!8!*TLK$_SZBS7WFTQS34T,T!B=3G858->79.W4PM'\DGR MV>2%(_DD^6SRPI%\DGPV<.%6L,_^J&[N_6[-`V3E%CCKRBPCF-W$&+$43Q+*CH2K^^ M2(T.3*XZ"TL')A_-MK.UG9?<*.->=%OM7F^%W'NJYR5WK"_SUOE%@$>`MQ7` MZ[1.3\$\`CP"/`($X"X!VUCMK:!I`$>`1X!'@$>/L&>+W6Z8FV^3P!WJ8! MK^FE.?K4^%S9?=HE.^^9YXN.-%5%.ULIVYE_/?>3-G_[O*>V"CLWUXSM/'/H MAN[UJ]R3U"?"&\(;#7,(;]:OJN(B+?N#O3GGOCF43:@Z,]N,:R M;T_VXCKMUDG[J-7ISC]5WRR[V\#M.+J+J#E\(PPD#%P``X^.CUMG-1H:$082 M!NX,WP@#"0/)#]P/728,)`QL+/OV!`//6NU^I]7O5-Q/23#8Z.1T\ZI4FY/) MI@8."PTN[M&LGMB,JQ6S@EYL]5"A@T95"PA*L3<.AYZB6T''7)8]YM(^[.C. M,9,;0:?Z".X([O80[G21$\$=P1W!'<'=_L'=$>7*">X([@CNG@CNVVIVS5K]WK%6Z9I]/V!=[1TA$2$1(U&WU>L>`1KMX M4HJ0B)"(D&A_D(A\HL9(%2'1LII&2+0'2$0^T;:EJDXVP:A>9/A'GUZ\TKF%=1;KYA M6WK:/FEUCXYVT):6J\[W4I4)`@D"&\J\O8#`H];IV5&K?](F"&RJ-!($$@0V ME'E[`8'D!39>&@D""0(;RKR]@$#R`ILJC752S=RCZASATS.+.BP`D=IDM6[W2F>NM-%7;!0#>X)\HNF.A& M]T8!(]T];IV<[H>1WDMU)A@D&&PL^_8$!D]:W5Z[U3_=Q0(8@D&"08)!@D'R M!I^".A,,$@PVEGU[`H/D#395'F=EKN5G)HB4^!A^&P2OXA\7S?O**Z56D_C] M,^*A,YS.D.HEV'\CV/\-V'^US'53\MLWOW^!KSLA4&ME9BM?F(YPS6['S`OY M87[]TF5-?OK)REHR,N^88;.0!6,8U3;"D1D:]TQ='<7@;8;O89)9O,08^H$Q M=#S3LQS3+2QRP"9^$#K>K3&)@HG/69&D/&-SJ>@=D(<=$8"7!GP0.+#<(@N.#:S/V(Y"R%KP0MREPF0-_:KKA%!;^CGD1 M@\^$-`T8*U37!PE-*&$^7ET&@C0&_`Q'('',L*(@0/&2[](0PCA\+.:CERD2 MJ?6*%"Z.Z=GY93VW_0E>57=N62@;*!+?`]^#GRTF(&F^Z'WRC,^1.\V/VVUW M.BTA%Q]CJ,F^XSH$2LS`YL8['_Y39.8+.?IIM]O^Y>/Y];ODU\XO+PV'\P@H M-CV09^;9`M-`(/%=9O*&XH@\>6'`7#.4,HR/*,%'^?9O/0?%$V35M$+'@L7Q MAR5!'C%0F)%AF0$S<" MEVBA`:,A<>@"Q!_"'P/\AF>S(-U@3,?"1^$A/[J5^BAHFX(/B$Z$#W1P0',N M/E*OC;G:.?F%EZ9I#AP7GP,)?F0>/60RO@.26 MZ_,(9VL._`A53RU)ENW&Q`>]%>S5<$N*DX!I):5XNR0P1'`@H0:Y5)"D`F5A M8'K<%.P`T;?H,GO?)T8V?*]H46S=/Q@J!52ID02L<#D^;8$6`CZ)B` M6V,`?`>C/38#QYV*KQ6&PCM#$9\$!&+,XQUD_A2.G,`^F)@!L!S&]`.PZ`GU M>8@>,-3$`HT<]'W8JX>`\J!0/&,E31_$"F+?M]@=#;BDD\ M&&.NL$2G4^Y+([P')X`![&&\BQ"*@,(L55V5+@X,ZK$P'BKQAM/! MQ))H7USM[\3P!X,CEE:*_Z[CXYM7$3^X-PN/X;22!P^-&PD=8KD5XU.>9%8;&*S"5!19X?'<,@`$47P'>,5$Z),"%QI> M&&3B`G4O)#+^=G[^7?[T,E;#'Q`EP&/7H9@%O/M\#"MHF:E["[!CWK(8',?F M7^"-)]-&?`!/*1K+'IG2P3"%[Z("$E0K%D?K^`)TK!2RN(YTJ!PU4NIG2H41 M\Q"17L4S\B4H2%)>695L%2!-0YJ8?.IUPY>41\H-.PJ0G^E#@KLB,W`(<6"( M+D\LLL!]%R<"+`BD7P2/\0S+#E/!RXO0V[Q\7203`<8*:9PFLEA;VKZG(@"S MRPUI'-XH.P>JZDUQ2O-Y)U,M+&LB>4#;AC.^`:`E,^>6!A0OD2='B%A4-?#T`AC?3\>XQE?&!O@`(&W[/, MB$MRY-\2Y&)9N<6W3Y1"MV*T#D>!""]CL@2E`1\Y$QQ80N>80:C1$K&JFBYR M!AUR#%P+`H?O'C.(*^W#KPD.PA.!8G$A(Y)XD,@O$R]$ MS972`+/#>0C4D,%,G8D@/8[@(F,919RE:T7<_R"F\U50GR[(94SL=R`"GY77V[(]S?CE,-/6/KX[GC*/Q5S8>L.`91,06@(++?WT&2MP^ M[+936FN_?SV$=]I%RLV'&93WEZ0\3SIP1ZCH)R4(FF?>3;_YG@@=`75`4N57 M9DZE,).97%^:@K>)RYG,YDH:F:LT1[&0*5Q!B"UOJQE`$0=AA1B$F>W`XYM9?./"(#:`$VC,%F`(5M$1NW$;L M2))Y*7[!\.BB,%L\"P_'UA4A8N@\R`?C_1T1EJ,.OW#N7I:3+,G##@9;)O?Q M@:EP.(""0^-:FX@0&3>Q'P#6Y=8#L'$L(Q3X(9..BC>V9(I(3:)Y%BZ3;R&^ M.%R@JPMD2G\!H3,V\7(0Y3RHV,\/`.[$"*,I!TQ$\`7K!'+@6(AYG&6)R25! M8;:N'.@.;"&&J(]W8`&+&B&["HL#DT6JD^-]2:5R1Q87/(::)A)%I&;<( M>YY84CEJ9M"OS';$(SA#^8LC+76:RN&'/^/)%KB<2=.HD0)_CL0N*TKV\9DVC@.GR$9H0!EEOP4X3^"QH5="O$0E9254@@%2D3 M?HOT1-&[L]0*#E@L>TQ:*.F_"=T8L/">L=RC:L5B1W+.@+,($W)MH?#8,M&; M91PX]OZ]6&D8$903518\7@SY,C(?AE]3O!'TIT]+MR6`/7!G:)4@W2XGG?Z1ZUV&QY_WCOIJY\Z_3;^)`9[WCGMR#\#_$UD2AHX]8Y)S]L4 M+`U-<0C,$`LM/7!%`YU2L6D=A*()A-$ M$6&W,O6?G21J3AH1IW&K")_5C-0&<%GODKV`812"P6DI)WML3I,78X`3P!L! M93G^HD)?.7M-$B/C=,YU`U1`:`W&#Z^_L5!]_SPSN\2[B;A=<&ZZTFLXGP1% MKR'CYK2?O87UA]5]\ZKZ+8DWMAPAU>Y+GA`0O_42TLMRI),2TBEQI+U>0OI9 MCLPBY+13EY`DD`$\.O=L_`]ZVW>FBU];UKW$800(B!\R`QJ(E!B;.ACD@;X` MB-^.0/Q=![X$^,9'@`0'Z..I<$M!#FH=8/VM@X`*FJC.B2@SR9I-#9490'_5S:4D$D]G;`9_ MH?$`7`9/=H)=)P_/Y39W*TL[;JZI+Q](/V*/VMEP MO$D4JF2$XZFIX"OSJS7TT3KPUZ!Y7T`?7:,#/UX.T*,7P8R:B1I-;.7#4YAS M1;7>KOPV_R49K3MCM)9*2HGD!Y(\9]26RL9B-C4=4F6_9+I,FB]T M]^5OOPAUCXGI`3$_O,RS:E8R5R/V4*6Q#D-7FF`_IM@V0S/FM++:A?QINO5B MX\O\B:B6\.]STI%1[5IJJHFV+R`H9VC<<<`KA__U/DDR+X&(V<%$2A6\$=!= M'!=0\:*`3(8,R$2^24B5S83CH)#0DF5NF81:-GA3.5,06$QSX\YG*W8NA\Q6 M>7\1#3+,BH\=&1:)4%SFPV(/&D.5:2XMYHJLJMJ>2:G"I'N,^;-0M@9+2Z;I M2B`6BM'2]N@\SCBG8PE2SY-`"?W]]WXT"(=14J'%#Y.?%&S*!P.UEV8C?]5> M"7I_<;X"8XN`9C8^Q&_$#BS@HA<'2V(RBIKD_;E4@@S04C1:83:AF"V0 MFUDRB9(A.+%E\^;KW?DN[C7GZE$RU@+?]V=DJP+C:W#?Q;>`]ZUZ+^`J/$#< M%-&7?%I.A*=R`'^2YBJ:@)9P]2(#$V9A4LHJ2V0@^D2^X_L<#@"9[L+Q3$0I MXEU!XBV36TV)/A@#%?_(RC$1M,A=#]3.=$H878KP6X:-$/])?LO0$3-D8`(E M8=;4,ER(H706XP62 M"96"EN!F@:BDB[,R=43&'(;H0J69C5R:8@@/A;D-G(>1*>0+8$%:!. M[.QAA@T_S%;Q*1ZJM_+,6Z4YC6-UQY5R:MI80<33I`%H69J]*DPT2W<"HJKZ M+?\JD.AT4AG9!MS`%#6\QY(^`9B*O\18F%X0?SJX!UD9(5%4?SP5=H"KCR,[Z#C'FW\,A,V?,O;_FN#R_**$`WR? MI!(X!M<7Z2+CN)XGKBH:9=\X95^V4E^:>3GP^GV+1CI/&*D07TAP&SB`*XP)3 MM-@QT`$NQP.`=62W/I8ZR+QK&DD:+QQ9Z+$>(G?/<&O'8GOPO_^5FW* M#..T+[XFA^\>M<5;VC``AAZRX`X%."T6,XP#44[7%Z^2/\,$7AHW/CI`(A.- M$8Z\72.WZ##54SG]WK&<>;DM;\F:`%=W\.PO$:,L&1M\@ MXOX"(9T!`QEB).,0*$-'2U15N<(IQ1T!#/Q0BF5=I=C0%5X+,D!\:8"-W)1I M1H5+'AI((+QG"*XH^`"IZ,IZ$6[\JP+',?K*.#)/BVNQ&B@458/"+J>U5"5E M.KS,>/GQA2?".*H,8/(*L6AR[S!T#I+.<_G2;OP<`V%5M&3'CE"R^9RM%JIF MD@1NH:R"[U4&?A MYT[K]/1,_7S4.FIWU,^]UND)JO)[YOEB'8NDX+^?2E`/8D'-BV=6)@&*VJV3 M]E&KTQ4X";\='1^WSCI=H_396:O=[[3Z"$1E#:N_S#B-]F$GGAW\>)K\>-1) M?Q2L*/Z[R&J!NIT<5R>^(%"L7WQ'ES'CD]Q`B<+A5U0[:@'0<6-68\8G<:O( M>1TAY5.R:P@.D9R=-RH_R100S8;+HFLL3PA?Q1E'^>UE(38YU&S$.;8ESRCK M3B5GC$H=H@L3_8Z9[.\"+XIG;=.]HO>,6X$S4=YZW?*BPLE=XU"=S'W,2=Q% M#]_F#]NFK%ITVJ6,9.:SR^$W=I\I_LX=&OWFA[^S,#Y;N@#SXJJ#N<=2C4-U M['3!DZ9Q7;]RQMEGGV'1GUI8YH[8:Z4Z]DZ6<"Y$?>//_'!P8__?G MU__T_K__^S_6)'KXW>N?V?^W?^?X_^\\6R^N&_>L.O_7^-@R_MGS_^YY_PP7IU_<^_?F-_ MG0\O^A_=?O3^-_?;S?_YF_1P/^;_[OCRSZ?'S5_F_S\Y^=[^=_]\+O MXT'[^/K>^N;UWO_/R=09VO\,@^G'8_OW\'[R]\7O[S[]=?[KK_^?<7%]=7`@ MMO/S3KVJ![XKFMSD'C)QR$J_Q)KOU96]>A:Z&N655_J'A>TU.JU"]K[K7!];J/ M'9TN>^.-IMU8>E;UL4W55M0Z#5U[%M2[]F,3W=/4'WZJH_T#,`@U&ZH]@I?@ MGH&0Q\P\7J@Y7??HL7?6R"6HU:INB[=X5%!9(G,+4K'A]XE<9-4U)MDT9%Y( MZTAL^8SW)B>&WFS5LO;:K=4UU7Q:5QEM!=+(/)!Y(/.P#12]=AXJ_3^R#V0? MMHIIL_H(4]3TZ#M.]TU<*DQ@=S%M7.)*5#)WRTH`YG;F(O$J;RLDL&ZR,T^H M1:BU&ZC5(=3:+^TCU"+4VGO4(E]KS[2/4(M0:^]1BWRM_="^S:?S9LC+MK)T M\Q/FNW##VVJ!=*;%6=U";42SYPK>KJTPB3>)-XDWB3>)]RZN,(DWB??^B7>= M2"(WAP%$X]B-R[,/0"CPW/+_NFA_A'^_S&:)6ISL"J1\7#X:J5"N+28`ZDC' MFN4##P;,J$6JZIJA#TW7EQ_( M2,DR)B-GFTT/I>_4)>'(UFU2R0AXEE8P`IX=!IYCK84GZ"'H(>@AZ%DG6X[( MYR'@:1Q/"'CV'GAZND(M@IZFI!8I6[C];&'<$;>Z4JG0*K=6"0LE"LEV[0!_ M=L&&:4T863!RGG=!P0B`=A^`.J?D1&];G`B"EE8Q@J#=AR#MU@4!$`'0+B@8 M`=#N`U#OA'R@!B<2J49QQ[*.XF*M:J@S\G=NU=`]2C@V`LO)UNV^K7M!MFXA M?KU<87!"T+.T:A'T[#[T=`AZMBY.!$%+JQA!T.Y#$-4J;EN8"("65C`"H-T' MH)X6@0B"&I)JI.SA]K.'OS&/!:9;H9TR>6C:8\=S>!B(FSPI@[@K$$TF;/=- MV&F?3-BVQ8D@:&D5(PC:?0CJ550M$@@1".V$DA$([3X(=8_:!$);%R@"H:65 MC$!H]T'HN*W?5"40:DA&L7G%BSF*EFVP_[13E.\=;L'8CAJN[808>[%HA06/N4MF% M<("0CY"/D*^B@'SWMG\:B'W-*RLGS"/,(\PC;V^7A)"0CY"OJG6SSG`3R8S+%\YE\-'DH9'W/,CG=^5G>!5/.98+F):'/'I6$WEJV M^<8/DW)8C?X;H%3>@67R$;P=IF18_GC"/"YRS_/%;L?RSD?;UN1=L,?`),/V MHX'+:ACDS;*O*;VL%^);E2G><.&M]G:A';/$>ZF_A'N$>X1[:ZOV/=8?FB/D MV[X&$_(1\A'RK:W$N$_(UU0-)N0CY"/D6UM=\\D.GO#:;^2;E7^6GYD@3/CQ MFU<1/[@US27X_,@+TS.;,O,MG*<]?U+?'3 MY?"*6?ZMY_S#[.\L<'P;+S[G-^PA?(=YV[>*N#?QF]2CS-:/_.$!?V1&Y#GA M%1O^^BSB]C,#BWAA1/$'J]/YXR.PLW,^";KM3O?&[[4_1Q[^^`>^^W(HVII^ M9>,!"YX9-K.GR7Y\=])Z][;3;[736]6AYN_()=+,3Z*03Z-28P/%2,UCY M%'IR"I]-;^$U.&K$&AQE)[#8&O2ZS5B#?J4>Q->)G7OV^_3.,#6F?E)+SFGU MLSJN5(XE9M4Y779:*Y_72:7&+#&O)5%@];,ZK52C)6;5.VG,:IU5ZM8U<\'2 MW\*TOL:=L6=.ZF#)2:UX1MUVI5XM.J-.0V;4J=2H16?4")/4[5;JTJ+SZ2TW MH97/J%>I1:IY%,SH/-TE9JU1/K5VK44A/KHA@V M8F+'E:JUU,2.V\M:JE5/[&0&JM^BP@;Q,3CI6F*HE]6L-\ZKV*Y:9UY(> M^ZHG586&)9Q;+DQ=^2KTJH2KA&#'2QJGFHZO7TQ1A1:YW!4GJ MJK2I!9#+@@86[*YCZ\/R43AC_AS/34`O6SDNF5HWA[_%5@Y5A&ZDP%;]X:>: MZL=R8I9BKY:L\;;>O\+D5I2+8(=C95=C1G0LDV-D)I2+8 M(=C95=@A;V=GE8I@AV!G5V&'O)U=4ZHZJ:MM]LF?`V=/N]?]MVB,55"P"%I9 M6)_FU5FNO=MBFFMH9H#$ZG*PJP:]NB9OIQ:.Y)/DL\D+1_))\MGDA2/Y)/EL MX,*M8)_]4?=T];LU6X.4FYNN*[-P,+]Q:N?T,2'-AC(+F=>N<_`O/N<5X:1A M#.%I0YTP<;S;JEO"#',R<1U+E+N'?O5R&MCM=>Q[!LBVVKW>"KGW5#OA[-B-.UOG%P$>`=Y6`*_3 M.CT](\`CP"/`(\!["H!WU#IJ:UO[$^`1X!'@$>#M&^#U6J/)(_A#>$-X0WA#>$-X0WC>,:X0WAS2/Y0WA#>+.*1.!&E)N^%'(0]/#5LL;SR32'ASMP366 M?7NR%]=IMT[:1ZU.=_ZI^F;9W09NQ]$ML\WA&V$@8>`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`AO*O+V`P*/6 MZ=E1JW_2)@ALJC02!!($-I1Y>P&!Y`4V7AH)`@D"&\J\O8!`\@*;*HUU4LW- M*WQ=27.+IYV7_O!@N9'-["H\,(R)'S(O=$S7G MN]4_W<4"&()!@D&"08)!\@:?@CH3#!(,-I9]>P*#Y`TV51YG9:[E9R:(%'[\ MYE7$#VY-<_+ZVAHQ.W+9Y?"#&7B.=\N_L^`:KSRZ8I;O68[KB!N,;O#1&_80 MOL,L[UOUYC?Q,.=>Z,09T>LD(1IG5#\"$R[\\20*Q5CE=YV/_0CX&WE.>,6& MOSX3=R[Q9^*.)7BG^)O5/?L#!^J<3X)NN].]\7OMSY&'/_YQC47#E[)QP5^=]7O'Z M<;MSN@=LZ$@V?#:])RT-W2P;GJXT]"JQX:<\2E#%@=/V2??H:`\X<%0)"[,Y M<'1Z=M0_:>\!!_J5B/!49."X$@R>B`QTJV!`,^7N,<3RNS_E7I7>EZ9\`HX[ M^.V[/^6C*D7?WU7N5VGV=E;YBO$PB*P0!O-NSSW[BKEFR.QS"UXBAG_O<,OU M>12D04/=-7S;X%*4)4+!&Q$*?H-0\$H;"JH__%1S&_BNG;Z]=YB)#VO^=/7A M^N;JQ\7-CRL(='5!NIQ,KA0%?AX$K^(?%V6^O&)X-=S_,^*A,YQ69XG6L`3I MRRZ]0N0,L.JX1N>L98!LMEO&/3-,SP.-L)AMF$9.#XSOKND!!2'S0+&,T"^2 M/O2MB!M^%!BH<:8W-7Q/_&H[YJWGP\0M@[/@SK&`W$'$82:<&_NV6>N^BFI,B[C+H6`#8CZ83_,=T(Y9^E>\%DJY5 MD6=BZ=$26/KQ_--5.;7YG_,O/SX87S^<7_^X^O`5N':MS842SE;B+"AP&1Q= MU[\7N(.Y1M#-\=@,G'\8;R'H&,RT1L;8_!-^M$";;OU@FD!&,H;CF9[EF*YA MN MN"K^/;-$.&7T.A(S"K8#OX-(9[E`C3-T+($ZQF!JN.R.N8BHC@>.EW'OA"/' MDZ@([RR2)$D8.0!;@36:@L,'\T3S,_"!RA?B23_B\#K^\O7,K/P,691,MYCK M3DS;!AZI%6\KV<%/^,2TRI_D]CC:NC3\0JGQJC]4/%_EJ:5"G,N(:Y/[M;=P MCDZ7/-BB*64NWK"E+17.9OL?1?G2)W(T+-OFCLCR?+)\E-^84=W%-I>69]\: M5[Y!ASWV14CV1)EF^D&S6;<:]>JT%Y+$WLGB9[KJ,W>+'K`%H04+ZI&Z>4GX MF'$V]!2)$,3X*KTHC/8XN$*U-$Y[UH6PKHDZ7*X;T-9HU'&C'G68;6GOJG)) M&AO[;EYVU$S??[BXO#J_^70)(A]Y-@MP]`R=-6A)OQV'1+-FA]%27D:U`G/N-TN]E6_<8/37@,*25!&4/94H.P+YDFK,FB&T:%( M9$]5E4".0(Y`3OSK$LCMJ:H2R!'($J5F+ZY7L).E2C448==7&J2=))TDG22=))T MDO0]F3Y)^KY+^FX5$QU-'@JAVMFDO"*K"0+/]BX(O##YJ#JGP_Z.'%@K5G6- MXYKCQ"WU`MMQ]5U%&7:>E$[ M=5"1OS2[K)TZJ#08ZYI7[=Z,H@?JH-*8#BK9%I*5X:ALA)L7TUHQY%8K[\FT M&VOTG.F\VGKE@)JH[*.=)B@C*'MR4$9-5`CD".06XAR!W)Z!'#51V5=5)9`C MD".0$_^HBJ6K=M#(U4=FEU'+Z8FJBLLN5#'.]A)VJ4JBC#KNXU"3I).DD MZ23I).DDZ7LR?9+T?9?TW:HGHB8JU$2%SH7IV$?GPAXC?$_K7%B_=7)2;R^^ M49;W21P-(SPD/"0\)#PD/"RPE/"0\)#P<"/,H[X!3==F`D,"0P+#C3"/P+"A MVCPO?,JX@>WICEYC6>JQ:GI]PZW7!_/3?,;]A"^PV3O6S':F])W M92F-.F9M7WI7S(J"P/%NWYG<21\W+)@>_'+%AK\^LX[^^`C>+@W& MNN85WS>C!H-ZNC2FIPO$$,SHM5NS9H=!1EY&:\6S6ST%0';=6*/;3&?GUBL' MU-!E'XTT01E!V9.#,FKH0B!'(+<0YPCD]@SDJ*'+OJHJ@1R!'(&<^$<-7?9, M5>OFE*FARR[EE=,74T.772YCF.LE[%2)0AUUV,6E)DDG22=))TDG22=)WY/I MDZ3ONZ3O5C$1-72AABYT1DW'/CJC]ACA>UIGU+JM_DF];:I&6=XG<4R-\)#P MD/"0\)#PL,!2PD/"0\+#C3"/>A@T79L)#`D,"0PWPCP"PX9J\[S,M?P\V]!E M?]JF+)FAIZXIU#6%NJ;4`DSJFM)X9=IZ(3MU39&_-+N4G;JF-!CKFE?AWHQ" M!^J:TIBN*>^9Q<8#%AB]3JM"]/!?M]TIG&^N%3=NM=J>3+NQ1L^9SJBM5PZH M<B)JG$*-4^@LF(Y]=!;L,<+WM,Z"]5LG)_7VXAME>9_$<3#"0\)# MPD/"0\+#`DL)#PD/"0\WPCSJ%=!T;28P)#`D,-P(\P@,&ZK-\S+7\O.X<VK[TKI@5!8'CW;XSN<-OV$/X#I.^;^.!W\0C M8![UW+/Q/Q_2I&DR[GN'6ZZ/@QJ1YX17;/CKLXC;SPP+)@RCBC]8[3_.^>6P MU_X<>7A9_3/#9I8S-EW^Z[.#WK.WW?Y)M]UNIV37?NG;-1#;.\E3^T?R_"=O M$H5F>`WDGN7)783YCYI*D?G7 M(:C#R'=M%G!\.)Q^\\/,(XG*Y.D_^N,C($/GLRE$Y\9/9?YM(XOS4AA9`@UO M!!I^`S2\6KRDLW^8@Q3]N<6'^C'CH#*>5ME^[,)+3-[]_`58[(0QG9-ZW0\3T.[S;"$3,F+'!\FQO,LYE='@M`AAF]=@M;&G0/9WEQM$*: M%;KT"CIW/@D#%GRY\XO+UNPIF`.QA.7 MA;I5,@T8]@X>,B80"XBV-=G%+KWGN_QV@;;O\;/95X/?'(X,T[+`NW/@Y<"1 M.\9#/Q`2=#]RK!$2QQ&"02C\)$9``_A MSWX4X-3&\"6.IM$P/;M`6.[C2118(Y,SX]X,8(HAU\+]#^ST(00\9,$87Y2G M#C]17$CGW8IG8O0.VZ<)[>A5<&/H:SH'/>\>=LYZG6X?]4A\44O-!Q.XA)^B M30>W&/F(4_>*2R#8@A]=^..!\]4,`^>AQ!U\+IZ]$?H)1XJ2W3X\`L)23N?' M"6$H@SVPP'*`F2`_EG@QSNBH/%&)S\+UPR4#K;&,P-;Z9W#;_-H+(A4E,W(@7./:\?=CNBQ6`!1(O MC#F#^@*<\O1+G.S:GQH`E[`%*V*WC>:B;'%8$Z`U'W#"'H1*RG.+F M"<0%&YEW#)04YX6S'CKPZY29@5YVD;1)X%N,V6+=X`4%X4U5NP5J%>*77'9K MNC!G'G(08Y!# MOW!2ECE!3P#E;.)SQ@^-;WY1UB0J".`9F)YX#$8R[3N'^P'8(`;C"[LT,1VQ MKLFD,H.`T$],;ZIERCF$\H''IAG/C,MAD>R`N28JE9A_D3;Q7G,"+'T`ISYD M[M1XWNEV6^#2MXP!QJK".`+7D9<)YX?@;]<`#>0O8-WQ48P7F[*2^^PI_HPU ML\Q*\C:JO0V(8T-0!Q#GO.#&0)>U%CD3H\`7]00MG>OZ]_IS3C7D>#6==2'@ MWGIKW6(B+)LGTY1WUDWJ=L]6U_6M5/9;^DXI`:C]Q@9.9J^1]'R%]?%"N>#N MT0J.1NNRK@T\%KV:FMZMGM]N'K$Z2K=PD'G/WW8,E!TM!GBF1!/0'1U.XO M:<$:U):!7(SY+D9OL<7IKN@2A17.YVD(W&-6K;>L'.I08COE`(MQK5P+L'`` M]*C3:_JX:-$F10USQ76[HQNI&)EI"#-Y2@TUX$>A*\#J%YBLQ`;NC7780F^N MADG]'@>@^QP`X&[OC*BVUV[MFL>/V]8;AK&GX5D16!-8-X70IPG6\5TD53ZE M(2XIV3V\7N`0(>'UT\/K5:1>"*\)KS<.;1]4,=%<2&X6(G_'DJX%CN\0)F\Q M.SD;V/('PVIN9VY>329.8&)M6ZU-F`TD-1?,7FXD?;]T2[W2@,T+K3;D5FRE MT1V)!(D$B<0J''H2B76*1'N^,=N17UP6ZOU M%"A3H+SJ0'E1K=DP@S84^!0G!2'/\?SBBP9(YT9">HK2MQ^E7UJAGY0+:8/T M]AD%Z11*-#R4Z+6Q<>\/8T+&$B/28^;I\=G_;-6[TQ?M$#JO![AW_8=5U3L M4+/8H;^YXROU$E);EWK2[7D6H)9R4Y(DKXKU5GR?4B=SZBH*O8NWF3A9A70_ MT0*,F:P[HG1,#3VY\4/3K>&=[EC&I=;B-\)9U48T0+YA^]'`935"M09,K'ZL M5C6SJF!MLR:IVSIMG[2Z1Q5'TW;,J]NP$I!:DUHW4ZU[K9/CX]9QC]1ZLTI0 MA_+MD[['B9C&4KYL.F;#LD\:OFC`JE7QIYV.69)%.[V^:TU(R,],<#;BY,T@ M>(4_OGD5\8-;TYR\O@XA+!_YKLT"_N'OR`FGW_R0O7>XY?H\"M@->PC?8>C^ M5HS[)G[N>^!;C-G$PC9)\XCT[/897!MNNQR*,F0'H34(T%[\7Z:XBNTAJKWV:)W7F M6S-46H/QPVN^)S23ORG=GS^-;)$_0'O.JG&02F%Y:7^M.WC\_> MM@^/D,`YK\TPSO'N&`]??Q+_&3,O5./S#P\LL!PNIUB+>[56N2OX>/3F5;T7 MOUWQ"A]U"QQ5;P5&37R/Z?AZC%QM]^NO?%[AS2E.CJNOQ.IVX?.0SU3U.LQL M/WO;Z7;SNCWC?26I?"0:]2K1Z!O3,%)@T?'1,EB41R)KQ.S(C;E>0N%8D"Z# M*W3R>(+%=3G\5M@UQ'_#8JX[,6W;\6Z5P6HK(X:?\(EIE3_)&SVMU5O(\ZCZ M0\7S<\QGK6K&=9+.?OZR^^.%8H'NT>(%+?.C@.UN8-0MP6XLH3I2 MFTJLCM*UA%+J#S_59`<`X!EB]OQ]T@^K%F3\YP\-Z;D9PL+-V$NNDV_,8%"\ MO;;G/!:.!(9O,[@\A'&-V%68SU0]XFR+H9=1R$/30[>D4GE-#G)44T!6M_=* M!48[Y6+T%EL<;4*XQHSV+X6Z88%[S*KUEI7#7>--<\:W5 M$LTTA._-<(:5!S]*)+PV7'^T-]:ANQB2+G%2A`+0K06@^QP`9)J#ZZ;?:[=V MS>,OUQ2O'<:>AF=%8$U@W11"GR98OV>6V"NJ\BD!KSN[B-<=PNN$0L+KM:1> M"*$KS<.;7&!QEQ(;A8BBXH-?3Z<,+EIVE M96CS&EK,C7J>X@9S^M+S2>"XLX+[RJS>&D-(NOU@,\9\CVX_Z+1ZG7:K?Z+? M,207@C2+-(LT:_LKOJ-WBS16A5;6.!./:#:%VW1+*`7*&PF4G_!%()G`IS@I M"'F.YQ=?-$`Z]^<6$(K29PKKI17Z2;F0-DAOGU&03J%$PT.)7KO5;FL;]Y/C M0CI%.D4ZM74I;9@(4F#^_.3PY+0IW*;`O"FA#P7F^QJ8YV,=77!>Z#G\E(-S MVF_?L4A^WEV=%,93R-'TD*-[UCH^/:60HW(^I%.D4Z13VY32AHG@:@)+"(4W M=KGCJL+W@PU$3:M+DJQ3PY^?'6KS=*3?^X;E*5<2;W]^%/LHL-^K[,(J[VE? ME5354@9-<%L^M[K><'=K<6VF_9`^LM7+^QHB6ZIIH$S((O)"45LC7>:=L/2= M5J==N?^Z/(?VS;E#7\6F9<^/-KAFK>G M<0$#Z3'I4CJFA)S=^:+HU MO-,=R[C46OQ&.*O:B`;(-VP_&KBL1JC6@(G5C]6J9E85K&W6)'5;I^V35O>H MXFC:CGEU&U8"4FM2ZV:J=:]UI0OGW2]S@1TUC*ETW';%CV M2<,7#5BU*OZTTS%+LFBGUW>M"0GYF0G.!G[\YE7$#VY-<_+ZVAHQ.W+9Y?`Z MA*A\Y+LV"_B'OR,GG'[S0_;3#`+3"_EE<(7HPF_80_@.X_>W8O`W\3@7KLGY MY5!]77W[,@IY:'JVX]T:D>>$5VSXZS,^,@/&GQD6R!@,)OYF'1W]<0Z/]]J? M(P]337^(FT7PVL2O;#Q@P3/#9I8S-EW^Z[-/WSX^>]OI==K]DVXZD7D$O(VY MM3*2^Y+DSGMF(:'K)-GQ[A@/7W\2_QDS+XR7Y<,#"RR'L^^!8[&4X(C;WV$9 MM60?__$1T*#SV12,OO%K\;S[["W>[?3F53U*5BP<)P7A4-UML;]%!:][;?BW M3>$X+0C'&DE>I7"<50K'S`F`>&"'\?KBL5IN]]L%`?EJ3F=PNGMV?'JZ(*=7 M2V^G(!WKHG>%HM'O5HI&COH_OCJ>,X[&%4+2;R\L)*N<1*_N),R'RDG@96B4FTG9TQ@8?%8*:>+=A)KH?'(:)7% MZ1V?G1XMQ.>5DENTD6LB=Y5"46T?\\3/1$%Q0F<1!%G]1([;M294E M)K(B`3K6F]&3"ODYZY_USA:"E95S?9X-U9`.;.XO:#57RN2":U5V3D[;)]VC M[:%(00;*J'%R?'S<>PQ]_GCL"(;S<\^^@'?#EYAG.8R_=[CE^CP*6!(6%_SI MJO5^]K:!V^C9?,(2V:8;D6WZQNZ-*VVV2?WAIYK?P'?ME(+CPTS^8^9/%Y=? MOWZZ^0H,N2YD.^XKA$PBR54)?,SIP(Z#?9W9+I&Z,.3`6/&&#@\XE*K3[N=DU^,@&+=]B_)E\7' MR0>=7U[*136'0V8!@Y0$Z*:-/@%'`D#K0$(\!Q8#Y,R\%70?N/`&UV`P#W_* M0!#O1[X!EK(HV!8:/F?HX#QYGD)+2$?GV+B4,L0S9,)[RS15"%AF&8SO4<`C ML+!RS=E,IK6$:(.P!*%C.1,336PR(9#:XE3`%_+=""0@<-QI^LZ,;+\0@BWE M&.5<"'&K.$XJT2C?^#TA\R_Q-W`U`#6X^&N&6;>^;Q=F$#"3^]F5-5X`@VT0 M3`\H`:7.35],^*5A1P%.$C[2:-^]?S!E9F!,6.#XJ*BNZ]_CU\TL*58BF)84 MS`P)I0V"&B3!0/AG6-N)Z4D=]THLX]'@3Y`77%6E_R`Y/JY>P%R&.HSTN*8S MYH9Y"P+-P\PD,_*3O"-=:`$C`_@#^%BA"X3"2Q2JO#9>."_ST.)[[&!DND.U MS65Z'B),!D9@'1SG)2@X`@=(A8&>,W(QD>ADJ(R[:0%IS.-FZ`,0,;$18ICW M9F#S7P3RP)@PJ,*U\E`7E^^NS@'6V=B)QE)Z<(X5HHT#,K!.#F[,E.3`9D") MC3Z^&,?$80]L)L4K=P6T>!'* MH)V;STV)S@PJI`.:-C#&X3"8)`PXAE^-_QS@HH(I&#E@4=$6:N52+#Z2+3W_ MD+%8,][Y(`;XRWL'Q!+&RMH=F$1I@GX@F.QGEI_IM:\E+'M>$N)1$FD9@^]B MW)MHE$!Y@.V.P*D0]06U,$C=AQ(IYBV876&*#RNW>,DKKN7$?0&7XE:(R(PB M8')_-9Q+5"1^6[?=[@K?3!RY$*@!VF*"'(>A],I2P07S`'[H-]/S;S-V*1WK MDV<=&B\R]E%]->]R^6ILX(IK(+PB'KOIBN9,S("%]XQY*8(SO:=9]'40H;E" MC3*ANLD))HC?A-4;FW\Q`SSF`$9RIZD7'?K%]5*33/WK3O>P_U_BW5BFCJ:0 M"5(`I.T('4T;W45_PNS"7*=&Q(5!0B\3O%+PBP"NN+"H\,>8"Z$D!%W7D0DH M"_S)#P3X!G[5)$JA+F5ORX@F2"2"LK378YE?-,RQ'^D,UO/.8=\8@RG*NY?I M3V@:QC+;JN%8D5VIV=.*&+C-QO-N'WMFHW6-!X3'0J=H#+/L8`\3,`DXWVZ[ M&CU(OH)K M&7\M<41D^(4?!13%B))S#!UD+'>(*&':1H*E]B MBJE;;F1+NR^YDI<*6%_0GW^D9<6'`L$/T*A82DS+DEZA],(\<3P9G?G\0"(^ MD]J`$1&LDAA3:]92MA`8U M>E$C&+?X;!9Y,U_*@B]GP1T*-Y=0;@I?&T*%1.^U@\4QB?QB=CR`J$PT$PEW M.(#O1D&HC5K%UU!\1#`/ZP!*X3EFHAL7"$%3_/`RP-"JX(%JPV!)%EH3=HO8 MC;@(4`YADO`=(7@S72X5;AB8$=9:E:<+45(D?4$5.0%$?A-B#0CYPT.5^8CX M\BGYG@J@RO''=W@K'T3![:AE?#]'YH`J><,K[*P(W`*&+K:<.$#NG>.[,KQ)K%["IY37Z10^(CN,[P&Z_(*Z,+] M"$O@2_0`<"K(P&]%'N*03&B$0`O8=-LL97[9PF3(S%F.6!_2E4O7D<#E9"C!!&]Q&TD(/&(@"JY"+2L&0B:`0?6`0>EPU M`(?H%J/?KE:1NUJ/ZR,011*4"SE7<'9':`@&":/L2\V$V*B$6#: M&,0"QD<$B2R+<3Z,7,,IVECY>I$(5!0XX4;"^?WQ>7!#MIR(@L=%[`;_E9%8 MP+*93IE,CK.:(`!@\TRW(#/"Q*K(R`P>HJ*L4W:^<1DRZS\-ZT#&LHI9X?2D0S#7QWX,"# M3.Q=H'HBA@!F@7#CWR<^E]LNNB"'`_D%W]T0F7<^,H:N?Z_GP[LX"BV9%1LS M>\Y`9J+3<$EFIS$/J()X%=V>6R;0V$)[G:00DTS;`_(K=N/$QEL5L]!"B+=B M37UBH^;LCRC/*]X1F<#2'5P.A\9[7,Q,OC7#K3'N"HK5C'`K,+9RI3%*$H!C M:CEY'F]OM9TB:]YI"T:3*JWR0:959-*CJJ_-)4*S& MT5*C?T&YP*H^`=7E0'D"^NTU$=#+A@$KI31 M_Q]02P,$%`````@`Z(,*07IZ.2K:"```95H``!4`'`!C8FUX+3(P,3(P-C,P M7V-A;"YX;6Q55`D``Y1O)5"4;R50=7@+``$$)0X```0Y`0``Y5QK<^(X%OV^ M5?,?O)DON]5%&\*2=%*=5!%(TLF00'CDT5-34\86H$2V:$GF]>M7,B:-P0)C MK!AZ^DL3(W2NSKFZNGKYZ[\S&>T:.(`8#%A:>ZS!TG^8_5\MHY6PW6^84+MQ M&/_69'``^#-G``C_FW_?8ZQ_JNO#X?"SR8M2$Q)`L4M,0,4#+9,YU\2_W_[U M58"4"!`0IUJSYVI%MZME3[1TPFSN<_HC_`D'GK6U0H(UL MY-"S@SFP49N@SYAT]<-L-J_/"AY,2YZ.Q(-`^6'>*YT[.3G1O6_?BU(85I!7 MF].?[RH-LP=L(P,=R@S'%``4GE+O806;!H/8B6"7)BTA_LK,BF7$HTSN,)// M?1Y1Z^!\RIRF?248@3KH:)[IIVS:J+A5OPFT@>O6AK;!"!R)S[HHHTNK MT,\3-_'&X;"@P?AG&SAQK5RL13]/GLR207M7"`]CFOC^J M<%,"1H(1`XX%K)F9HKXME//YX*`(FP$@)%P;DQD.,MH`G1VX--,UC/[?14H! MHR67$$^<>SY<_7#@P$*^1%EG)(&0,G>ZC@5R@H@G1@-]E#PI?),$V&L2 MC"A^"9VZMNW5EH&\`\Q^WR'87J,DPQOSAXD%R-E![D`;`MCM,?'1CPN;>Y=I M8I>#U($).&`;@7O`5#K;*KR@[^VD1*OY\I4Y7%`FGC0-M]]'$%`5,KS7O0>4 M_^3!IS>?"+TU`OH&M"Y'?>!0P+M=E?4`41YMH\#JY[NN223R?+G^MRC75@.A MNA%P+H:FQWEHS`FE=3'\Q^:U1G"?3S#&-9ZL,"ZE&'KZ(H>[!XIZP`J\78E' MX4Z_BBA9[(\KBZB=C>\`ZV&>7`\`90)*B?_+H'99#"D]LD$BK@Y\+FXX7YJR(I&FG2`B"54!1IMB"#CJ8+"\3L$ M91OOFN63-6,LDDD>5?@3X@+K8UJS"7SZT4#.25B*'HE2V6`:<_[;A\Q`%6!0 M4&TCV/4:I%*_-8BI)Y+1%%O'FWQHW390*(X0*ACQ6NDTNU*R\K",LMWD!70`)\3RZE6V MP!@&,S=,I.%`;PNCFT;.VKY7\)(-[!&XWZ9F*2[;-&RH##5 M0#4#\FF0'S649(H2J/0C:30QI%0ENJA8!\R`#K`N#>+PJ0[EF:=K"T*`508= M:$(EXUT$U+T(5E'84S9GY/.$CQD!UV*FO4\5E11)+KDJB=RS5H65DL1P;SM9 M7]A//O^(7>;%G?J][JQS50(#Z-34`&4`34$7+U#*H]`>\ M194"'BLC*-&%CCH>&XB-?1PEWA)$2'GX6L7X(A?2'"\6T]6^.";&!T-_JTU) MUUP&V68V0%FU(]9XO3#KNV"#QU`U\P(I6KHS!*ENP0F"G*NU8^BFD9T";K\X M7E+FGHJPMW'E&ZV\W_]^6SVW=&+4SBQ M)L>#[LO8:97=X?4Q.3G^X_"UU1Q3=#PP)UETR[ZT2I6:]?(=Y0O.<[M:*M^, MKYL_W)?6=3?V>0-S`GEI+!7HZV!W%D%5?R[=!8LDS/+2.QJ6+9T(&4"?,&0*$VZR#W M0*"UK"5]5,;&A,&)9WNUL[@9JV1Y:#5BZK._2#*MH\U7J9!P:C>=P%4P59O< MS<'LRO"[W/+@`#S+NMKG^9UI ME=[U%_Y$S;$:"5;*?6*MBL'C-3+"DMZ_G=6LT*46(5(?*S:48H$@:>^.R?\L MN%QQ&TO8X4:YW"X_K&!'R9@1`37E[A*=E]!@/!^S=W*U.E[[5GANTEN/]X"I MS5N"`.FONH8V.!@)UDN6[,Y[$+$,J3D%!=9/3&YVM=,T1D7&"&R[3!R):^(Z MZ(M4EV2F7(Q;5&S4O^>?1?%N!V4GD#=`WV+9X1^8 M`&ZH:2`U#]*5Y!WN,N@38,(I&XXUOXJI0I=5<&E'L>TT6DEDXL>M_2C+PPVV MQ21-F6`2I/W62D9?TM?_//,HK_H*DS)VVZSCHMD-(Q5BK<3;]R"XFDS))EC< M3)&(NQ-E,/W_QHER+4Q1RY!?KTM'8]]W@.*G-SO!&3#?$ MTII8A:'';R(/D=ZK#)JX:/YP(0'2]TXHR3^BH^]H`KG"%P*YR`8T+\_6,O%3 M$XG95]`Q'#,M%PY#W\*%"38!L+QUH1M*7?$6O&IG[CZC.IL\KM%]( MG]?1FN2Z0IW']VD?J78JV.DV`;$E]Y+5G"".#K_ORFY$=;(G#,)?.E@#!(H7 MZP0'?14R;X2?<@H5AZN%1<#(*=B:"SN_4/-#!^PUVZ"_4/-#0\2J6\FAFR)? MWU]_[)7Z/U!+`P04````"`#H@PI!MCDGX-(;``"<]`$`%0`<`&-B;7@M,C`Q M,C`V,S!?9&5F+GAM;%54"0`#E&\E4)1O)5!U>`L``00E#@``!#D!``#M75MS MV[B2?M^J_0\^.2^[->61$J]SJV2J9,M.G+$MQ7)NY]2I%$5"$A.*T("D;?G7 M+P"2NE"\`!2:EPSF)1I90#>^#Y=&H]%X\X_#PX-WR$7$\)%U,%X>V*?_X\__ M]^#PX!3/%R/3/KAP??I7T[?O$/W.O4.$_C_]^\SW%Z\[G?O[^]]-^E//M`GR M<$!,Y+$O#@X/_SA@__WW?[UA0DX)8B)>']S.@H->,#WHOCIX>ORZ^^+U\G!\^Z3Y^%A6@)QW9_C@T/'3S,'==[^V1#V,.8.+]C,NT\ZW:/.O$/GX2_ M?/W`OMCZ_?T1__735Z]>=?A?5S_U[+0?TFJ?=KY>78[,&9H;A[;K^89K,@&> M_=KC7UYBT_!M[`KH=9#Y"_9_A_'/#ME7AT^?'1X]_?W!LU8JTM]8_DK,9@7' MG?"/3SA@!P=O"';0#9H<\#:^]I<+]/:)9\\7#E.=?S/QPRL+O/ MC[I,V#_9-]\IM1YV;(N1=&(XK,FC&4+^DP-6\:>;BZW&4H+']MSPB?W`/G?8 M;SJ9573^`%7Q^]`@R/5GR+=-P_$4:)RL$:`!%R[5`HU\^GE.1954.EE+!Z`W MG!K>[-S!]R557!5GNBE1[AK[2$(9_G-%#+*ZNI*RNVI;WI66'RF@4@5Y';K* M^F947PD58B!4:E%&C:ZJ[M@S31RXONU.AW2XF3;R3I;\TU)"JYQ*%/>;6V/L M()GY>:.0TC$4UBE+75P*!!7ICK0JIFIMS&&2_/`]=D MGPSG[(%]C4[IM#[%A'84KH.$WJ5%*(3\!IG8-6W'YK+QA*I#%WG7ZMM.0)>K M2^QY0T1&,VH!R#9/NFIUT]&Y[5+KQ3:TJ-J2VJ@U%.)*RRJCVF18U5M:(67&PW:MY?518]_VL1FP+4S/M(O M+]P))G,^DTJHEEO-!I4&,45US=C!QQMPMG4_YDVP;"K9HX(.+30Q`H=NZB(Q MFZJOZK!=OT.+=*+?=':+QT0#*XOGANV6UC4L#0SMC%9!S&",#E>2Y11.JV!S MV@.!F$-S.$?S,2*2^&X578\O"#4-QY%3CA58JT0[J^W:;'Q=4N%;:J$''[D6 MLF+%6.D]W$CA:*`B'6QNR7&8/PZ36(QCC)'S]DG@'4X-8_%]Y1VA^J$+^M%+ M!8HW=V)X8][FJ'"'S5$=Y/A>_`V?M0Z[3R-/W3]SI&STK_)*1V8/H,)KTRW2 M=,UHCVSK3'M`K$K4&<1Z2U1F0O! MN450-F#%)*FEZ'NWR@#X*:A`2P MQ29AJ9^C(V"Q<*Q$8PA'-?=>/37 M*$1('ZE'>DC0PK"MZ'B$CLR!/T,DU`UP6(B(A;2`5=`C!%W$W/\IMH#!"4JC MHL%,-W9^LNA8X3.8+J(+9C5=XV`!DJ.O,;3DH]6Q-)S]2PQ.?[R M"ODS;%VX=\CSF5"0Y21+5..YR<0HHN6%>EHN7-]PIS8U(T+U:"\X>S"=@)VE MOL/8NK?7/CV5'`G);>061PZYB+F7..#ZE]N["E=5K6N5[2B1A$=B$E':?;&I1PH>25KR& MGEZJGR7]*ZE0"#A9]MJD#XTEVW-2A>DWM$IK0XL*]NPBXFM:YDMS6@IB`6], M25?:PO8-YQ(9'AJ,'7O*PRD@J2V06,^\N#>913C".6JJ&9"_T+C+&5YYWAV5 MP^L:NV;E(VQ#:%NI$X"SV-NS]S`#'E^M,E!2X2GT_90;2W@^M\,=,CN^P/Q> M`W)-($;RQ-5RPK/_Z,D#L-@3)&_#[[F7RM\]M0;^0B@$O#UE#Q8FB$Z+%K^; M`78HFB:FCBB`O<='*EX"#IWRTQEV8:G9D=&F<9,-5*$;J-R6U[+L\*;2T+"M M"SL$L*+K+.#.+29^=@'C@LLKA/<3-M M$--:0&HKISX1-&,N`:+4^.#>4A8D[&!72EL'7!I@,3^Y/H9]]SY,TTK(*I39 M3AN\&,J8QB)?Q)O.]O6,C1LOE=W;2";3T-+_!GF-B/:UL;CKX=B6T8@$6@ M%9[)*J/JPO."ZFB*I-48<%>>GQ@IH)CZ-)$;R7ZJ8FA39"MIVL*L.!)_W_.+ M*M[C#MY=9>;NWEUEYN[>767F[MY4[A MZ0;=(3?(NNFE*H(G(:/Q&_Q=5(H9*#=,#`=YD;01(G>VB3R@._59HFHV:+,Z MX-;8R$():/*ZP4O#\9>11)`AL2VAS@Q>(@0D`8&Z&A?K`CD+M:'#KW$H/C\I M!?1@P=ZHHKO!*(\+Z/R?+:P-7L,GN\/S!A.4WX/%JT7PWP@Z0+RI3 M6HW+=&'_W/9V9`,&M@>Y01ZB#6)IW?ITM#J89WB)U(69O_($UKF"2)%5@!N4 MG84<^O64"KTRR$^TH2R(J94MK2UC*@\PL#/]\.E$AUW+M^84'*8>>RD1D*HB MD6WAJQ`ZD61ZY>*DYICX]B._%CR8)%/V0'!6(+%>HT**M2+LH&Y6[RA9B=E7 M[]&C%#$I`,%EUUL)"P\^V,-6H'QLB&E^ZNA4<-1G!@W?R6*I+$,Y<7Y+FD/D(QL8:VA)0DTZISJ'Z3T"*CQ: MM+`+LI`+2&W^NBX"'9S)M2V];WMFJ`"RUO*OD3^8W!H//=\G]CCPV>GW+;Y! M"V:S4\N0/X@'S^\^RK4B6$DA%R*YE#>ZG%@L%CH\LJT(.YV#Z2ADC#+3`ZU=8-R:K6N0Y1$7W4&Z5BY.'%*'+N? MD`Y!>Y'(QF[SA3$3R1Y4BJTOR)[.J(C>'>TX4W0=L*8,)IM=!3JN6U:%%@Q0 M:52%,@K5&?S-WL@Z=_#]D[W#=7>`TS'?.N9;E@\=\ZUCOG7,MX[Y_A5BOD./ M:NP@[9F^?2?_RD=>^08;3,5MAXNQ_WLXCT1[5[$+2>%A%E>J9_T(HG>^F,^0 M6A"FS=_T9%)O,7O<,S(Z^39WWQ&B4%Q]QY-B/"J'%RJPO(\6A,ZPW&/!8J0V MXFX@!F2>N/J2:*H?!YMC.1?BPI%=SN"(7!ATUXCG[*`/C-`,2;\JEUG`0F7D MPGX4>1=N]-R@:Y5^6TZHIE]M M.,J`"/6<$K7/"'O[IX_"?ZD>.QG[@$Y8BN76];:"5,=.'*@(H`GUPN"N].@U M[WZ4SRKU5>]JV!72I#9[6"'A8I##K+39W2_O1<1JAW>N)K]"!Q"#'"9@+5J( MN"E@(>MD^X!4#IT(UNO9_X5V`11^BGA_G+H&*Y/1S1[66(Q!TH,+2&]OF$DT"NW-B<2 MB(*=,66,Y92F5#@[IDEO#:TRB(HXX.5GQW/;->AFK/3LF%>^Z;-C;MO5WZ': M<#28"%E\I\N20[*,[X/)1DY"(*=.@=`Z/3L"O3#AJBE"$.[BSPW=GX23\6!R MB=WI+2+SC%>`(8B4$=\B2J50!3V+3)N04QI3X1*7)KW!EZ]&C_8V0)>U:<,_7"@EN MP>`41%#@QI"\S7F-7>[NW]/T%*BFN2-*&(CB>T,E1U#JVDH',7M>"":55H'( MNDXKQ+OC]@`J`%#8`JTRE/P:^TB_B:DCQW7DN(X93++#(V#&?5)(]='Z6*!`3=TFGXQ`%R!"K7L15):I43 M(Q2`4+5EU]6W`K5MIVT[;=MIVT[;=MJV4VK;C>RI2X69+-PBC%"SW>F0&A*F MC3Q0BTU0K0_D*O*1E=*C!8?^Y?`5O'1>O2G6U4\?:V-,&V/:&-/&F#;& MM#&FV!@[-VS"HP#71@&LGRM?8'-#^00!$V:J!D,JLJ2T*:5-*6U*:5-*FU+: ME-*FE,*S0W8G<88=6K_';EOX2[;N5N3,$A?>^/3\$CB*/91TL;6Q1;_YQ M>'CP[R]7GX_^\^^OYB)X^.8>O[(>7]Q-ORW=3_W@_MT+\NK%G\]^?+I=>LZ+ M._.QZWSP7WXZO1Q:W_[E'!V[7\>#T_[%\MWM7\&W3^\^S3L?QM[QZ?/'2>=; MT#];#$_.K/Z/^\'C^S_MG[W>QQ^]QX\_1K^-WCWVC>L/X\^?+X+>R:/_]/S9 M;X&UN#^ZP[_-/E^:YK'__FAR=?Q^3BZ[7SY]??0?S,[H\?T[]+,W.3T^=XZ# M_COG^O9?E[TOG9/X^?C#U^']^]'7T\Z/G^\_OGW[GX/3T3&8./. M9VC]`6\#%"\_7>H!&_>0*;@&!@@@*),4KN\11 M4\\/7QV_L;V?E7F\!.2VP,\E@EYQ-KR2BU[\MDD5,V:.M,;3E(<44**\]+>^ M!HLH>\@%[S?V'6*)V`&GR3)J-)[.4MA&/+]4S/.905S;G;)DIERM"D9BD(6<35*]5C,G3(WJ`%>T0Q\NPO*V!,3'`+C!5!!.,=N7I?ZY#8F(2)@^FD M[AB>Q],"<*!6C\7UD6<2>P'U:J6T#JW8!LHC&[,,X'C9D#.87*/[C=,X@EWZ MT0QS;%UC_QOR>Q9>^##)9\LIT@K"2V(=OLT7#EXB-$+DSC91^H:\Y_#JN'T1G2X\(BLT M,4^QYP.G/P-3MOE72@&)JJ1W)?P#\1KRQ5=1T935K5+Z0@%G[RLQZ3 M7R?7TT:_-OJUT:^-?FWT:Z,?*I]+S_.0[UTA@YUN6P.7F@P!81GAJ#UI5Y3B M152'5CA@Y9%M:GKCR`S3B?6T(:8-,6V(:4-,&V+:$(/SCZ7G,_EB$&*PA]#) MC3V=5>9=E56F#5$NY9%N8-)CWH8=G^]X>1ZX)OMD.&U.#+ MAW:J:5NN1EM.\1G&R3*,6F-M!S,+H75N@X4)SAN8L:I&X;6Z<)8ND*856&!Y M-G)%(WXK%!F(U?4M[!]U"*DO>R/8018`E M9.BC.^3@!>M4D7L-CE@1L?4.R>JX%J)`]!R]Q)SL..$;>5<&^8G8[`/.?J', MO\DH+\:^,(RU%.?OD$L7"H?*[5ES"J['TT'<(7#BQ03_3=@79*$PDU&I+A"U M`%GI#8QT@.@#@I);$0\EBF(3HZ"VX^?QA$5NF09=@VPGH"VZQ-XJU'Y]N*:/ MU_3Q6EW':SVZR[%8YZ1SY(C%&_(-TMF#Z02T\Y_3AK&Q%_C1O)R\+W*R3*\` MRJD'J6X+#M5`V0([3TL7>FW,`4_&"F76[3VL8.`5]YQ-#FJC'\;G*-8!ZO4Y M-JP/B/DI2R[[V/P99N:"]$GN2JG9XA6=^G:>*4M@!76.'(6PP5&R+:"%;"00 M$@SL$R;"',\?OE\'<^9CQJ0W9OM5T]]F@OV&X]M]?M3EZ&:4:G!,958[X M!&GEFGL!/[NIQ5?KR\WOB$4F(ZMW1]F;(MH#J.:#2>2.X%:$-PA\SS=J9]K*4:?":I0!I@8SY M=;AM>G.6XJ^!#II(L>;.X(H)$,C'7[T3>Y5_?OM",G:-Q(WDV(.MW=?:?5V/ M^WIU=_YDN?KXWJ;3,C%GRTMV\`_EB1:4#+GC5>A8%L41QI19B8RF&IYO=E83EM(#QD$LS7F=GN**&`?T`*]$7KC4+/*XSD_A M_(YYXFK=RS:OE[]LOR]TPF(E$=?T?5\G?TR_)W)!Q: M*,T?]TR%&['8*958#C,\H\DR-0?C%_M%=QJI^JPEUB7]K;P5K^NWNR`&AKCP M&M[OR>MLQ:\-IB(HM&.HTKNQX9J-$WC$C@SMQ]!^C'K\&&%2F0O/"Y`ULET3 ML`C`"?_6H/\+Y(N+3'!D9J[A$=75'M,GV MX=7"+P.9^@V.I`I)9X0BWNH-1*N`.L%+L.7NVQGN%&QZ7%?>ADP!&U`H=N1P MOGGU$M/7YN_KS2JSTT=6?7BK32!KPH8$P>DC@5N]LX,0='`Y1*YHB^?!',Y7 ML2V@IAC%K.&U.;@32(!YYZ^,!V#$MP0T&?%M))1?&`XWW`MB.Q2I5'=XEG[TY)BW?M\DFV7'F7YF(&IH]I]<^ZW5<2$.^6JB\T;0^,4QJO=I[F4JZ, MI22\VR7JG`/V`#?1;,51G)LB+B[DL5V5:>?LL--R@6BZ$@!_"!PFYZ4$OHDB MM45T[P%NLM4"D6AE^^X+Z9[[XE>8%5XDH#U6[#,\98]S#R:1$SM*0@T&Q#9SO/`>,G^?XKM.6$_( M5O@YR9.@I!J.EL0X$D5**(5+U<_?])%OV(X.B-4'2?KIF^9Z2/73-_KI&_WT M#1!%,*E.X]NK_)Y=F-7-Z]O&U,6>;YNWU%3P>@0-$9E@,E^OW$6WIT6K:[!- M*XT,7(!A>DQ0SS^E%MR2FM4\,@AD3R(DN,$D2B(H$&-8G_6KW^#6]F^=]J\. M!<@)!5!E-^E0`!T*D`.=#@70H0`Z%*`LXN&YPQ7R9]A:^T$']RXBWLQ>4%N> M;KY\8PIB;(@+;ZP+N02.0%<>Z1C%A)TA4<.'4/DILD^6U]AEEA%MN\-2BO"? M`,UL)95IPJMJMZJZJ.:ANY@]5&-/JK11S5-.*JI:XWNZ@I5NZBK=UHP&4D5";=DYXFK.T=&85JAA3?RC.?>\C=FG%(-;N=)=QP+!5`&XX*)BQ4MH' MD=(BEB`1RI(H`G?]+W=.R>1_!SSA.6-?]`1#6E+PJV>0RT(H:HW+X_B.8"_U M9;0,"#=_7U>BP/21LX)NJTD0$6C1-,L>6L`N2G_%+`.^C*+U7?`OP#*KJ3#/ MD2$9*->_KNT:=`%X&^T!RL\Z1"3G);T,X'8*U7C*+V"BK^#<;2R4+3HDV$3( MXL_NQ%>N!V1D.&@P"<-[(`Q2`:EU]'2YK;D(='!W0?@3EC/LT/J]4-K`GT5/ MWP!Y>/($-I^N`L"`IBW6'?B%ZOA9HL&$*_*)(B1FR.554%,LIT3@4G[["^.7 MRNVO\7R.72XF9#?,,`&RL\X0U6AB"G$2>3)+9V=H0G:&[(0GY:P!8\DC"Z-! M&J]JI]A+QE8JL@/RY+5B#.4C%K'TO&@@U7>JU-6Y-/2YD@[]:)YK5H=^U'N, MI$,_=.C'/AN_2XK&E#]-.T*^'\ZB61?+,K9^!574DW%28N]7!`&(9S6Z0]AS MWV9AO,-&>3,M?I4K_UASJRYT6MC/B9"V69+ M3"8[/FZA[,UR4TNNC,9S(H*36GME+748C!W;/'>PX:LB8[/*1D]!*0@H/W=A M(PO5&WR-T2%B_@-6F#BT^6! MJ1CD;"TDX4^OO>$333XR$1;7FW3YYX,,&+<GIZ>[Y_L_[>Z"MS"&J9?#`-QL0'CT)%\^ M!;O@*%FNKOP0G,8Y^JN?A_<0_2Z^ARGZ;_3WNSQ?O=K;>WAX^-I'GV9^F,(L M6:<^S/`OP.[NCP#_W__^S_<8R5$*,8I7X/IN#6;K6[#_$AP\?[7_XM7S;\'[ MZR/P;/_@&1V$1D1A_.G&RR!X7$9Q]L-7#62/-VGT=9+>[CW;WS_<*S_\BG[Y MZA'_HO7]PR'Y^N#ERY=[Y*_5IUG(^A"!/=C[_=W9E7\'E]YN&&>Y%_L801:^ MRL@OSQ+?R\,D5J`+<+_`_[5;?K:+?[5[\&SW\.#KQRSXZD?*.0"^3Y,(7L(% M(*2_RC-#HO0 M$LQ@(;?!F/"OZ"8BBP,!BV^1[.+=]U=?_=B$!@IP@,(#3PJ(@(($%S\.*^]H M!%'O#R9K\+&$^\]*[."_4O#[9+%KF:UUMGOK>:M_S;(,H6`;I((UA"T++[LA MO"D&[F%#M0>C/"M_0TS7[OY!L9G\F8.A2>FX1HE-`,?498^GP36HJ8<92[2+X6S^TV+JN$-T`4K6EJ\O9XYW_+/]7: MM(Z\[&X6!_B?DW^OPWLO0CBR67[DI>DFC&]_]:(U^Z#2:'EHWA/ M(GS6-WX!,3R_JA@"TFK,#HAA#I(%\*(H>2"^_B))09"L;_+%.@)>.01]\I>_ M?_-WHJ!_.3P\;!H\)RZ$@NQ;#H6,72U#H:6&5^O5*@IA-H;*5;!MJU>)F*-* MY9^=G/%YC&_*NT6_N6PO4KCRPN#D<07C#")S-L_O8$JWT!$MC0K:$6)*(H50 M((FC*\5(`.G0C-B0!(\N'"E'KJJ!C)L:ILJ0GN&`,?4U*19=O(2*9OKE885+YY!_.[)#B-[V&68[BC>#$\ M5+:5B4,'1X\:7X`P!NO8;X;&L_5-%@:AES:](%=J)9%E4Z-$/#!7IM,X1ZP+ MD5M-+1]2SY-'/UH'Z*#W-DF"AS"*QM`L);PVKF)T".+9+:176->PV8I"G_A* M;:OE0K5T)-O4,V5&](@]4GL]>G9Z?7IR168G1^# MJY]FER<_S<^.3RZO_NJMDNP[9J_^J/ M0XGH_J_)]LFLU,%DT.LZL(RS7W@;'&1'2Q_])EW#H(',PA6-"GI7-S8*M,DN M<%84Q`Z^G\$0&+%5QQD>^FK`NJU1997YP?7(6X78)X=>!NM(MSVI;64'<;Q?#L6T)*ADYYD ME8U:.[S?V%H='W'5+)4M@W2."+9NDQI(;6^64HJX630<2U1E.OAMXS5)"]65 MMH*1VN*-N0HV='ID"V4_P-9`+K1'D[1#$@/4-YQZE"R7(;T.P(E;29R'\2V, M_9'T0(3.GQ)N14PU@N;L-<0E!%=Y MXG\:+3N;A6;PO[8WD<3C:ED'A\VK_FWD`EG[AS$(3X%.1%%UX8G,;%&6F4&#,'E?5X,IL. M7NRX^AK@M-7=,"ZC=LY3^<6B:\6%!5,V/^]>PMP+8QB<>&F,EE(V\_WU`N'<*82\;SWUU;*+[46B4G[-D.$H?#*1165$>*<_@3H$[,CDF3 M:B"/^$R353)5:7."?WS.&)=7EB6!;Y+TN"@([);1C7F9KT6`Y8M3+>)X.Z>D MZ/()M3MZ=//>'SHR!"+O6J*&T@(1"S677@ M'U\G.QCMUY$*J%%5P4ZDQ+5Y5!,K7]N8C!C(`%+8IR1N9$O!"FPVXW%\,C2U MBD;8G!Y@Y0*4J5)CYH/=%E#(\SKJ:$N;FBA=JU2#%DV]8ET,3$6Y&$*5:=@V M(WIF'A318)O>F@I:V_F8MXFFPX=+=IROUQY]!+A"?5GV_D: M1GM&=KR$^)SKD=SM8BK3E)(Q5`0J5"NFQ]6O0SK90TGZWWPQ7^%'`'`J_^_U24+P(9@78*YC>AS[,1NHDQT-EO9DIFPY>$G_QA=O> MIF(IM?).!+/KD127;+PHWQ1P1['';0QVD]U:N'EVF'[DUD8PQ="R$-VI]#$/ MI<$9F"Z6=O=?ESB#:$7JN[\*;BV^+!K:CNEY\9#:[;DFIX6A& M]7W59L-9.9>R])H:(YZO5;LK)(7ELS%X/Q7W;3@9[/>*$F;Y?($[*I(4P&+_ MOTJBD<+,7&QV2V]X9'##-1DI_L^V?3M'@4"9S-IA0.%D>YVZ,XC(QL]T'*-= M)4I(:^%"0\=Q`$0(+9<["$CA'LSI&))('-2C'-]V*8FQ[4+(YM[K@`DC].M; M!/R=EWZ"#:,WRAF3C\VF1>*3P3MEXE,;4:1E.<#Y!85<P2?8XX MPFV_@F48AWBGQ(6-(ZJ1#*5-79+0PE&H8A11*:\USNUFIRC,IF:I,*!/K>@2 MM_[Y3&+9\\5VH^HQM$N"T7;I@I`:87=RX#7&$E5+2?C!?9L<-:&V"A+D;##. M).JX^U9.U2Z*LSI$",,K2>6+=1 M#'F(>$F5)(:W.`E(M,-O42%3D<+$.-[?.=+9>KZH,R_CT\!Y$B=M7V%$O>`C M&^.N3>8!4V_$\S76H-K#?(-HHVTZUPA%G9,WCHF1 M8K5_II`3Q5&M\Z(W$<#B+3JVXH'EH;35KMZ585(5<]M6*7&DWW[61'$<9@7[ M8%`C0?R=+ZZ]QUF>I^'-.L?M'*Z32T@:;:/3,QHP3L^:X8BSG9@V&.7*X:2AX1T(W#T^KN:U%NOP"LP MJ4?,_#<8WM[A^L![I/6W\'R]O('I?-'4\[&KV75)L&NQ-:E35MJ'`B[P*&#D MT="B^$XU/%%FBLAY;TE#=6DJM`E#C=ZVX57''GG9W9LH>1BX=EX`UOJ#Y?HT MZA?/8UB``&,6ST^FH%HN;FD]M81MUAXU-Z-/LVR>+=>)7#0[$[+IP^=5YLD, M/_BA__*Y:/P(.63B9!$^+=)<(:\:\LJ9%Z8JD#I703)A6T%H%6+$)5D-]C-7 M\I*`Z(:_%Q4:T>$HYSX?5"$`>0+2$D5]3$:_Q3_[>*-?D(V>1(42 MF;&V;B2&5ZK*I@PL!DMU`2.0SC)?PZJ0ZRK@+TN5^K6,.88K)*V0Q"]Q44ZC M<&*,T(T(G=TPC8`2CIULCJ"E6(TQ3N\]%838W,5E4S<-49?A1A@<)4N<&36: M&G$PV=4@-A&\^_$DWB7&C_2PQ+&[:H3K$)U8;*VR4/Z,377F(DWNPPQ!83P= M,X;F"/'9?[N%3PRW`7TQA+PK=./A8O6;W&W:A8H,VQWG)=,V;7YZAS@%L].8 MEODAT]9\1$LK9*L$R78X18DJ7ER6C@4AVKK(:+*#-5Y0>^4T2J4 MP)"2X2);?913A51>YY7U:A4A.[(#5A1(58M.'U4GM2?4KKKVNOLIBUBUE3G8 MLVZ`LZ(NO`U>3OAHZ?OI&C8MO%V[*Z3$7ARW'Z$RT[RB8W?PXZ)X*$/GW2>T M]E`5-3,NY6`?72]"8].@.?QHS(W!CZK8'=09<0=>H$I0,J<6'G M=V.:*K!U<:;#)*/T)5KQ;'Y%)AIO^Z@KH(5;#U6,F$[F@()`JF.1;,)63[`2 M8ECG5B;[IY$Y,*`8S,^D:'LJ+GQF_K_780J1*4"+/]]<(#;F:-?"K[J37HVC M1#W5L0^XTM4/`>KT\<*BB*@[#_L\R0+Y_G0P\7]@.=*UPZ^O`:V8J1Z'3-64 MLT\QEH5%1X>%?3J.#H,Z#4+JA'3<704!%+ML+()6W5T),2P'!TF^Z?AZ`PHAAZ.3IKX$`8DZ$J0.KG;%%`GVB%4QMM@ABM'8L_%;[V#&,'=>H*8L[JT+ M8`7F]'C@"*X*=VF^.$OBVVN8+H^\58@W>!PUFM]$X>UXO75TT`^JE^H.MP:) MW(;Y!02BEW0HB/!8D-2#G;?/UU:$=C-]/2[U:B/"[%0'["R2!$?W$\@_P`:^".G[LQT(?6`SBZ#!O#CUL1 M=%>YE^;ZPIVA=9>F&[3$?O4B^D@?,Z^')[\=<`-OPSB>PB,A2C-4%R.3-8,O M2BJ]DUCH[R@3>*`G.SB1Y^='%]R!83GK>1*38H:>(1L%,);+LN04R3+!62Z( MP[[HZI*J@@B*/+!9ZZ1&$K,$4RB7B92SCR:D?E5$G$,1VL'7.`%I'$]0C-+J MFX5B6OBI_(QK*K`JKK("L(X#F+;/UH[/TXIR;N\P`T?\]<(S2>]1@MC(;?;)&"D67`W MOQR"`[`+YO?XL4OX0)3_M>=_NDT3I.\N&PR,K$QU=X(Q66[^K-7`5(UA\P>G MT?+K;$/3SVNBTD"S`UJ(R')KHL+1VPI9L[%/C0Y\Q`@!P>CH>FML)6T]_32& MD,P.3U?A;1PN0A]G>-`T5^2_72""?.2]F>U:FB"M=:K2HTNTNSQ#N\O5>KGT MT@U6[@9@4$,&)6BG[2K,Y%MM)`8\,[^A4$,VAM57Q&S[AE>-+%ZABE@K)V1R M]>3>JA979Y!AP>\E1*J]]O-U&I+'BB]AA"\^ZQ-N7Q^_%P*;88\^A(J,Z2$R MIBW83NWE$/*NK&=OEIG>H9D@'B=-P8`.NRTV3$CDYBLT0!$WN``&:FC3='K[ MZ$L[F\&0F69)FEZ8DMN#&JJARZH&R>)CG$H$B:SJWY%5Q4``@0+>00_#6+:N M<^UG#^H(K,XC5.9%G_BR$,L8ME&,T.J3G4)2>#G"M7(U1G%LFANKIB32IOF2 M\\'X<6:2&9Z`X=SMD/:RA*GD9`G<6YA[`]P]C8$;<^&FA$H,J3?($/:@$I. M*2VX3D_?_63=:*=OS+8>5E4/ZR@)"WH46,U?T"*-^_*'0'%5;*R3A`8CM6CE M-^CSSM38"@.JP]T"N3A2*Q%D&$M_4HYW^-:,ENC4+GA&KYH4YS\JT\;*M5.] ME/M/DY-Y6>7[#,X7)UD>+KU\G"*@+0SVNV.U">`L]O<9*82L/MNA2K,!'XM_ MV9N+B[V%+;+FWL&8<:\LS&:V`F7'R!Z-`)]5BZ1"D?3!,I(MHZ1-CEP5N73; MCHF$%WWJ:^]AO(;XZ0)D^"QIFQRI$Y63DL6]CR+C0&.@JO8YNH52E'G[RDF% M.>:*R"D?LV#ZE!!;;":B11C/%)9U3N2'DV:=TX054TL'%&H/V0K:[]JJD2MX M&N-;V&6-:M3K*R%B!^JI1)C\4JN5M-H8/VE%U=(&YLV7E&G&9=V8^CBGSYA? MAMDG:S$Q!;R#/S.NX$5*J>)[D_50@,9/*$M_R*M5XTR-66W=DM[&5 M"[!9USP^+5POLAHP:=LG%VG;;12RH<_E*O,%H_FJR.\_)W>D*+&)JP=0*$1I[."!PC`*6MS#RV2/Z/:5C035XNJJH)?B6<53FCWFGRC!)::LAY'!$ M7I:1.QQB?:L76H]AYJ?A:JR'++5I`I! M:]ULM^#AM$.P@3DH0+(#`RX4OY<6M=\8-F5MCQ)5_PX&ZPC?J2Y74;*!\`HW MF?`AV]&>1000`::PUD=NEP=I/:-OMM8%`L&\QAA M7:>XEA,MS-!2.9PJ#;:;,>@2*+UB1%L&?7ZY!`7P?4X)#!!HTU-V4UUAWC;J ML'((IXU=L?*;EZ8>[L">7H:W=]:<,EUB[-;%&].I8./%Q5([H(0-DA10Z--; M![V5BFWW39AM5#Q/$'7\K=>;-^C_[P?_9Q_^_[H["+X\'_1X?/X]YOYT?'IYNWUO]A_7QR>KB]4EP_,?#_/-/_P@_S6:__#'[_,L?5W^[>OOYV#O_ M^>;77T_7L]>?\X,WS_ZV#E8/A_?)W^Y^/?/]Y_E/AXMWSW]:IF?[O[W__7/^ MZ.]=??[I+?PT6QP]?Q,]7Q^_CM[_N?O[G<_YOW M\Q\'%[-_'^87RYO];ZX>_//X\/CW%]^&=_>7-U>;RW=GSYY%>W'X[-WC^]D/ M/_P3'%U=[N[VN*`=Y.!-;TW.PA@>)TLO'.7J8B1*;=8]CC,%W@7RP-&JG>+Z M#V#,X"/%[=KQ&E=]6Q?6X\FN_STWXUWO\1:B%*?ELXF$'/&=-DX)*I]^;S3F M8JBWT_MLJ8`95]EBCIC>8AMP/PR.GX M9*H";NV&*APQBMV>KY?8STM2O0?..J-LOT3?H8#G'97?O7+:C8K+YOKA*^:$ MK+ZNPR2!^?A8Q526N?]2F+MO-7IS&B//'.(M`[\C3CLOK='QJCAG%8\RL[A- M-ECR#+!?C0))-0QXJU44^N1.*T^J1]<;'2[!DS`&QTD4>6GVU''(1?.X\KV@F"_`;Q?30,9O=H3=]"9+)O8#I?%+XV<;*S^3K/\54,`JR7'9KA=%&U`=GK,*F^LV8H/JD_Q$ M;<)4[=3%63MW4>_Y$5V@]GMQZI+(RWZM6NHPQ7AR^5&(JY M?K3$A%_V&HN;D,?:TO7D.9$7SIT(=[]'`G.5+]U\QJ?ZY4\A<@]2_VXS7JQ9 MCP#+3]YJ$:>0E=\$L]-\1*D"-9VXM)%F,%/QE9EG]LXL72GE@MA7VA:WQXR@ M5^)-;XL`WA4&^%=!G+67E+P<1+1:0-^]CB`L=M$,EZC M&L.VJR.W^EZ$*E6B1J.P'NFVV8.V@.5-1'FL,'WYH1%P*JM-M,XPHO&V[QD% MM/#>LZ]'5-5'3@VZ@C@J8R2;KM7[2`DQ+,//8OXD=H$!A6!XS45+P$ZS;`V# MJQ!1>THH)N43^+?H&,),,>$L4@UP%G.?U*GB!<84`#!]=NL:I2_/2L$TN60< MX;I$G-71J>;WUES*!E)>EB/^@B%T^SEM77[6N6I;T^C1IAYW?YHO"M-3U(DR M[J$&]1QE..UFH,G($74.S7":Y!&]="3E:H`L*9R>02ZEJFUISKZ*=.)4*HJ\ MY4NJ\$AWIPKC>YCE_SHE_^``0LFMDT>8^F$&+]+0%YQ=,NA_?9O<[U$X5/_H MS]N:IXC)AAE2(X5[DT._`>0CZ>6F3>W2$R;6+0U.F,6.R@OR=U[Z"9VZCT/O M-DZR//2O$<)LEL(+F"Z2=+G=;(Z?!ZD*SD&"I")I_,Q)!``;LP($J&$``@3@ MB_8*C,-]45^JS2>*>6J?Y4=H<6R0I25G=TS>,U[T@OU,BI>#$D01 MEN8D"DXITK$U;?4H!Y-?QG$VZD*_@_E=$M3F:OX0(V'>A2ND-;@=MG<[2IQ- M';G]=M6JI`G/7X`"`#6$'5#!`#40QXVK=76@51&LQ:@>!27OPCA)\7$O1L)# M:!@H7F_.T6R3.$R+C,"'@&),U4>M&P^;3.""GZ(@F[]A M^S/D7GMIH!'HW!IB+UFKC9C;>:2-*G'8QK`/"ECMI^S+B>)H3SF01CNK.Q-D-_!@TI>7^OCLCZQ_] MT7VL0TG0K2X]4L88W]IA#29QUC+9O6@E^CX.%?MUB@#8SS<7D<-3(6RI:$"] M[FQ1=IL%>*!3SUE%0O4.*9N^_55-;\<(%51AZ54T+ZFC>9FV4RS9'4#'\%:Q M$V>4/2VF(RKB@,WD5/4;%Y9DZF'5M>8.:-](.3D>C'GSU"?[_L+;D/-KL01+ MKX$T]QO%LQ3A<_,XEX`BGD-9#*D-<.54TH=0)M3>0$7`+1]2Q@[#YF9G81[> MDMJU*YCG$CBZ4P\"]2CF!8*#;5Q-2-5&KL``H_C% M.^\Q7*Z7LSA>>U&-I%!-)5V1@+"N*V)Z.+I2#`)T%&BH3C'.;4<'-3%5VJ+` M`C-M"6,,]Y>UER(91!M#A9%"L7].D-+$TQLZ#E0#1:IC7VU4Y55KCA(?C&_. M+Y.-%^6;$5N];F&P?[YI$\#+*J4?E9W[71]>V&)IO7/?G56_V):7DSWL"NU@ M7AHFL\=PI)@6"Y'-"B0F!=S';>@GX"/^R.WMBE!$[6@4;X+]NY/CHB3:OP0& M=?N2=Q#G;8VB+@IH+9'`OJP>`C'>Y8S]0ES>A4+F6+\595%<:] MWG3KF,_@/>+02#9+$;.SA^N$9"D4QC?JW]V;.3TQ,TO>Y?PP#QJI5.N,I8?* MN"U;1%6ZQ%F&10B9```5!)QY59=Z$?4$3X[A*H6D(3VH6>7XVE)7,;KIAXH, M-/?U80;Q6L!-QO!J2%;88!<>Y'A;N`I:RPJK0!*WQSX=29NNUV.K)[\FL85K M2+IUIE!DB[$&%F'\\72MC<#VAMS"SE&@,G.KHR>.3II,D;2:6G8F-7"JWUB[ M)1^996O#)40_RZ_MGDTGR8^WL8FG[JJQY>L-&\!8FC@FN38C)R/.0^\5B2F< M4RSHX(`M,J6\[Q$:J@Y;IS$B(",GK6?C[?$B='83N`64*)RZZ:`=0(:!9RR/ MP.GYFR]-YJ&;PP/3M^GPI?M\@=.E1HPN=I%8K@#8QL_S"-!W).$"?SD9UY$K MHG9N%6N*IEI1OZ<^S!N>KS?U*YZCW7B,3;/5RY.1)\.]AZ%H2<+ZX(_AWFS: M[^&Z=RYLZ7DK@&]#M'UNH(K;K/=QMH)^N`@AL\AGJ$7+0V;[MHE'B.3&<@UKX%:?)ZC0BKMFN;=L'>:W`I"M6?2NU9FO MQKZ=[F*Q'7/LDB`JQ`'%ETP?TEVM#5-0G0*;[BS-(Y%5C@3C9>WB)GOT#!@) M:JOV0Y$H?HTJ'$S-;S=$=9#7$=C<:)9HX6E2,):YR>_3T_&4MH3^\#89S>JJQ=K;'6+J=9.'F'E4V@'XV`8%R6-RH MT^].R6Y3608%K(5252Q[T&HLD/IK>WT]*YR"9L!3$%J' MD\T^OYT-PVYG9;'ZVYAY;:30)B\H MA;$N1QZ7*W$RYV7[&1D6$:SE(>'N%\+>[=Y[ZFNF`(73U9(8:JT)Y<7VN>6%\W59??8\D+E MT/*"L9HAR4V`8+C"HN?DV>H28O1YIE'_S3O;E6(8V#5H7,R MJX(7ENG.QLFJD$2[!/R&OYC"0F#P MLY+:]C1LGU>V\+/6`(^/DV:D^A#`H8*T3$5>_"+::7H,<)_Z:E!O$P4F< MDW<;\=/(M#;S!F>Y^&K=GY4`6?.\5*CA++!R*,EGHH-!8S3X6(YW;$IU)%=I MCC)?+$8J]9[K9M[C*$/X;WC0?-_>,E-J*\X\L\H&.G7_1NJOOF]S5B&)F MF@G&_.<\CF55#/(G&]@A'=$HM_&=@5^LV+>;4<%^=YB3'-#]V.V6W_-UY5%> M(>,R6_ZT#8OKXE$N-7_PEWTL:7Z9P7X6>C=A1$J,C]9I*K`^C2]W0/&MZ]*0 M+O5-CLOF:+G;2E75750'<&U,7>9>?NFTJT:';A:/.9.SVV>`ULC3SD"(E(LD M"OT-_?_7\#%_C4Z\G[A>3M%&H!J]`^A(\+'X%X,`!(;K6DFEB;*DI,$AJY)# MF].1E]U=I,E]&,#@]>9]!H/3F+[1V.J#($K:PR!`"0,WWGJ"P8`P?@HJ2(W. M$:Z-E_JD6:+499EV("B`8148H)VW3N+@V,L%#SEET/_Z-KG?0T-IX1OZ8;O> MC0_6DCGF$B"+_!1]W4YP2RS&XC-;BJ7H$]2^+;:Y@NC[Q5 MF*-3,/0R.+^)BM.!8,6L&H_D8B"[.8(""C"`P`$-0(Y=%8TILY>?)L'W/X@#_@]^VN?; MU?[_609S60R"?C29\$.+9A;+&9.R_AH1\5^*)KHDRJIV'BX&@L9();/ET('C M3U+@VQS#STW!%6Q^?PX>9[R?KF)S5TR1&/_HD9IB=)_D'F,^"9)7S M;T`;P/#^@\"!&AYH`P0((M@@=[&`"3XR-R47XC7B"4OD/9AKD).'CV$S!"_` M,-]$WFW_@W,;G)T+JPY>7@I2^0W`'SG:*[D\+\_%W9G8;L%TA'Q59&@"3\,8 MM\:H>H]NG!3![)A.B90;UC=,'R+?Z":"F?).68V8\`[)FQ5[:Q3SP/:2V7YP M2%$PY3#LTM.''"85C_S.4YP#-5_0 M!X&YJZ\8"3"+ZM>1DY0\$$7"6&2\[L$5JIJ1>= MQ@%\_`>LB#!W^ME@+=Z6,0G@G`**U.CB8T"^!NAS9[=E0J&4IP+^#&V&P"[2 M,$EI/`[9#_RZ:;@(Z3-(=A.F;VD3=AF^5C1W2HN4KCR MPN`8+F":PJ#(FT'[_3R_@RF-'&INK07(JL$J=I((-$#!.;?99EQ0VWK5^6ES M37/N(]^$,=IYAKC"K2!-_PJ7,6F-*UPNR^SFF#'?JZ.O!R%=0VJ)C$UX#['S M7AR>N1EGW*<%*3BR?"N`Y."3336^8,`6ENB-N6M2#MK8^)/E,HE).0"A()NO M\PQWK47:-IC_)L)AZWB@1H[$M2,C`1FZ0\,J&6B,=F5\],2YY?G)N#&10_>% MM\%G2MQOW/?3-0P:JE&\* M_X7KX].O2E?/N6?7IIH95&;,RR9?.Z_6>UGH(YD?XW?K^7>HK"`R&4H63#'8 MM<,EF9M*\)C)#B*LF^*T)4.\7AAPYW M+2/AW)C.D)P9YE&J-V$$TR,OA[=).EB,J@W4OE/3PB_V8LBGH/S6<72**8RV MA]*=6J^$_C=AYGO1!^BE;]!O!$^1ZJ;T;P.VEZ/`H4"6U4\_!_A[0`8XVTH5 MY+.=W<^:J_7+66*:WL'\#J<1XNH3\H3I0XS,UEVXDA=W4@"`0@`U"&2^2R#` M>;&G]FR9>ZX>J_H=:B_6-^A\_"9*O'PH^]X$:<-U8V(6VW7Z(2!?NLE:$TJ@ M;=2W9Z7?];"&]6L2H;.,E]*=8@"+S@9K_=IIBP"Q]*N/Z?[NUI8+Y=)6!-8D M;9Z-JO(8=$A.EO`LR12*D^FWX`G^VG5N/&,"+`/,G:=-9C>B"^B\U?7R%0KP MJ_27"=S#RZ;#DH,:"ZP&W<07;IW[,W?E!BQ^;MUN]0F%TUJ%JD((4%$AB3L3_F@,H#*<8\=;X709*TV5*4)U/1H%5:E!_@U'TCSAYB*^@ER4Q M#'"*J>B]<+W=D`?>?J2=0XEXB\2#=C_A4:`;O)2,IG M1^X=&9CE>1K>K'.2`Y`GX,)K5U9/XZI,[7[,26;G+")6`0;LY"6)/U.-!KQT ML,X5OY.CI](DF4=3#?;T+;)E)`H/4&O;A&KM`,+"+BV\;7SK+O8MDD:G"G=[ M=H8:4-Z'7:/OAKO+)-!LW7,TD:-%Z:_>M$: MSA=%MC"NYD`G7$*4)!T7#P9D-"YRJL:#!H#)NL5*$V=99PV.N6I+JQ`.=QR7 ME20>LK()K7HH%U4++>(RE65O1TG&#WA?-+J,D5%U*2`9YU3=11-B24#.`,L^ MX[LP3E+RSD8.$6Q6"L#KS3EB1!+G"!@"<4L_$83%&M^"$BX[A0(7D&P-H)\Y M7D?&7&')O">+C8(`17"]SLH9K&,J%[+-HS^/"(Z[4MZ8-#.L.LU3[?NG,B&5 MOHQPM@,DW]&*Q5'2[YJ@K9U8N"0H9N`5??+:)899\Y+/T^JCAFA%4Q.*,V>#MUUM_"R&S*E8B!=?##* ML_(WVZN0@\%R/+")F[/NJH_`1_*9X\)!ID#:8;[.I$QNJCO@SL(8GJ(?!=9W M`"VHL=BOI=@F0:X0^%-`OG7?28PO**9VM&=968AB&NBOG\JIH%^A_\*!5K(V M_Q]02P,$%`````@`Z(,*0;&G+RHD'0``Y_4!`!4`'`!C8FUX+3(P,3(P-C,P M7W!R92YX;6Q55`D``Y1O)5"4;R50=7@+``$$)0X```0Y`0``[5U;<]NXDG[? MJOT//CDONS7E6(DWDTLE4R5;=L89VU(L.Y=SZM0414(2$@K0@*1M^=C@OX]%(Z,;7C49WH]%X_X_]_;V/``%B^<#9FZSVX/'_^(O_W=O? M.\:+Y=B&>V?(I__7]N$MH)^A6T#H?]/_/_?]Y;N#@[N[N^.R#O?W]W_;8/__]7^\9D6,"&(EW>]?S8*\?S/9Z;_=>O'K7>_WNU9N]F^OC MO9>]%R^C']%?N!#]G%@>V+M?N,C[\"Q%['Y"W.>8S`Y>]GJ'!\D7GT7??'?/ M/LA\_^XP_/:+MV_?'H3_]_&K'BSZ(AWVQ<&WB_.Q/0<+:Q\BS[>0S0AX\)T7 M?GB.;[A^^>'[O.<]^BY#;VWM/L`NNP'0O M9/V=OUJ"#\\\N%BZC*/PLSD!TP_/[,GB?I]AV/OUL,?&^"?[Y$\J,0^[T&'8 M'UDNF\EX#H#_;(\-?'-UEID#E=L$+BR?P'OV]P'[SD'I$`>_:67QSY%%`/+G MP(>VY7H*.,Z/J&$"9XAR`<8^_7M!24DRG1_EX#?UVG!L>?-3%]])LOCX<\:; M$N8NL0\$F`F_KDB";*R>(.V>VIGWA.G'#*AD09R'GC+=C,>38"$!0B47,FST M5*ECW[9Q@'R(9B.ZW&P(O*-5^-=*@*N*013KS;4U<8&(?4[]2.D:BL84%5WR M*RVH""O2X\]4K:NQC^V?1]3'<)A'!Y`7NBZ3U6F`;/:7Y9[>D0"EV!`?`MZ`HNW/A'2@U:-*:H"4E^I=B@Q<-*V<@UPM\$'4K6Q7:&DLL2!)@DA%QK`MP/S\I& M\HZIQ:5\ M0=X2V'`*@3/`"PLB+=B7$LL8'9,B*%*_C"3*\8JETR_?)[: MYH75*0H>BOVD33:>5!2BK)'F9X":H"=\PC(4J9"CGQ`/!!^ M4WC!QV:^2D!ECD3A+XU:S.)9,,Q+IFD$\H1;EABG;BK[U\E?`;RU7,JAU_>/ M:;2ZHE'K%\L-M'A+?(33J[U1LA3$+[4;"LK83<0K[?G&J57O"MB`,DC-[B7P M8UW48@6KZ!GS,?E%6HU7:BN2E:2<,Q0LERX$>OS.9.P62&>-0RR)PUU+8D3` MTH).G"2FBW_HSP&).->XK'C(FG95MXN/"[Q8LO]7RUK6\!%U&L<">35:8,6B M>27AK&#?6,. MB8S,I?!5DP&3S'$N(3/.P/+`<.+"60BL3M%OH6C*[M81]C803>7%=K.6G\J2 MK5B9$GFT>C[/%LVZQ,C>^0I-$6VE?#FP5))0,G?_56H)5Z"G(N0D*M68L61T]MD,R'*&C1#9- M38PR2FB&MQ*TG;87D3%3GE)G:16"I29K)F\I,=(KN@T:K5EWY2C)I]G<>EM; MWW%@=,=G9$'G#,7^DI;POX14*_W*4MR2L%XBR5-_^5VQ\G\$G!.+(+K)>GW; M#A:!R\J(!V`*;:@E=."@VC[3R@-E(NLZ.1S)`FQJ.C)3T5(%LTFEE6NU"*U$ M=!+IF8T@OW;LQV:T$XENI=G"\&([CHFL525TWA_D[RDE5^-V>'\IWPRCN\[4 M76?JKC-UUYFZZTS==:8F3,;`=2;7Q7?,MIQB,L#!Q)\&[F;INL[S;2$&&J-V M&]M0)LX5`U6^PJ%F'B.;":.^T9"$$W3"!$O2WT-_)K&4LO$*2SYY\^)H\OY. MEL>0(:\?^'-,X,/:O=8GXPV*[5C*VV!34+"@3IYGGA?L3I8QM69X8L)"3+!2 MZE/&3;86RY`)2O:JAI<5/<[6+[ MK")G^$*SL#1+]\UZ)0R*Y*AOVRPCU1*_MA0I!;>'U(E/\YY92:^M@BS:,574 M/AC+\N>[1XOV#DD-]3B(-YP.EZQ+/"M^K)_3YQU7_GRS2^:W(9DOJ%\"B?PN MD]]E\KM,?B,FL_M,_A6X!2@HNSRHJF@I1Z,9B[?2]]G$1=V-0KEU;[G`B[D: M`W(+;>!I:CU11LJXVUJFK)F54H:3BO,2R36&5Y;KKV*FM*RP+`6SUHQ'2GE( M#-[03-C5:?G:L7362,B?3^2KN*1$$ONW:!:W:M*Z.Y43:XR/4[E358"EK#>! M9,K%\X=3UF(DK!:,;?$8NYJ29J74C+H;6W4YFW$IATS)_B5M(SU`I\RZ30ZH MD7!QV,DIGI$>PUE%T.S^)B31+<@IV??D_$G@TH]GE*\+B_P$J?EH<2G+J;5G M=59!IN)$7U:4T:N4+NN!X2P@@FP&[!%*C?+<1K(]0MT*GI*C?MDZNP4F/GP( MP1M.\YV\M!3655,T[1()B78;>@:[$6S,8R>>K>D38"'I%4!DM`'H(S_1H1%[ MRTRKT%)D&I*=Y`M#TO"HBB.%!!9V]8VX2%K]BAR^5?R\P7G+JDG7:+*3[S,@ MV[XSZ2$:<1@^E$T_T;%^2FF9643;E3';J[,,*`71GVSGU9`#C;YDGH0I'T-4 M5#E@)$*YMY&$$)BQ$][:_3PN,<)9*ZQ1:N7$VB&_"K"493\E5URR?Y[2:44] M?`+*Y/K07\\BW$JU#5X(#WCR;K\"+S++X`!Z=L0C<-8L7@)_.+VV[ON^3^`D M\-FA\#6^`DL6SE!_.'S64;\2U&'.^'F'C+K4DH:*`F-IPP]\O4%)ED!+A)M# M1;YV6%$7BNVV:01(^&)V__'%;&WE__+,M***O`;6:JJ4M6\.QG1%CJT6:HTD M_@9?4D@:*"777G(,ZM"-;20;G#+A1DW=PPQ24OT*X&S.2GQOJ0[.P&6PF``R MG*:U3O=M!E$66K':A7%5V6_.V)4']EKDJ8OOGDD\.5%2CIX,J?BV0\6P7?.B MO]5]A^T*UO4M:D1U>G?;H;OMT,3;#H^'DWW;A[?BKR55_;[1OD[EQ(T^_OUW MR5EQJ-[VI-7.COWZSH\@?NV1Y3AI_&O#\`UJQLXU9H]1)WLQ"Y'KKBN%Y`P= M[_))5R6LIAZ<2S1T`"A5&T;H(B==9*5C&5>1,V1ZU2^2M`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`60K.%R3'+KS ME9Z@KU1/S3J'J0D;7.M,5I#]K3.1^I\I)WY2.__L;^_]^^O%U\. M__/O;_8RN/^.7KUU'E[?SKZOT,T@N/OXFKQ]__Q5\O_EXLSCX-/%>'?_Z,#WX'@Q.EJ.C$V?P MXV[X\/L?\&>___E'_^'SC_$OXX\/`^ORT^3+E[.@?_3@OSA]^4O@+.\.;_$O M\R_GMOW*__UP>O'J]P4Y[WV]^?;@W]L'XX??/X*?_>GQJU/W53#XZ%Y>_^N\ M__7@S>?YQ/OL?3X%P:=?KWJ_6)]^O!CU_SKT1XM)[]?QG7V)#@??7A\\8.?^ M9^^NYY]-YI<_#KZ-K:O7_0\?_K-W/+[:WY&$Y//)\Y!7KZ9N4H-$3W M*MV^/"A&W^'*7">,W#+-7GP%O9;<*:C&3.$#3;*%C[<`!8"]<4&]G!W)=3O1 ME@B7`SUEO=BE@_'B_FH[6+UF76QX+3E)WN\\0J[M=K/G56JM3 M2;@5HN;$L$8?0B6BIML*]:]]$@)X!;V?.TNL<=!M1HRX;5OFP$^^"Z&2-F?K M1X)V8:\KJ+5`H%58R3<55"+&XI?[ALNX*<=9J(GP%K"7!#0::1DV6B!X*70- M]R\\L0B":,:ZW(;L[V!U;R/9`DEO12V6ZAM3ZQS,V!RNP)(]PQKGB%<[D"T? MX5:X7YP8QI)^:\K]&A&(2=2CFFX\KN5YX0E!".?CVY$#X-D$+G4]?BO,0TN" M:G%LDRR*F:Q8BI7A]!+_`[SMXZ>MI42O'2$NT0A+E M1#64O,&U\U+"\%C"Z[J8=2?AS3\)[[J8-?P$LSL1[T[$FUPU.+;GP`E<=MZY M6+IX!<`8D%MH@^((O^^&PX7^0'P`\P"Q*M40X:9G>"($L?TQN]JITY+]+==SK>L%T'GO7 M"Z;SU#M/O?/4F^:I/UJ5ONW+./P3'%;X8).[D+EX#, M_>I"6D=5M,3],H768* M%(N-3'N$ULUN@7>A\A/^&DN>42.K^;@WQJYG6>E+Z,5P"IO74`#Z^N13?MM&>1]Y"NC6IP&T0JMD_XB'9 M@4/8YB\`3DP8(XW./P]9XWZBF#(7W"RK1G7#T:\EP0(F-1X<;*-I>M^O+;H* M.(O=]&8;D\USA<-:AC[>8(!3O/_$OHX.U>.DW)(*#%X<5;7B,G),D*VWQ5-6 M5&);-!*&;D"G?HZ]Q]+_4.UM#&RS0YH!4%`W&-@3[Q90G\W227@W?C MHH)*$WYI+32FX[;2-!S![5BPVT50EFYIY%:CO)[L,EBP>!@3(?]Y\U=-R0L4 M!F4%DS3:`OD,T1`*,.\RTOZMI.RWE$@!5;`J=_2Q5@!J@2T:U[.(U#MW"S M\(:![_D6:/&9!%DP9"0KM#3C`XD"JBQWI,/43\[OEBO!]%!:YUR=NGQQJ;'9;5+J`=$S=OC1ZO'/W^'=#65E,CK?&#!565\G=MRM\ M\JN@GYH.(\!/W$A]18DZ;G\QK1`^5:G_G68'4MG4I(?`.A$@I'`%(PF%_%6_ M[YHZ/L78GD-C]+=RC'IHG'E>`)PQ1#9@#RTMH^OX[%.+_J>N.)Z;=F/VO%)7 M@1_&FMF7_I)`E^)9&+B7N1"YWYB&4U3G0L4.AWKK0#^F[\R M'+?)"*!@ZH:.GR^LE:``LK\PGA>4@3\W:5-G>C$;9V?BZ#_^IHWF9V/>JMX( M%D+_4^`R-MX(@)_[B=G#2AGD\W-6^&*OC.J_%E;\U^TW.Z]SX"MX2%<,>Q[6 MBW)Y)8(1&*Z%.[4(6*DG=>NC?`CIZYE+;=8(;H% MGO_G6?@O-H4D(WER#X@-/3`BT*[('WO`?C[#MP?1.)%(H[_SPN2DU(P+IX6" MY,5*P6M79EYS&`#?@JY$+>20S"P$'T)^CC'RL`N=2&[(&:5X'4X?Z]H>H?;J MOOJ@C7A76_E$SU\T:^L.:C"[IR2XG)_N*8GN*8DFU@,E%[RB/J;4IE@SA#T? MVM?4L_#Z!(P`F6*R6&_BV^X$\P[7:$]9!!:CMXB+JV/Z_C%U"%?4E0]K9'97 M6)0GW&@A"V*H[JS1I$\M]83L&,X0-9DV#3'ZMLUN8E%81M1;L:'L6[*"0W:- MMYZ>]RNG5=I[;G4G"24G"37KO+J3A.XDH3M),(_04SQ)J/>.7G1H2(];BFU)U6:.+\"N:=BY)9IJR:"NUH@;6BH,N_KP(\*_`+4`!Z#L_@DB- M/2[C7_S+!J_=DJDJK.\T&N\*OPA^1364!+8?D.B)GRO@LA[>J5;Q-8^):A&H M\QI$%PLW-A96H70"D7%WU-,=]71'/4V83.UHQ]B^VA-^R:'@TJYD]IAOI.[2 MZE/<*H6T2/_UU6Y7[';%)HB@VQ6;L2OVQ!LWA$]&S+%+I^%%&;1PQ)IAIOBH M]3>A;KMLW'8IK5S\6Z>Z\GU=>V:DB9_C\@$M\7+#5.N`=LXLO%G$VS4_IWIKZ05/. M8#8L2'9:RA+Z0M!^)-@K?'"L!-GT]XU8EB)=8&!F)F*DYC-6?-8G'2,@9+1+ M?FI(<\L@+IN@LD-`T2-``837WS830I5AFIJ%J8XM"6L"%32YGS0+TOQ\LK=9 MF[@1<$3/]>[BC@BV`7#"ET&2!@]#,K9<,)Q&08<.QX:#:D/R&1O19EHJ/.`9 MO62P&4(._7G\,(>F^+F*8!MDN@4R53N:F!VF&A5>#$X>51E.0S9O$.3,*%4- M8+PA(]*9C1 M@E%9);MF&#Z<-P/(5E!**#ET=]#S!`]ZZJF9YM.>KDJBJY)H@@BZ*@FI/,\Y M].$LG.,8^+X;CEUV+:IDJ]HR1&,TI-#/V39_4V_,Q+<<^P@%EKMF,G;'N.2R M98AFRV7;_$U='XJO]WX.+$('2HMDZ2L/#`PX8S&9>KO#*T(2PL7K58,)Q6Q< M`XGZ>PZ`?T:C78$99(,@_]):<"2>Z"\C;:9_Y)6X=%0S:BPB`J;0Y:#4+)QB M`R?,7-/OU4/)BE4MFU)#,*)BZT3UUL^:H$ MD1ZR-1:G`(U4=EG*[/0I#P[CX]2U%&AY=CA#%58RT.9PR+_+(8_K`'@V@>'S M'PKA38_:'G>D&)08Z]6>45_Y_@]0470C:+-SPYI*"M2PTGE@ M8LC?2.164Z-&._(56&+"LNTLO@HJTMJ"J!>/WB*34HU2+(*WTA8F&OX+=@,* M`5F=0K>R/X\8^OEAVZ?S&\`D44]/=JN,Q@V'.Z:.YPP3928F.V@+_<`<*@G6 M=4+,:."OP'7_0/@.C8'E802'P$"L:,L M-"T>MDW&I@28!/-#66.3C+N.=T_I)PKL>]G`+=I82[%)4*\1<&;'CJ2J!?GT MT.WQX"O@2`L` M`00E#@``!#D!``#M7&E3XS@:_KY5^Q^T^;(]Q:9S3:"A&JI"TM!A@``)?/>^EPWG_KVH5G"*"*.3( M!.,EP-TWW/X%5$'7L>=#`X,^X>*IP?$#$F7D`5'Q73R?<3X_J-4>'Q_?&J(J M,S!%S'&I@9@L`-7J$9!___S'>SE(ER(YQ`$8S5S0<:>@O@\:[8/ZWD'[';@= M=4&SWFAZC42+!3M@Q@S9$"QLB["#Q9A:^+`2&E.6O'7HM-:LUULU3!B'Q$`5 MOSYQ[?3:)JJK<9*$@N3^S1A&OO[^S7U-*B:J!FE0CX>0R:H0!:R$>$G#K5[ M:`)=BQ]6OKO0PA.,S$J(69.O^@OWU:YY#RM'GAX!(/4"$N)PR+%#COQ2OWP^ MQV3B'`5EHE1".0CPW*`)4'(;"1+"8Y?5,>!TD6D(]5I"&=#ZX4*),0W72B4K*I:L/1*" M`/GA]J:O=5"J:Q$ZF&-A4P:!8VA)9SV<(<0K`)N>Z-\RJZSL/PQA3<"1\+AMZ>A=/6#` MF8#!7*:KHID@>FN\SZ*Q"]GLQ'(>,_A;/4[.882T7XN3)KL$LL\M:9N0=NEP M%"))?-^2AV7F*E><.L' MDUS48V34\TQD-Y4*%(6@OE2`9CFX0X]0UN$L%&5L+*4Q"DH5ZD0S@72H1,L2< M0$S!)VBY"%P@*)^JL+*EI#@E*9PH4K2,[*[Q4GY8AHC25\F),HQ$G+B7(_T?NOGL=BD6J7YB^/-W2ES"K$1Q;B,7LRB_4 M9VCRU.'%&1IXXXVUW4[8A*ZX'PQ*<^VIM6FJH.=G2U`601D,%GASC$5HP>!UO;6IE^7Y+;G/I[NT?V]WYIWMZ,EL_8>C*>Z M=<;?W7;/K\ROOUNM-ODR'G1[_>7IZ+O[]?;TUJZ=C5F[N_LTJ7UU>Q_F5\3;^]*GO=HZ?>..DN>.:\\?6@[,S M^W1N&&W^L36Y:'^TZ7G]\^V7)[XP:L.GCZ?HOC/IMD^LMML[M2Y'OY]W/M?> M7<_&[)I=GR#W;/>FO@//[AI7G>\M?F6/Z[O#1^.2M'I?]JB[\VC4/T[LG?K. MO6D[%TX+PNO#PS]!=WCCW[EXJ1(/N6/<'T,Q]?(2""),L3)>GKC$D)^@]6$A MBU$7G M,*V7*=(-,ARQ!+6P&MN9B%F6G)@];+D<.8U>(JG0@KD`;-\W9S&BD;R\] M7V^B`&5C!5$%3Q\DD"CE&:27\6PSF^+!,R-Z%DH\T[>M$CNZV[SFF=1D<9.[ MH=A,W\#2KMNV'!7FZ`03*#P2M#J,(<[\>31%^!*^RJ52YZ6+2L3JS=KIEQ?- MQ%9788IEE0`)\*`$%4T@/"P$*SC*U6X#$9FFVFW!?:>F^F[9-FK^6R[W3(4 M9FC@1<' MFNG;9[F'/3D1<\M6A*V>8[AR(CO$_"`FD2_[9.)06R'QJ-/6R#M`3>0[06]` M=`>\_D"HPY_'P-[7(E?V5:E7%KG>[Y6+8FS/'<-84C!O?O7F\$(VCT+AOY5CPP@"D2XY13" MN6I80Q9GJ[ZJZ[Y6B#:3K-T4F)]Y*3LV^G)K&[LN!A-^XV0R,0RXU>`H@ M2GW9I:BZ!`WDX.WD-/@OWZA1#RM9U["9?U':NR>]NI?9&8MU,C0$&.]M!?7Z MU8$H$V&FSY$M;;D"H%_KL"(6U?(]`U5KKKH:J7:F2WU72K!ER9PEJ,MHGP/L[[Y/9BL+^N7W+L4!9TY M`P,^0]1[\\$_+"B/H!IL&S,:O!SP=R)4@UGG='P](-..?/^Y9%Y'!TZ3"G3, M.Y=YJ\>1$QQBH$O$Y6'%R!$?5I-U0AV[U%/PBK*$T^N8'0X"<% M8>W0Q1>ATU>A_8[!9'5>L/;UZ^V6$5KP8\LQ[LLS+7^99+$59RS57!]J)R\Q MEW"6-L2;FR*K&+4#7V;.-X>L25O6IP1">R)G!*6>@V?BSIX(K3LIC]S%8.;I>^+*W;'N MREV)I'\!^&SJHW>T!MXELD[J);+R3,5S0&?&0+5##;E#RR-?$I)&J7N(.+;( MA4HE01JH;"7,N%XS()WH]9KRR+]>E(F*DR3<0(M]A<)N0%: MK1K>R.V1\H@5AJ-;[+OV&-'!Y`+2>R37@'!*'#&`,1++`]:A2(0">7U`_J!> M6!TQ$6$2T8V$\@[`^8L\>U&P.IN[1/P&/2#BHM#^7E0\VR&(0[I$FG>L[%W MGBC`"^>&7R)W*F!-1BJ-%E*S/-H80Z1C9P@M=$6Q@8(D9#!1R=LMP2N7*.68 M^X]_K`IJT6G]P[E85$_5-`X1Y]XCT8DA]V2F*":9+/VQ@N7`T[B0"[C`MFMW MA'9!:]W-%5QZO^#U8KM:R18S*Q.-7V)5.;AU$F,B6UZ[4/Y6K;7\.PF="UUK MF[X9=Q:8_?#TQ.0')A9@F"CNI[L7A4M#W,#@CH@@\CK-!9*QI`R^,0E*ZTY`E,&I7W*\I=#^&&RB1%!K(" MRK]7'B&B@+)3,M]$R@9\/Q>XZ(.Q\L`.P]%H_9EK2?'>E0=X#)'.Y73F%%O- M>J-1'O1Q2)D>7G>=O3P;&X50*AG5G7'OQJRG;?\%4$L!`AX#%`````@`Z(,* M0?#05./??```::@'`!$`&````````0```*2!`````&-B;7@M,C`Q,C`V,S`N M>&UL550%``.4;R50=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`Z(,*07IZ M.2K:"```95H``!4`&````````0```*2!*GT``&-B;7@M,C`Q,C`V,S!?8V%L M+GAM;%54!0`#E&\E4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.B#"D&V M.2?@TAL``)ST`0`5`!@```````$```"D@5.&``!C8FUX+3(P,3(P-C,P7V1E M9BYX;6Q55`4``Y1O)5!U>`L``00E#@``!#D!``!02P$"'@,4````"`#H@PI! M(@ZPU@(P``".8`(`%0`8```````!````I(%TH@``8V)M>"TR,#$R,#8S,%]L M86(N>&UL550%``.4;R50=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`Z(,* M0;&G+RHD'0``Y_4!`!4`&````````0```*2!Q=(``&-B;7@M,C`Q,C`V,S!? M<')E+GAM;%54!0`#E&\E4'5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`.B# M"D$#4OX&^0H``-)@```1`!@```````$```"D@3CP``!C8FUX+3(P,3(P-C,P M+GAS9%54!0`#E&\E4'5X"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``!\ %^P`````` ` end XML 39 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Note 4 - Fair Value Measurements (Detail) - Financial Assets Measured on a Recurring Basis (USD $)
In Thousands, unless otherwise specified

Dec. 31, 2012

Jun. 30, 2012

Assets:

Cash equivalents $ 5,771 $ 2,572

Fair Value, Inputs, Level 1 [Member]

Assets:

Cash equivalents $ 5,771 $ 2,572

X

- Details

Name: cbmx_AssetsAbstract0

Namespace Prefix: cbmx_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8

-Footnote 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 8, 9, 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

Note 4 - Fair Value Measurements (Detail) - Financial Assets Measured on a Recurring Basis (USD $) In Thousands, unless otherwise specified	Dec. 31, 2012	Jun. 30, 2012
Assets:
Cash equivalents	$ 5,771	$ 2,572
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents	$ 5,771	$ 2,572